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HER2+ breast cancer is marked by the overexpression and/or amplification of the 
HER2 protein or HER2 gene, respectively. Current standard of care is trastuzumab-based 
therapy, but resistance remains a huge hurdle for metastatic HER2+ breast cancer 
patients. The loss of tumor suppressor PTEN has been regarded to contribute to 
trastuzumab resistance, but the exact role of PTEN status in HER2+ breast cancer and 
its prognostic value remains controversial. This dissertation aims to unravel the role of 
PTEN expression status in HER2+ breast cancer to gain insight on its contribution to 
trastuzumab sensitivity. We aim to understand how PTEN deficiency alters HER2+ breast 
cancer subpopulations and how changes induced by PTEN deficiency could result in an 
aggressive cancer phenotype and/or impact response to trastuzumab. We hypothesized 
that PTEN deficiency in HER2+ breast cancer increases the aggressive cancer cell 
subpopulations that are responsible for trastuzumab resistance. To test our hypothesis, 
we used an unbiased single cell RNA sequencing approach called Drop-seq to profile 
transcriptomes of cells constituting HER2+ breast cancer in vitro. By profiling four different 
HER2+ breast cancer cell line pairs containing a parental and shPTEN cell line with Drop-
seq, we were able to dissect the functional consequences of PTEN deficiency in vitro. 
Also, we investigated both the intra- and intertumoral heterogeneity effects of PTEN 
deficiency in HER2+ breast cancer. Comparative analyses of the transcriptomes arising 
from parental and shPTEN cell lines provided information about the intratumoral 
consequences of PTEN deficiency. These studies revealed that PTEN deficiency in 
HER2+ breast cancer cell lines resulted in a global increase of quiescent features in the 
shPTEN cell line relative to the parental cell lines for HCC1954 and SKBR3 but not for 
BT474. Furthermore, PTEN deficiency resulted in a 84 fold, 120 fold, and a 2.4 fold 
increase in a quiescent, epithelial, early EMT subpopulation in HCC1954, SKBR3, and 
BT474, respectively. PTEN deficiency introduced intra-subpopulation heterogeneity by 
altering the expression of a subset of EMT, cytokine, cell cycle, and cell adhesion genes
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in HCC1954 and SKBR3 but not BT474. Comparative analyses of changes to the single 
cell transcriptomes resulting from PTEN deficiency between cell lines afforded insight on 
the intertumoral consequences of PTEN deficiency in HER2+ breast cancer. These 
analyses revealed that effects of PTEN deficiency were similar in HCC1954 and SKBR3 
due to the similarities in magnitudes of subpopulation level changes and presence of 
intra-subpopulation level changes while hinted that BT474 represented a unique case for 
studying the consequences of PTEN deficiency. Altogether, these analyses captured the 
context-dependent effects that PTEN deficiency in HER2+ breast cancer.  
Additionally, we aimed to elucidate how transcriptomes shaped by a pre-existing 
PTEN deficiency could impact trastuzumab response by performing treatment studies 
with two HER2+ breast cancer cell line pairs (parental and shPTEN cell line). Treatment 
studies of BT474 and MDA-MB-361 showed minor changes in cancer subpopulations 
between treated and untreated cells, and these studies remain inconclusive at this point. 
Collectively, studies presented in this dissertation could have important clinical 
implications about the consequences of PTEN deficiency in HER2+ breast cancer as we 
highlighted the intra- and intertumoral consequences of PTEN deficiency. This insight 
could contribute to the identification of biomarkers that predicts patient response to 
trastuzumab and facilitate the discovery of alternative therapeutic strategies for patients 




Chapter 1: Introduction to HER2+ Breast Cancer 
1.1. Introduction to HER2+ Breast Cancer 
Breast cancer is one of the most common cancer among women. In the United 
States, approximately 12% of women will be diagnosed with breast cancer during their 
lifetime.1 Breast cancer is heterogeneous disease that presents with a variety of 
histological and clinical manifestations (Figure 1.1A). Breast cancer is categorized into 
four molecular subtypes depending on the expression of surface markers such as 
progesterone receptor (PR), estrogen receptor (ER), and human epidermal growth factor 
receptor 2 (HER2, ERBB2).2–6 In this dissertation, I will focus on HER2+ breast cancer, 
which is characterized by the aberrant overamplification or overexpression of the tumor 
associated antigen, HER2. HER2+ breast cancer constitutes 10-30% of all breast cancer 
cases and is characterized by an aggressive phenotype and poor survival as exemplified 
by the sharp decline in the five year survival as cancer of this subtype progress from 
localized to distant cancer (Figure 1.1B).1,2,5–7 In 2019, it was estimated that roughly 1M 
women in the United States are diagnosed and/or are survivors of HER2+ breast cancer, 
signifying that HER2+ breast cancer impacted 0.3% of the entire United States 
population.1  
 
Figure 1.1. Epidemiological Perspectives of HER2+ Breast Cancer. A) Incidence rates of breast cancer by molecular 
subtype. Adapted from doi: 10.1038/srep11085. B) 5-year survival of HER2+ breast cancer patients. Adapted from 
National Cancer Institute Surveillance, Epidemiology, and End Result Program. Abbreviations: HR (hormonal 




Clinically, the overamplification and the overexpression of HER2 has been 
reported to have different outcomes. Amplification of the HER2 oncogene contributes to 
an aggressive cancer phenotype by enabling tumor cell proliferation, conferring invasive 
properties, and upregulating of the PI3K/AKT and Ras/Raf/MEK/MAPK signaling 
pathways.4 Overexpression of HER2 protein has been associated with poor survival, high 
grade tumors, and positive-lymph node metastases.4 In the clinic, the use of fluorescence 
in situ hybridization (FISH) and immunohistochemistry staining are used to ascertain the 
amplification of the HER2 oncogene and the overexpression of HER2, respectively.4,8,9 
FISH is a DNA hybridization assay that uses fluorescently labeled probes to quantify the 
HER2 gene amplification status relative to the chromosome-17 centromere (CEP-17).4 
Current FDA approved FISH assays include Vetana Inform test, PathVysion, and 
PHarmDX.4 To assess the expression level of HER2, IHC staining is used to determine 
HER2 status in the breast epithelial cells and the patient’s eligibility for anti-HER2 
therapies.4 Current FDA approved IHC staining kits include Dako Hercept Test and 
Ventana Pathway.4 Between FISH and IHC, IHC is the primary method to determine 
HER2 status.4,10 A score of 3+ from IHC staining (i.e. high expression of HER2 protein) 
signifies HER2-overexpressing cancer and makes the patient eligible for anti-HER2 
directed therapies.4,10,11 According to the American Society of Clinical Oncology 
guidelines, IHC staining yielding a score of 2+ is termed as invasive breast cancer with 
moderate staining and often requires the use of the FISH assay for validation.4,11–13 
HER2+ breast cancer develops from the amplification of the HER2 oncogene and/or 
overexpression of the HER2 protein, both of which are assessed during diagnosis.  
1.2. Trastuzumab: Standard of Care for HER2+ Breast Cancer Patients 
The standard of care for HER2+ breast cancer patients features trastuzumab 
(commercially known as Herceptin) in combination with pertuzumab and a 
chemotherapeutic agent such as taxanes.14–16 Trastuzumab is a humanized monoclonal 
antibody that targets the extracellular domain IV of HER2 receptor to exert its cytostatic 
effects on HER2-overexpressing cancer cells in breast cancer, gastric cancer, ovarian 
cancer, and esophageal cancer.16–22 Upon binding to the extracellular domain of HER2 
receptor, trastuzumab exerts its cytostatic action through four key mechanisms (Figure 
1.2).14,23–26 Trastuzumab is predominantly known for mediating antibody dependent cell-
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mediated cytotoxicity by attracting immune effector cells to HER2 overexpressing cells 
(Figure 1.2A).14,23,25–27 Secondly, trastuzumab prevents the proteolytic cleavage of the 
extracellular domain of HER2 (Figure 1.2A).14,23,26,27 It can also prevent the 
heterodimerization of the ectodomain of the HER2 receptor with HER3/4 (Figure 
1.2A).26,27 Lastly, trastuzumab has been shown to elicit its cytostatic effects by promoting 
endocytosis of the HER2-trastuzumab conjugate (Figure 1.2A).27  
The inclusion of pertuzumab (commercially known as Perjeta) in the frontline 
therapy (e.g. trastuzumab with docetaxel) has been shown to dramatically improve the 
overall survival and progression free survival of HER2+ breast cancer patients compared 
to patients who did not receive pertuzumab in their treatment regimen.17 Pertuzumab is a 
humanized monoclonal antibody that binds to the extracellular domain II of HER2 (Figure 
1.2B).28,29 Pertuzumab binds to a different domain than trastuzumab and attenuates the 
HER2 signaling cascade by preventing the heterodimerization of HER2 and HER3.4,28 
The use of pertuzumab is to improve anti-HER2 targeting by dually blocking the HER2 
signaling pathway.28 Patients who develop acquired resistance to the front line therapy 
are given trastuzumab emtansine (referred to as T-DM1 or by its commercial name 
Kadcyla), which is trastuzumab conjugated to the cytotoxic agent DM1 (Figure 1.2B).4,28,30 
T-DM1 selectively targets the HER2 overexpressing cells and is internalized via 
endocytotic vesicles.4,28 Once inside of the cell, the cytotoxic payload consisting of DM1 
is released, which results in cell death.4,28 Unfortunately, patients who continue to acquire 
resistance to the second line therapies have limited therapeutic options because there is 
no standard of care of advanced patients following treatment with trastuzumab, 
pertuzumab, and T-DM1.28 Currently, therapeutic options for these patients include 
combinations of trastuzumab with different chemotherapeutic agents (e.g. vinorelbine, 
gemcitabine, or capecitabine) and capecitabine with lapatinib, which is a tyrosine kinase 




Figure 1.2. Mechanism of Action of Anti-HER2 Agents. A) Mechanism of action of trastuzumab. B) Mechanism of action 
of other HER2-directed therapies (pertuzumab, T-DM1, and trastuzumab deruxtecan) and tyrosine kinase inhibitors 
(e.g. lapatinib, afatinib, neratinib, and tucatinib). 
Since its approval in 1998, trastuzumab has been used to treat early stage and 
HER2+ breast cancer patients with metastatic disease.16,24,29,31–33 For early stage HER2+ 
breast cancer patients, the use of trastuzumab in combination with taxanes resulted in a 
93% disease-free survival rate (7 years).28,34,35 In contrast, 10-40% of HER2+ metastatic 
breast cancer patients initially respond to trastuzumab, and 50-70% of these patients 
develop acquired resistance and experience disease progression within 1 year of 
treatment for advanced diseased (Figure 1.3A).36–39 Approximately 40-50% of these 
HER2+ metastatic breast cancer patients develop brain metastases during their disease 
course, which decreases the therapeutic effectiveness of trastuzumab in advanced stage 
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patients. Moreover, 10-12% of metastatic HER2+ breast cancer patients actually achieve 
clinical complete response and/or progression-free survival at 1 year when treated with 
trastuzumab.19,40 Consistent with this finding, Murthy and coworkers (2016) identified a 
group of “exceptional responders” among HER2+ metastatic breast cancer patients, and 
these “exceptional responders” comprised 7% of the patients evaluated in their study.32 
The vast range in patient response to trastuzumab-based therapy among HER2+ 
metastatic breast cancer subgroup underscores the need to find alternative, effective 
therapies for these patients. At the beginning of 2020, two additional treatments were 
approved for HER2+ metastatic breast cancer.18,19,41 These include tucatinib, which is a 
tyrosine kinase inhibitor that is more selective than lapatinib, and trastuzumab-
deruxtecan, which is an antibody-drug conjugate of trastuzumab with a topoisomerase I 
inhibitor (Figures 1.2B and 1.3B).18,19,41 Both of these new treatments were approved after 
showing clinical benefit for HER2+ metastatic breast cancer patients in the HER2CLIMB 
and the DESTINY-Breast01 clinical trials.18,19,41 Both of these trials were notable because 
they demonstrated efficacy in HER2+ breast cancer patients with brain metastases, who 
in the past, were often excluded from studies.18,19 The use of tucatinib improved 
progression-free survival, and the use of trastuzumab-deruxtecan improved tumor 
response in advanced disease (Figure 1.3B).18,19,41 While these new treatments provide 
HER2+ breast cancer patients with a new hope, these new treatments are similar to 
standard of care agents for HER2+ breast cancer in that they all target the HER2-
dependent pathway (Figure 1.2). 15,18,19,41 The development of resistance to the primary 
arm of trastuzumab-based treatment severely limits clinical benefit of the second and third 
arm treatments as evidenced by poor overall survival rates and low progression-free 
survival rates, especially since all lines of therapies feature trastuzumab (Figures 1.2B 
and 1.3B).28 Acquired resistance to HER2-directed therapy, especially among the 
advanced stage and/or metastatic breast cancer patients accentuate the need for a 
deeper scrutiny into the development of resistance to trastuzumab, which could in turn 
facilitate the discovery of alternative therapeutics for patients who present acquired 
resistance to trastuzumab. This knowledge is critical for clinicians to effectively identify 
subsets of HER2+ breast cancer patients who could benefit from trastuzumab and to 
provide effective therapeutic solutions to patients who will develop resistance to 
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trastuzumab at diagnosis or shortly after diagnosis. The need for the discovery of 
alternative therapeutic strategies for metastatic HER2+ breast cancer patients could be 
addressed in two ways: by capitalizing the understanding of mechanisms driving 
resistance to trastuzumab and leveraging this mechanistic insight to predict how HER2+ 
breast cancer patients will respond to trastuzumab at the time of diagnosis.  
 
Figure 1.3. Lines of Therapies for HER2+ Breast Cancer Patients and Their Clinical Benefit. A) Patient journey for 
metastatic HER2+ breast cancer patient treated with trastuzumab-based therapies. B) Clinical benefit of first line, 
second line, and third line therapies for metastatic HER2+ breast cancer patients. Abbreviations: OS (overall survival), 
PFS (progression free survival), and mo (months). References 1: doi: 10.1016/S1470-2045(13)70130-X; 2: doi: 
10.1056/NEJMoa1209124; 3: doi: 10.1016/S1470-2045(17)30313-3; 4: doi: 10.1056/NEJMoa1914609; 5: doi: 
10.1056/NEJMoa1914510. 
1.3. Introduction to PTEN Loss and Resistance to Trastuzumab 
 There is extensive literature covering mechanisms that contributes to trastuzumab 
resistance.14,23–26,42–47 Three main mechanisms have been proposed: steric effects, 
overexpression of alternative tyrosine kinase receptors, and intracellular alterations 
(Figure 1.4A).23,26,38,43 Resistance to trastuzumab by steric effects occurs as a result of 
the “shedding” of the extracellular domain of the HER2 receptor and prevents 
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trastuzumab from interacting with the HER2 receptor.23,26,38,43 Alternatively, the 
overexpression of alternative tyrosine kinase receptors, such as IGFR, HER3, and c-
MET, enables the cell to bypass the halted HER2-dependent pathway in the presence of 
trastuzumab.23,26,38,43 Lastly, trastuzumab resistance can develop as a result of 
intracellular alterations, namely the upregulation of HER2 dependent intracellular 
signaling pathways such as PI3K/AKT signaling pathway.23,26,38,43 Of these three 
mechanisms, I will focus on the aberrant intracellular alteration as the key source for 
trastuzumab resistance because there is extensive literature highlighting its impact on 
poor patient prognosis and association with trastuzumab resistance.20,23,42,48–50  
The driving force of these intracellular alterations is governed by the loss and/or 
deficiency of a phosphatase and tensin homolog on chromosome 10 (PTEN).20,23,42,48–50 
PTEN is also referred to as MMAC1 (mutated in multiple advanced cancers-1) and TEP1 
(tensin-like phosphatase-1).51,52 PTEN is a cytoplasmic tumor suppressor, and it is linked 
to cancer through its phosphatase domain.25,50,52–55 PTEN dephosphorylates PIP3 to 
PIP2, which serves to negatively regulate the PI3K/AKT signaling pathway.25,50,52,53 This 
pathway is upstream various effector proteins, such as FOXO, mTOR, CyclinD, GSK3B, 
and BAD, which controls cell metabolism, cell survival, cell cycle control, and apoptosis 
(Figure 1.4B).54,56–59 Thus, PTEN is a critical regulator of various signaling pathways 
linked to cell fate. In the event of PTEN loss, the PI3K/AKT pathway remains constitutively 
active and thus, enables the cell to bypass the HER2 pathway in presence of 
trastuzumab.25,26,38,54 Thus, the loss of PTEN has been linked to cancer progression and 





Figure 1.4. Mechanisms of Resistance to Trastuzumab. A) Three mechanisms of resistance to trastuzumab. B) 
Regulation and dysregulation of PI3K/AKT by PTEN loss. 
 In patients with HER2+ breast cancer, approximately 10-40% of these patients 
exhibit a loss of the PTEN tumor suppressor.42,48,60,61 Common mechanisms for PTEN 
loss in various cancers include hypermethylation of the PTEN promoter and loss of 
heterozygosity of the PTEN locus.51,52,61–65 In breast cancer, hypermethylation of the 
PTEN promoter or loss of heterozygosity occurs in 30-50% of patients.51,52,62,63 A less 
common mechanism for PTEN loss in breast cancer is the somatic mutation of the PTEN 
gene, which occurs in 2-6% of patients.52,62 Unlike the cell surface markers used to 
categorize the subtype of a patient’s breast cancer, clinicians do not evaluate PTEN as a 
parameter for breast cancer diagnosis.2–6 Interestingly, the loss of PTEN is uncommon at 
diagnosis.55 However, its loss is associated with disease progression and acquired 
resistance to HER2-directed therapy, which highlights the need for reliable markers to 
identify the subset of HER2+ breast cancer patients who need alternative therapeutic 
solutions at the onset of diagnosis.55  
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Since resistance to anti-HER2 therapy is postulated to result from constitutive 
activation of effector proteins downstream of HER2 arising from PTEN loss, targeting 
these proteins has been explored to overcome trastuzumab resistance and to mitigate 
the effects of PTEN loss.4,53,66–69 This approach includes targeting PI3K/Akt/mTOR, which 
are critical downstream mediators of the HER2 signaling pathway.4,53,66–69 Feasibility 
studies for using PI3K/AKT/mTOR inhibitors for HER2+ breast cancer led to the 
evaluation of repurposing everolimus for HER2+ metastatic breast cancer and the 
discovery of AKT inhibitors, namely MK-2206.34,53,66,67,69,70 Despite the significance of 
PI3K/AKT/mTOR to mediating the HER2 signaling pathway, various clinical trials showed 
that inhibitors did not significantly improve the PFS or OS of HER2+ breast cancer 
patients who developed resistance to frontline therapy.53,69,70 Furthermore, studies with 
everolimus and PI3K/AKT inhibitors documented extensive toxicities, many of which 
resulted in dose interruptions or discontinuation in at least 20% of patients.53,69,71 While 
there are currently ongoing clinical trials aimed at improving the efficacy of these 
inhibitors, none demonstrate significant clinical benefit in HER2+ breast cancer patients 
who developed resistance to the frontline therapies.  
Since PI3K/AKT/mTOR inhibitors had limited success in overcoming resistance or 
restoring trastuzumab sensitivity, researchers also investigated the relationship between 
PTEN loss and trastuzumab resistance.20,42,48 Stern and coworkers (2015) demonstrated 
that HER2+ breast cancer patients with negative PTEN staining (i.e. PTEN loss) had a 
significantly lower overall survival rate compared to patients whose cancer  showed PTEN 
expression (Figure 1.5A).42 In a separate study, Rimawi and colleagues (2018) correlated 
PTEN status with trastuzumab response in HER2+ breast cancer patients treated with 
trastuzumab and lapatinib and observed a statistically significant relationship between 
pCR and PTEN status (Figure 1.5C).48 In their study, 32% of patients with high levels of 
PTEN experienced pCR, while 91% of patients with low PTEN did not exhibit pCR while 
treated with trastuzumab and lapatinib.48 Stern and colleagues (2015), Nuciforo and 
coworkers (2015), Kim and colleagues (2017) also assessed the relationship of overall 
survival as a function of PTEN expression and presence of trastuzumab treatment in 
HER2+ breast cancer, as neoadjuvant therapy for HER2+ breast cancer, and gastric 
cancer, respectively.20,42,60 While these studies showed a negative correlation between  
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overall survival rate, PTEN loss, and trastuzumab treatment, this correlation was not 
statistically significant.20,42,60 The lack of the statistically significant correlation between 
PTEN status and trastuzumab response ignited controversy surrounding the role of PTEN 
in HER2+ breast cancer. Furthermore, Gschwantler-Kaulich and coworkers (2017) 
reported that PTEN positivity, rather than PTEN loss, was significantly correlated with 
progressive disease in HER2+ breast cancer.45 While PTEN is clinically relevant to 
HER2+ breast cancer, the entirety of literature surrounding the relationship between 
PTEN deficiency and clinical parameters suggests PTEN might have a more nuanced 
role in HER2+ breast cancer.  
 
Figure 1.5. Overall Survival of HER2+ Breast Cancer Patients by PTEN Status and Trastuzumab Treatment. A) Overall 
survival of HER2+ breast cancer patients based on PTEN expression levels. Adapted from doi: 10.1158/1078-
0432.CCR-14-2993. B) Overall survival of HER2+ breast cancer patients when treated with trastuzumab based on 
PTEN expression levels. Adapted from doi: 10.1158/1078-0432.CCR-14-2993. C) Effect of PTEN expression levels on 
complete response. Adapted from doi: 10.1007/s10549-017-4533-9. Abbreviations: Tzb Tx (Trastuzumab treatment) 
and pCR (Pathological complete response). 
The paradoxical role of PTEN as observed from the literature could stem from how 
the loss of PTEN affects the mosaic of cancer cells that constitute the entire cancer.72 
Within a tumor, there exists diverse subpopulations that exhibit varied growth potential, 
metastatic potential, and sensitivity to therapy. The phenotype of these cancer 
subpopulations is a direct result of the tumor’s intratumoral heterogeneity, which 
manifests from genetic and epigenetic influences that shapes the tumor’s gene 
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expression programs and adaptability to its environment.10,72 For example, exposure to 
therapeutic agents could expand pre-existing resistant subpopulations and/or alter gene 
expression profiles of select subpopulations to aid the survival of those 
subpopulations.72,73 Hence, intratumoral heterogeneity is thought to be a key driver in 
disease progression, therapeutic resistance, and poor survival in patients with metastatic 
disease.72,74 Furthermore, this intratumoral heterogeneity could be at the crux of how 
PTEN loss shapes the phenotype of cancer subpopulations and could explain why PTEN 
loss produced contradictory clinical observations in the literature.  
In HER2+ breast cancer, intratumoral heterogeneity manifests in a multitude of 
ways. Ferrari and coworkers (2016) reported that HER2+ breast cancer represents a 
spectrum of four additional subtypes with distinguishable gene expression programs, 
somatic mutations, and copy number alterations.75 As a result, patients belonging to 
different subsets of HER2+ breast cancer have distinct cancer ecosystems, which 
explains the variation in therapeutic effect and overall survival among the HER2+ breast 
cancer patient population.75 Additionally, intratumoral heterogeneity in HER2+ breast 
cancer could result in cells that express high levels of HER2 and cells that express low 
levels of HER2, which ultimately generates a heterogeneous group of cancer responsive 
to the HER2-directed therapies (Figure 1.6A). Lee and colleagues (2014) reported spatial 
heterogeneity of the HER2 gene amplification, also termed as regional heterogeneity, is 
common among cells that exhibit low HER2 amplification or expression within the HER2-
overexpressing tumor.73 This spatial/regional heterogeneity in the HER2 amplification 
was significantly associated with decreased response to trastuzumab, shorter time to 
cancer progression, and lower overall survival in HER2+ metastatic breast cancer 
patients.73 Due to clinical importance of intratumoral heterogeneity, a wealth of studies 
were performed to examine HER2+ breast cancer on single cell level to account for the 
heterogeneity that influences the patient journey.74,76 For example, Rye and coworkers 
(2018) analyzed single cells derived from biopsies of HER2+ breast cancer patients to 
reveal the clinical consequences of heterogeneity of HER2 gene amplification and ER 
status.74 Rye and coworkers observed a statistically significant correlation between the 
intratumoral heterogeneity of HER2 copy number, increased frequency of relapse, and 
shorter disease free survival.74 Additionally, Rye and coworkers observed the emergence 
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of new subpopulations of HER2+/ER+ cells following treatment. 74 In a separate study, 
Brady and coworkers (2018) tracked two HER2+ breast cancer patients during cancer 
treatment via single cell transcriptomics and uncovered significant changes to each of the 
patient’s cancer during the course of treatment.76 Specifically, treatment with 
trastuzumab-based therapies revealed mechanisms of acquired resistance in both 
patients: one patient had increased expression of ABC1B drug efflux pump and mutations 
induced by reduction of BRCA gene expression, while the other patient showed elevated 
expression of ESR1 and ABC1B drug efflux pump.76 Brady and associates also revealed 
that these resultant subclones emerged from minor subpopulations that were expanded 
following a “bottleneck event” during cancer treatment, which underscores the functional 
consequences of intratumoral heterogeneity. Furthermore, Brady and coworkers’ study 
highlighted the existence of  therapy resistance programs present in only a subset of 
cancer cells, which signified that the response of the collective cancer represents the 
combined, varied response of the individual cells to therapy.76 This study effectively 
highlighted the value of single cell transcriptomics as an unbiased approach to study 
subpopulations of HER2+ breast cancer on a single cell level, which enables the 
dissection of the evolution of resistance mechanisms to HER2-directed therapy. 
Specifically, this unbiased approach would afford insightful analysis of how intracellular 
alterations such as PTEN deficiency affects HER2+ breast cancer at the single cell level 
(Figure 1.6B). Previously, in vitro studies performed by Korkaya and coworkers (2008) 
using HER2+ breast cancer cells with PTEN knockdown (k.d.) indicated that trastuzumab 
treatment resulted in the development of an aggressive mesenchymal phenotype.77 
Furthermore, single cell colony formation studies performed by Dr. Joseph Burnett of the 
Sun Lab demonstrated that HER2+ breast cancer cells with PTEN k.d. generated 
mesenchymal colonies at a higher frequency compared to parental colonies. 
Furthermore, trastuzumab treatment of colonies with PTEN k.d. further increased the 
formation of mesenchymal colonies (unpublished data). Taken together, these studies 
emphasize the impact that intratumoral heterogeneity could have on the functional 
consequences of PTEN deficiency in HER2+ breast cancer. Importantly, these studies 
accentuates the need to scrutinize the functional consequences of PTEN deficiency on a 
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single cell level to reveal how the combined effect of intratumoral heterogeneity and PTEN 
deficiency ultimately governs trastuzumab sensitivity in HER2+ breast cancer.  
 
Figure 1.6. Depictions of Intratumoral Heterogeneity in HER2+ Breast Cancer Cells. A) Intratumoral heterogeneity in 
HER2 protein expression. Patient tissue retrieved from Protein Atlas (Patient ID: 659). B) Cartoon of intratumoral 
heterogeneity resulting in four distinct subpopulations based on expression of HER2 and PTEN. 
1.4. Use of Drop-seq to Generate Single Cell Transcriptomic Libraries 
In a clinical setting, a patient with HER2-overexpressing breast cancer could have 
numerous cancer subpopulations that vary in expression of critical genes and proteins, 
such as HER2 and PTEN. Figure 1.6B illustrates a simplified cartoon of four 
subpopulations of cancer cells resulting from variation in protein levels of these two 
genes. Based on the gene expression of these cells, these subpopulations could all 
behave starkly different, which collectively shape the course of the patient’s cancer. Some 
subpopulations contribute to aggressive cancer phenotype, some are therapy-sensitive, 
and some are resistant to therapies. We are particularly interested in analyzing the 
steady-state subpopulations that constitute HER2+ breast cancer to elucidate how PTEN 
deficiency affects those subpopulations. To gain insight on PTEN deficiency in HER2+ 
breast cancer, we used single cell transcriptomics, namely Drop-seq.78,79 While there are 
multiple methods for single cell transcriptomics, Drop-seq is suitable to address our 
research question because it has good accuracy, good statistical power to detect 
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differences in gene expression levels between cells, and is among the most cost effective 
methods.78,80 Despite these advantages, Drop-seq is limited by high amplification noise 
resulting from PCR, low sensitivity (i.e. median number of genes detected per cell), high 
dropout probability (i.e. the fraction of cells with zero expression counts), and lower 
sequencing depth (i.e. genes expressed at low abundance will not be detected).80 Drop-
seq detects approximately 4,000 genes per cell and is limited to detecting high expressing 
genes.80 Despite these limitations, Drop-seq is an appropriate method for analyzing large 
number of cells at a lower sequencing depth, which is sufficient to address our research 
questions and for unraveling the functional consequences resulting from PTEN 
deficiency.80,81 In summary, Drop-seq is an appropriate method to evaluate the effects of 
PTEN deficiency to reveal subpopulation changes.  
 Drop-seq is a critical single cell RNA-seq technique that enables the profiling of 
mRNA transcripts within single cells. This technique involves the generation of nanoliter 
droplets containing 1 cell and 1 barcoded bead.78 These barcoded beads contain millions 
of oligonucleotides on its surface, where each oligonucleotide contains four regions on it: 
a cell barcode, unique molecular identifier (UMI), an oligo dT sequence, and a PCR 
primer.78 Cell barcodes allows mRNA transcripts originating from 1 cell to be traced to its 
originating cell following sequencing.78 The UMI tags individual mRNA transcripts so that 
replicates of the same mRNA transcript could be tracked and quantified following 
sequencing.78 The oligo-dT sequence enables mRNA transcripts from single cells to be 
captured onto the beads through the hybridization of the poly-A tails of the mRNA 
transcripts to the dT oligos of the barcoded beads.78Lastly, the PCR primer allows enables 
downstream amplification following the reverse transcription of the mRNA to cDNA.78 
Together, these components of the barcoded beads technology provides an effective way 
to capture mRNA from single cells and to develop single cell transcriptomic libraries. 
Using this technology, we would be able to profile gene expression programs derived 
from single cells that constitute bulk HER2+ breast cancer cell lines to reveal the 
functional consequences of PTEN deficiency. Furthermore, subpopulation level effects of 
PTEN deficiency in HER2+ breast cancer could be dissected in vitro to elucidate the 
contribution of PTEN deficiency in trastuzumab sensitivity.  
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Previously in Sun Lab, Dr. Joseph Burnett generated HER2+ breast cancer cell 
line pairs, where each pair consists of the parental cell line (wild type, wt, PTEN) and 
PTEN knockdown (k.d., Table 1.1). The expression of PTEN was previously knocked 
down using lentiviral shRNA as described by Korkaya and colleagues and provided to me 
for this dissertation as a gift.77,82,83 Drop-seq analyses using these cell line pairs afforded 
analysis on the intertumoral heterogeneity (i.e. cancer heterogeneity arising between 
patients72), intratumoral heterogeneity (cancer heterogeneity arising within a single 
tumor72), and how those phenomena affects the functional consequences of PTEN 
deficiency in HER2+ breast cancer. Intertumoral heterogeneity effects of PTEN deficiency 
were studied using comparative analyses of the single cell transcriptomes between 
HER2+ breast cancer cell lines.  Intratumoral heterogeneity effects of PTEN deficiency 
were evaluated by scrutinizing the cancer subpopulations that make up a HER2+ breast 
cancer cell line. Functional consequences of PTEN deficiency was elucidated in 
comparative transcriptomic analyses between the parental and PTEN k.d. cells for a given 
cell line. Single transcriptomic libraries of HCC1954, SKBR3, and BT474 (parental and 
PTEN k.d.) were evaluated to understand the functional consequences of PTEN 
deficiency in HER2+ breast cancer cells. The impact of PTEN deficiency on trastuzumab 
response in HER2+ breast cancer cells were evaluated in treatment studies of BT474 and 
MDA-MB-361 (parental and PTEN k.d.).  
Table 1.1. HER2+ Breast Cancer Cell Line Pairs Used in This Dissertation. 
 
1.5. Research Question, Hypothesis, and Research Aims 
For this dissertation, we investigated the role of PTEN deficiency in HER2+ breast 
cancer to elucidate its role in trastuzumab resistance. Ultimately, we aim to contribute to 
the discovery of effective therapeutic solutions for HER2+ breast cancer patients who 




• What subpopulations exist in HER2+ breast cancer?  
• How does PTEN deficiency affect the steady state of these subpopulations? 
• How does the status of PTEN affect response to HER2-directed therapy?  
To address these research questions, we proposed the following hypothesis: PTEN 
deficiency in HER2+ breast cancer expands aggressive subpopulations that are 
responsible for trastuzumab resistance. To test our hypothesis, we proposed three aims 
for this dissertation, which includes:  
1. Characterize subpopulations in HER2+ breast cancer with wt PTEN and PTEN 
deficiency using Drop-seq 
2. Elucidate how the transcriptomic composition of HER2+ breast cancer cells 
change as a result of PTEN deficiency and trastuzumab treatment  
3. Identify and validate markers corresponding to subpopulations enriched by PTEN 
k.d. and/or trastuzumab treatment (future) 
For this dissertation, we addressed Aim 1 and gathered preliminary findings for Aim 
2. The bulk of this dissertation will focus on the characterization of PTEN deficiency in 
HER2+ breast cancer cells. Chapter 2 describes our approach and findings from 
analyzing the transcriptomic changes induced by PTEN k.d. in three HER2+ breast 
cancer cell lines: HCC1954, SKBR3, and BT474. We describe global transcriptomic 
changes as well as subpopulation level changes that result from PTEN k.d. in these 
HER2+ breast cancer cell lines. We sought to address Aim 2 in Chapter 3, but could only 
provide preliminary observations from trastuzumab treatment studies using BT474 and 
MDA-MB-361 at this time. Additional treatment studies are ongoing. The purpose of these 
treatment studies was to gain insight on what transcriptomic alterations resulted from 
trastuzumab treatment and how transcriptomes shaped by a pre-existing PTEN 
deficiency impact trastuzumab response. Insufficient number of treatment controls and 
the lack of reproducibility between biological replicates limited these treatment studies, 
and thus, only preliminary observations were described. No conclusive findings were 
identified from the treatment studies described in Chapter 3. In Chapter 4, we provide 
concluding remarks and thoughts about future studies. A chapter in the Appendix 
summarizes a drug discovery project that performed during the first 2 years of towards 
this dissertation. The Appendix chapter details the drug discovery efforts towards the 
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identification of small molecule inhibitors of the protein-protein interaction between c-MYC 
and WDR5 using high-throughput screening and fragment based drug discovery 
approaches.  
1.6. Significance and Innovation 
Research presented in this dissertation is significant because it elucidates the 
effect of PTEN deficiency on a single cell level. Previously, the role of PTEN in HER2+ 
breast cancer has been controversial due to the confounding contribution of intratumoral 
heterogeneity existing within the bulk tumor. This dissertation accounts for the 
contribution of intratumoral heterogeneity on the effect of PTEN deficiency in HER2+ 
breast cancer cells through the use of Drop-seq. We evaluated the global transcriptomic 
consequences of PTEN deficiency in bulk HER2+ breast cancer cells and determined 
how PTEN deficiency affected the intratumoral heterogeneity within each HER2+ breast 
cancer cell line by dissecting subpopulations that comprised the bulk cell line. We also 
elucidate the intertumoral consequences of PTEN deficiency by comparing 
transcriptomes between cell lines to gain insight about the relationship between PTEN 
deficiency and intertumoral heterogeneity. 
This study will be the first (to our knowledge) to describe that PTEN deficiency 
enriches a quiescent subpopulation with an epithelial, early EMT phenotype in HER2+ 
breast cancer cells. Furthermore, the evaluation of PTEN deficiency in three HER2+ 
breast cancer cell lines revealed that PTEN deficiency also enriched/ maintained pre-
existing subpopulation phenotypes, which suggested that PTEN deficiency also displayed 
context-dependent consequences, depending on the phenotype is enriched or 
maintained. Furthermore, the context dependent effects of PTEN deficiency observed in 
vitro implied that HER2+ breast cancer patients with PTEN deficiency might also endure 
context dependent consequences. These observations hinted of the need to evaluate 
HER2+ breast cancer patients on both PTEN and HER2 status. Taken together, we 
assessed the functional consequences of PTEN deficiency on a single cell level, which 
revealed an enrichment of a quiescent subpopulation with epithelial, early EMT 
phenotype and context dependent consequences of PTEN deficiency in remaining cancer 
subpopulations. Findings presented in this dissertation could contribute to shaping the 
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Chapter 2: PTEN Deficiency in HER2+ Breast Cancer Cell Lines Enriched 
Quiescent Subpopulation with Epithelial, Early EMT Transcriptomic Composition 
 
Abstract 
HER2+ breast cancer is a highly aggressive subtype of breast cancer and characterized 
by poor survival, especially among patients with advanced stage disease. Standard of 
care for HER2+ breast cancer is trastuzumab-based therapy in combination with taxanes 
and pertuzumab, which is unsuccessful for patients with late stage HER2+ breast cancer. 
The role of PTEN has been considered to contribute to an aggressive cancer phenotype, 
but the role of PTEN as it pertained to HER2+ breast cancer remains controversial. In this 
study, we used single cell RNA-seq to unravel the consequences of PTEN deficiency in 
three HER2+ breast cancer cell lines: HCC1954, SKBR3, and BT474. For all of these cell 
lines, we observed that PTEN k.d. by shRNA resulted in a shift in the cancer 
subpopulations that make up the bulk cancer cell line. Notably, PTEN k.d. in HCC1954 
and SKBR3 resulted in an 84 fold and 120 fold increase in a subpopulation characterized 
with a quiescent, epithelial early EMT phenotype. In BT474, the magnitude of PTEN k.d. 
on the BT474 subpopulations changed 2-5 fold, but also enriched for the quiescent early 
EMT subpopulation. Furthermore, the k.d. of PTEN in these cell lines slightly increased 
the heterogeneity by altering the expression of genes critical phenotypes of different 
subpopulations.  
2.1. Introduction 
HER2+ breast cancer constitutes 10-30% of all breast cancer cases and is 
characterized by an aggressive phenotype and poor survival as exemplified by the sharp 
decline in the five year survival as breast cancer of this subtype progress from localized 
to distant cancer.1,2,5–7 The standard of care for HER2+ breast cancer patients features 
trastuzumab (commercially known as Herceptin) in combination with pertuzumab and a
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chemotherapeutic agent such as taxanes.14–16 Trastuzumab has been used to target 
HER2-overexpressing cancer cells in breast, ovarian, gastric, and esophageal cancer.16–
22 In early stage HER2+ breast cancer patients, the use of trastuzumab in combination 
with taxanes resulted in 93% disease free survival rates (7 years).28,34,35 In contrast, 10-
40% of HER2+ metastatic breast cancer patients initially respond to trastuzumab, and 50-
70% of these patients develop acquired resistance and experience disease progression 
within 1 year of treatment for advanced diseased.36–39 The gap in efficacy between early 
stage and advanced stage HER2+ breast cancer patients underscores the need to dissect 
mechanisms that contribute to resistance of trastuzumab to facilitate the discovery of 
alternative therapies for patients who acquire resistance within the first 2 years of cancer 
management.  
Among the resistance mechanisms hypothesized to contribute to trastuzumab 
resistance, the loss of PTEN by epigenetic silencing or by the loss of heterozygosity has 
been regarded as one of the driving forces for the development of a more aggressive 
cancer phenotype.20,23,26,38,42,48–50,54,84 However, the exact contribution of PTEN status to 
the progression of HER2+ breast cancer and trastuzumab sensitivity remains 
controversial due to conflicting literature reports about the prognostic value of PTEN in 
HER2+ breast cancer.20,42,45,48,60 The key limitation of previous studies is the use of 
clinical tumor samples, which are not ideal for accounting for the intratumoral 
heterogeneity that underlies the cancer. This heterogeneity governs the phenotype of the 
cells that make up the cancer, and thus, different cancer cells within a tumor responds 
differently to treatment and cellular stress based on the gene expression of those 
cells.10,72 Thus, it is critical to evaluate the consequences of PTEN status and loss in the 
context of intratumoral heterogeneity. Additionally, it is critical to assess how the 
consequences of PTEN deficiency varies across HER2+ breast cancer patients and 
understand the contribution of intertumoral heterogeneity. Therefore, understanding the 
effects of PTEN status and loss on a single cell level would reveal how the cancer as a 
whole is affected by PTEN loss, and thus, enables the understanding of PTEN deficiency 
in the context of intertumoral heterogeneity and intratumoral heterogeneity. Herein, we 
describe the use of the Drop-seq pipeline to evaluate how PTEN deficiency in three 
HER2+ breast cancer cell lines affected the steady state subpopulations that make up 
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these HER2+ breast cancer cell lines. By examining the effects of PTEN deficiency on a 
single cell level, we determined that PTEN deficiency increased the intra-subpopulation 
heterogeneity by altering the expression of key genes governing the phenotype of 
different subpopulations. Importantly, PTEN deficiency enriched a subset of quiescent, 
epithelial early EMT cells, suggesting that PTEN deficiency in HER2+ could promote an 
aggressive phenotype.  
2.2. Materials and Methods 
2.2.1. Cell Culture 
Cells with silenced PTEN were generated by lentiviral infection to introduce short 
hairpin RNA of PTEN. To target the human PTEN gene for silencing, the pLentilox 3.7 
vector containing shPTEN was used to generate “PTEN k.d.” cell lines. As a control for 
lentiviral infection, pLentilox 3.7 vector containing fluorescent dye DsRed, which resulted 
in the wild type (wt) PTEN cell line derivative. Knockdown studies were performed by Dr. 
Joseph Burnett as previously described by Korkaya and coworkers to yield HER2+ breast 
cancer cell line pairs based on PTEN status.77,82,83 
The following HER2+ breast cancer cell lines with wild type (WT) PTEN and PTEN 
knockdown (“PTEN k.d.” derivative) were used for this study: SKBR3, BT474, and HCC-
1954. SKBR3 DsRed and PTEN k.d. cell line derivatives was maintained in RPMI 1640 
and supplemented with 10% FBS, 2% Pen-Strep (Gibco cat. no. 15140122), 1% sodium 
pyruvate (Gibco cat. no. 11360070), and 1% of 2mM L-Glutamine. BT474 cell line 
derivatives were maintained in DMEM/F-12 50:50 and supplemented with 10% FBS, 1% 
Pen-Strep, and 1% of 2mM L-Glutamine. HCC-1954 cell line derivatives were maintained 
in RPMI 1640 supplemented with 10% FBS, 1% anti-anti, and 0.008% gentimycin. Cells 
were cultured in an incubator at 37°C and humidified with 5% CO2.  
2.2.2. Drop-seq Experiments 
Drop-seq experiments were performed in accordance to the online protocol from 
the McCarroll lab (version 3.1, 2015).85 Barcoded Bead SeqB beads were ordered from 
Chemgenes and referred henceforth as Drop-seq beads. Microfluidics devices used 
during this study were generous gifts from Dr. Michael Brooks from Dr. Max Wicha’s 
group. For these devices, treatment with Aquapel was performed using instructions from 
the McCarroll lab to ensure a hydrophobic surface through the microfluidics devices. To 
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ensure high-quality droplets and maintain consistency between Drop-seq experiments, 
microfluidics devices were ordered from FlowJEM (PDMS Drop-seq chip, standard 
design, containing vaporized silane).  
2.2.3. Sequencing of cDNA Libraries 
Single transcriptomic libraries generated from each cell line pair (HCC1954, 
SKBR3, and BT474) were sequenced by Next-seq (150 cycle, MO) at the Advanced 
Genomics Center at the University of Michigan. Approximately 7M reads/sample (75K 
reads/cell) were desired for sequencing runs. The following read lengths were used for 
Next-seq: read 1 length: 20 bp (26 cycles), read 2 length: 50 bp (96 cycles), and index 
read length: 8 bp. Illumina adapters (i7) were used to discriminate single cell 
transcriptomic libraries derived from parental from shPTEN cell lines. The following i7 
adapters (and adapter sequences) were used to prepare sequencing libraries: N701 
(TCGCCTTA), N702 (CTAGTACG), N703 (TTCTGCCT), and N704 (GTTGGACA). 
Transcriptomic libraries pooled by equal molar pooling of cell lines and ensured equal 
sequencing coverage per cell line.  
2.2.4. Read Alignment and Generation of Digital Expression Data 
Read alignment and the generation of the digital expression data matrix were 
performed by Dr. Joe Burnett and in accordance to the Drop-seq Computational 
Cookbook.86 Reads were de-multiplexed to separate reads corresponding to parental and 
shPTEN cell line based on i7 index adapters. Reads were aligned to the reference human 
genome (GRCh38.p13) to derive the cDNA from each read. Mapped reads were then 
organized into a digital count matrix based on the unique molecular identifier, which 
enabled the quantification of gene expression per gene for each cell represented from the 
single cell transcriptomic library.  
2.2.5. Unsupervised Dimensionality Reduction and Clustering 
Digital count matrices were imported into R for analysis using the Seurat package 
(version 3.1.2). The gene expression of the parental and shPTEN cell lines were 
normalized using the NormalizeData function, which normalized the feature (gene 
expression) counts of each cell relative to the total features of that cell. These normalized 
feature counts were transformed using a natural log transformation. In order to perform 
downstream analyses with the metadata for each cell line pair, the metadata 
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corresponding to the parental cell line and the shPTEN cell line were integrated. 
Integration of these metadata was performed by identifying integration anchors 
(FindIntegrationAnchors) with the dims and k.filter argument set to default settings. 
Metadata was integrated using the IntegrateData function. Cell cycle heterogeneity was 
minimized by regressing the difference in the expression of G2/M and S phase genes. 
Analyses were also performed in absence of cell cycle regression, where the data 
changed minimally compared to using cell cycle regression. Analyses presented in this 
dissertation represent data where cell cycle regression was performed. Subpopulation 
clusters were resolved by using principal component analysis (PCA) and Uniform 
Manifold Approximation and Projection (UMAP). The resolution argument within the 
FindClusters function was optimized for each cell line pair by clustering the metadata at 
each clustering resolution from 0 – 1 in increments of 0.1. The multi-resolution clusterings 
were evaluated using the R package clustree, which guided the selection of the optimal 
clustering resolution.87 For all cell lines, clustering resolution was set to 0.7 after analysis 
using clustree.  
2.2.6. Differential Gene Expression Analysis 
Differential gene expression was performed using FindMarkers function to 
evaluate differentially expressed genes between cell line pairs and subpopulations using 
the wilcox test. This analysis was performed to scrutinize the global transcriptomic 
differences between parental and shPTEN cell line by specifying ident.1 as the shPTEN 
cell line. Additionally, differential gene expression analyses were performed to identify 
characteristic genes expressed by each subpopulation by specifying ident.1 as the 
subpopulation of interest. The FindMarkers function was used to evaluate the gene 
expression of PTEN and HER2 between the parental and shPTEN as well as between 
each subpopulation. The FindMarkers function also afforded analyses within the 
subpopulation to identify genes differentially expressed by the subset of cells with PTEN 
k.d. relative to parental cells of a given subpopulation. To identify differentially expressed 
genes within a subpopulation, the following arguments within the FindMarkers function 
was specified: ident.1 as shPTEN, group.by set to “orig.ident”, and subset.by set to 
subpopulation of interest. Genes identified from the FindMarkers output were considered 
as statistically significant if p_adj < 0.01, where p_adj accounted for the bonferroni 
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correction. The most statistically significant genes were exemplified by a volcano plot 
generated using ggplot, and gene names were labeled using ggrepel.  
2.2.7. Gene Set Enrichment Analysis (GSEA) 
After differential gene expression was performed to assess the genes differentially 
expressed by a subpopulation of cells, gene set enrichment analyses was used to 
elucidate the functional consequences of those differentially expressed genes. GSEA was 
performed using the R package fgsea.88,89 In order to perform gsea using the fgsea 
package, a rank ordered list of genes from the set of differentially expressed genes was 
generated based on the log_avgFC of a given gene. This rank ordered list was used as 
the stats argument in the fgsea function. The minimum gene set size to set was 10, and 
the maximum gene set size to test was 500. The number of permutations to run using the 
fgsea function was 1M. The rank ordered list of genes was compared a priori to the gene 
sets downloaded from MSigDb (msigdb.v7.0.symbols.gmt, accessed from 
https://data.broadinstitute.org/gsea-msigdb/msigdb/release/7.0/). Gene sets with p_adj < 
0.05 were considered statistically significant, where p_adj is the p_val adjusted using the 
Benjamini-Hochberg (BH) procedure. Gene sets that were identified to be statistically 
significant were downloaded from MSigDb and imported into R. Genes from the imported 
gene sets were intersected with the genes from our metadata using the Reduce function 
and the intersect function from the dplyr package. This step enabled the identification of 
genes from statistically significant gene sets that contributed to the enrichment score of 
those gene sets identified using fgsea. The output of the intersected list of genes were 
scrutinized based on avg_logFC, p_adj, pct.1, and pct.2, where avg_logFC is the natural 
log fold change in expression of a given gene from one subpopulation relative to another 
subpopulation. The p_val adjusted for BH correction and is noted as p_adj. The 
percentage of cells from the subpopulation of interest that expresses the gene of interest 
is quantified by pct.1, and the percentage of cells from the compared subpopulation that 
expresses the gene of interest is quantified as pct.2.  
2.2.8. Quantification of Western Blot 
Cell pellets isolated from cell culture were placed into -80°C freezer for at least 24 
hours prior to preparation for Western blot. Cell pellets were subjected to RIPA lysis buffer 
containing 1x EDTA, 1x protease inhibitor, and 1x phosphatase inhibitors for 20 minutes 
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at 0° C. Cell pellet solutions were sonicated at 33% power with 3x3 second pulses at 0° 
C. After sonication, samples were maintained at 0° C for 15 minutes prior to centrifugation 
at 14,000 rpm and 4°C for 15 minutes. Supernatant for each sample was retained and 
total protein concentration was determined via Bradford assay.  
The Bradford protein quantification assay was performed in accordance to the Bio-
Rad instruction’s manual. Briefly, a working solution of the Bradford dye concentrate was 
prepared by diluting 1 part of the Bio-rad dye concentrate with 4 parts of MilliQ water. 
Following, 200 µL of this working solution was added to 10 µL of standard BSA solution 
or 10 µL of diluted supernatant (1:10 in water). Contents were vortexed afterwards and 
optical densities were measured at 595 nm on a microplate reader (BioTek). Analyses for 
standards and samples were performed in triplicate.  
Measurements from Bradford assay were used to determine volumes of 
supernatant required to load 20 µg of total protein into a well of 4-20% Mini-PROTEAN(R) 
TGX(tm) Precast Protein Gel (Bio-Rad cat. no. 4561094). 4x Lamelli sample buffer 
containing 10% mercaptoethanol and lysis buffer were added to the calculated volumes 
of the supernatant to provide a final volume of 20 µL and 20 µg of total protein. Proteins 
were separated by gel electrophoresis using 1x Tris/Glycine/SDS buffer (prepared from 
Bio-rad cat # 161-0734) for 80V for 20 minutes and then 100V for 45 minutes. Proteins 
were transferred to nitrocellulose membrane using 1x Tris/Glycine (prepared from Bio-
rad cat # 161-0732) and containing 20% HPLC-grade methanol at 220 mA for 70 minutes 
on ice.  
Successful transfer was assessed by immersing nitrocellulose membrane in 
Ponseau-S stain for 5 minutes with agitation and observing crude protein bands upon 
washing the nitrocellulose membrane with MilliQ water or 1x TBS-T (0.1% Tween-20). 
Following, nonspecific binding sites on proteins were blocked using 5% BSA in 1x TBS-
T for 1.5 hours at room temperature with agitation. Blocking solution was removed and 
membranes were washed for 4x5 minutes with 1x TBS-T. Primary antibody solutions 
were prepared using dilutions and diluent as recommended by the manufacturer and are 




Table 2.1. Western Blot Antibodies.  
Antibody Dilution Diluent  MW 
(kDa) 





CST rabbit anti-pAKT (Ser473) (D9E) XP® Rabbit 
mAb #4060 
1:2000 60 
CST rabbit anti-vinculin (E1E9V) XP 1:1000 124 
CST anti-rabbit HRP-linked Antibody #7074 1:1000  
Nitrocellulose membranes were incubated with primary antibody solutions for 18 hours at 
4°C. Excess primary antibody solutions were discarded and membranes were washed 
for 4x5 minutes with 1x TBS-T. Membranes were incubated with secondary antibody 
solution for 1.5 hours at room temperature with agitation. Excess secondary antibody 
solutions were discarded and membranes were washed for 4x5 minutes with 1x TBS-T. 
Enhanced chemiluminescence reaction was performed in accordance to Bio-Rad Clarity 
protocol.  
 Quantification of Western was performed using ImageJ and were normalized to 
housekeeping gene, vinculin. The expression of vinculin in each experimental lane on the 
Western blot was normalized to the lane with the highest vinculin signal, which afforded 
the lane normalization factor. The use of lane normalization factor ensured that the signal 
of vinculin was constant across all lanes and ensured accurate quantification of PTEN 
relative to a normalized signal of vinculin. For each cell line, the reduction in PTEN 
expression was calculated as the quotient of normalized wild type PTEN and the 
normalized levels of PTEN in the shPTEN cell line.  
2.3. Results and Discussion 
Table 2.2. HER2+ Breast Cancer Cell Line Pairs Used to Evaluate Consequences of PTEN Deficiency. Each cell line 
consists of a parental cell line that expresses wild type PTEN, and the PTEN knockdown cell line has reduced 
expression of PTEN by shPTEN. Bulk cell line clarifies the use of cell lines that were not derived from single cell colonies 




2.3.1. Validation of PTEN k.d. by Western and Single Cell Analysis 
 Using single cell transcriptomic libraries generated from these cell line pairs, we 
addressed the first aim of this dissertation. The first aim of this dissertation is to 
characterize the steady state subpopulations existing within HER2+ breast cancer cell 
lines and elucidate how PTEN k.d. alters those subpopulations (Table 2.2). To ensure 
these cell line pairs correctly reflect wt PTEN and PTEN k.d., we quantified the expression 
level of PTEN by Western blot and by single cell analysis in HCC1954, SKBR3, and 
BT474. (Figure 2.1). In HCC1954, the protein expression of PTEN was reduced by 2.7 
fold after transfection with shPTEN (Figure 2.1A). Using single cell analysis, it was evident 
that the expression of PTEN was very low in HCC1954 as it was below the detection limit 
of Drop-seq in parental HCC1954 and within the six HCC1954 subpopulations (Figure 
2.1A). In SKBR3, the protein expression of PTEN was reduced by 4.4 fold in SKBR3 
PTEN k.d. relative to the parental cell line (Figure 2.1B). Similar to HCC1954, this cell line 
also harbored low levels of PTEN in its subpopulations. Levels of PTEN were observed 
in parental SKBR3 subpopulations 0, 2, and 3, but the difference of those levels relative 
to the PTEN k.d. cells were not statistically significant (Figure 2.1B). Lastly, in BT474, the 
expression level of PTEN was reduced by 11.4 fold in the PTEN k.d. cell line derivative 
(Figure 2.1C). Expression levels of PTEN were observed in parental BT474 
subpopulations 1, 2, and 3, but those levels were not statistically significant relative to 
PTEN k.d. cells. The relatively higher levels of PTEN in BT474 compared to HCC1954 
and SKBR3 observed in my findings were consistent with the literature, which also report 
higher protein levels of PTEN in BT474 compared to HCC1954 and SKBR3.90,91 As a 
technical control, we also assessed the single cell expression levels of HER2 in these cell 
line pairs. For each cell line pair, HER2 was highly expressed in both the PTEN k.d. and 
parental cell line. Between subpopulations, the expression of HER2 was not statistically 
different for these cell lines. Additionally, the difference in HER2 expression between the 
parental and k.d. cell lines within each subpopulation was also not statistically significant 




Figure 2.1. Validation of PTEN and HER2 Expression Levels in HER2+ Breast Cancer Cell Lines. Quantification of 
PTEN k.d. by Western for HCC1954 (A), SKBR3 (B), and BT474 (C). Protein expression levels were normalized to 
vinculin. Violin plots depicting PTEN levels in PTEN k.d. cells compared with parental (top) and within subpopulations 
(bottom) of HCC1954, SKBR3, and BT474. Violin plots depicting HER2 levels in PTEN k.d. and parental cell lines and 
within subpopulations of HCC1954, SKBR3, and BT474. 
2.3.2. PTEN Deficiency in HCC1954 Caused Global Increase in Quiescence and 
Cytokine Signaling but Decreased Epithelial Phenotype 
 To explore the functional consequences of PTEN deficiency in HER2+ breast 
cancer cells, we performed Drop-seq to compare single cell transcriptomes deriving from 
parental and  PTEN k.d. cell lines. We sought to evaluate the transcriptomic differences 
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in HCC1954, SKBR3, and BT474. We started our comparative analyses by elucidating 
the differences between parental and PTEN k.d. cell line derivatives to dissect global 
transcriptomic changes. Then, we scrutinized the effects of PTEN k.d. on a subpopulation 
level for each cell line. By dissecting the effects of PTEN k.d. on a global and 
subpopulation level, we ascertained how the steady state subpopulations of the HER2+ 
breast cancer cells were affected by PTEN k.d. 
To visualize the transcriptomic composition of parental HCC1954 and HCC1954 
PTEN k.d. cells, a nonlinear dimensionality reduction (uniform manifold approximation 
projection, UMAP) was used to analyze global transcriptomic changes resulting from 
PTEN k.d. Nonlinear dimensionality reduction plots, such as UMAP plots, provide a two-
dimensional depiction of the spatial distribution of cells based on their transcriptomic 
composition.92,93 UMAP plots represent cells with similar transcriptomic profiles as 
subpopulations or clusters in close proximity while cells with starkly different 
transcriptomic profiles as farther apart.92,93 Thus, these plots are powerful tools that 
enable the visualization of the intratumoral heterogeneity existing within a cancer 
ecosystem by revealing the cancer cell subpopulations. With the UMAP plot, extensive 
spatial overlap was observed between the parental HCC1954 and HCC1954 PTEN k.d. 
cells (Figure 2.2). Despite this similarity between most of the cells belonging to the 
HCC1954 cell line pair, the knockdown of PTEN enriched a subset of cells that was not 
present in the wt PTEN cells (circled in Figure 2.2A).  
After visualizing HCC1954 cells based on their transcriptomic composition, 
differential gene expression (DGE) analysis was performed to identify global 
transcriptomic differences between parental HCC1954 and HCC1954 PTEN k.d. cells 
(Figure 2.2B). This analysis identified 1,024 statistically significant genes that were 
differentially expressed by HCC1954 cells with PTEN k.d (padj < 0.01). From these 
differentially expressed genes, 476 genes were elevated (padj < 0.01), and 548 genes 
were lower in HCC1954 PTEN k.d. cells as depicted in the volcano plot of Figure 2.2B 
(padj< 0.01). A volcano plot is a scatterplot of the differentially expressed genes plotted 
by statistical significance (-log(padj)) as a function of fold change (log2(fold change)).94,95 
Thus, this plot highlights genes with different magnitudes of the fold change in the gene 
expression and the statistical significance of that fold change. The top 20 statistically 
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significant genes were prioritized for analysis and encoded cytokines and inflammatory 
proteins (CCL5, chemokine ligand 5; LAIR1, leukocyte associated immunoglobulin like 
receptor 1; LBP, lipopolysaccharide binding protein; TNIP3, TNF-α interacting protein 3, 
and CBF, complement factor B), which were higher in HCC1954 PTEN k.d. cells. 
Additionally, statistically significant genes encoded transporter proteins such as 
transmembrane protein TRAPPC10 and zinc transporter SLC39A8 and multidrug 
resistance associated protein 2, ABCC2. The k.d. of PTEN in HCC1954 appeared to 
upregulate inflammatory mechanisms, which was supported with findings from gene set 
enrichment analysis (GSEA). GSEA was performed to explore the global phenotypic 
differences between parental HCC1954 and HCC1954 PTEN k.d. cells. GSEA enabled 
the comparison of the differentially expressed genes between the HCC1954 cell line 
derivatives with predefined biologically relevant gene sets (obtained from the Molecular 
Signature Database, MSigDB.89 GSEA of HCC1954 PTEN k.d. cells identified 387 gene 
sets (padj < 0.05) and low enrichment scores for cell cycle gene sets (Figure 2.2C), which 
suggested that PTEN k.d. resulted in an increase of quiescent properties. Additionally, 
GSEA also revealed high enrichment scores for gene sets critical for inflammatory 
response, such as cytokines signaling and interleukin signaling; these GSEA findings 
were consistent with differentially expressed genes represented on the volcano plot for 
HCC1954 PTEN k.d. cells (Figure 2.2). Interestingly, GSEA for HCC1954 PTEN k.d. cells 
also revealed low enrichment scores for cell adhesion/cell junction gene sets and high 
enrichment scores for cell motility gene sets, which suggested a loss of cell adhesion and 
increase of cell motility as a result of PTEN k.d (padj < 0.05). It has been well documented 
that cytoskeletal dynamics are governed by cytokine signaling; inflammatory signaling 
could trigger changes to the actin fibrils of the cytoskeleton and ultimately impact 
mechanisms governing the cell’s motility and adhesion.96–101 In summary, k.d. of PTEN 
in HCC1954 resulted in a global increase of cytokines signaling and quiescence as 




Figure 2.2. Global Comparisons of Transcriptomic Composition of Parental HCC1954 and HCC1954 PTEN k.d. A) 
UMAP plot depicting parental HCC1954 (cyan) and HCC1954 PTEN k.d. (pink). Circled region denotes subpopulation 
enriched by PTEN k.d. cells. B) Volcano plot of differentially expressed genes by HCC1954 PTEN k.d. cells. Cells in 
red denotes statistically significant differentially expressed genes by HCC1954 PTEN k.d. cells (padj < 0.01). Top 20 
statistically significant genes are labeled. C) Gene sets identified by GSEA. Gene sets upregulated are denoted by 
positive normalized enrichment score (NES). Statistically significance is denoted by p-value adjusted by Benjamini-
Hochberg (BH) procedure (padj < 0.05). D) Heatmap of genes identified from GSEA. 
2.3.3. PTEN Deficiency in HCC1954 Resulted in an 84-Fold Enrichment of 
Quiescent, Epithelial Subpopulation 1 
 The subpopulations of HCC1954 were scrutinized to gain insight how the k.d. of 
PTEN affected the steady state of the subpopulations constituting HCC1954, which 
revealed six distinct subpopulations (Figure 2.3 and Figure 2.4A-B). The relative 
distribution of parental HCC1954 was the following: 35% subpopulation 0, 0.4% 
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subpopulation 1, 16% in subpopulation 2, 14% subpopulation 3, 27% subpopulation 4, 
and 8% subpopulation 5 (Figure 2.3B). After k.d. of PTEN, there was a dramatic shift in 
the relative distribution of HCC1954 cells, particularly in subpopulation 1, which increased 
by 84-fold (Figure 2.3B). HCC1954 PTEN k.d. cells consisted of 20% subpopulation 0 
(1.7 fold decrease), 33% subpopulation 1 (84 fold increase), 22% subpopulation 2 (1.4 
fold decrease), 14% subpopulation 3, 7.1% subpopulation 4 (3.8 fold decrease), and 2.5% 
subpopulation 5 (3.2 fold decrease). Notably, the relative proportion of cells in 
subpopulations 1, 4, and 5 underwent sizeable changes after PTEN k.d.; subpopulation 
1 increased by 84 fold, while subpopulations 4 and 5 decreased by 3 fold (Figure 2.3B). 
Since one of the aims of this dissertation was to elucidate the mechanisms by which 
PTEN deficiency altered the steady state subpopulations of HER2+ breast cancer cells, 
we analyzed the most upregulated genes from each subpopulation to gain an overview 
of the phenotype of each subpopulation. These analyses only yielded high expressing 
subpopulation-specific genes for subpopulations 3 and 5 (Figure 2.3B). The remaining 
subpopulations (0, 1, 2, 4) were characterized by a combination of decreased gene 
expression or heterogeneous gene expression within the subpopulation (Figure 2.3C). 
With these highly expressed genes, it was observed that subpopulation 3 (decreased 
after PTEN k.d.) exhibited inflammatory signaling based on the expression of chemokines 
CCL2, CXCL8, and CXCL3. The expression of these cytokines were at similar expression 
intensities in subpopulations 1 and 2, although not as homogenous, which suggested 
subpopulations 1 (increased by 84 fold) and 2 (decreased by 1.4 fold) also exhibited 
inflammatory signaling. Subpopulation 5 appeared to be very proliferative as evidenced 
by the high expression of genes critical for the cell cycle and proliferation (CENPF and 
MKI67) and cell transport (GSDMB, ATP1B1). While these analyses revealed highly 
expressing genes for subpopulations 3 and 5, they revealed subpopulation level 
characteristics, particularly for the subpopulations with sizeable changes in the relative 
cell proportions after k.d. of PTEN. These analyses suggested that subpopulation 1, 
which increased by 84 fold after k.d. of PTEN, exhibited intra-subpopulation heterogeneity 
with modest high expression of chemokines. Interestingly, subpopulation 4, which 
decreased by 3 fold after PTEN k.d., also exhibited intra-subpopulation heterogeneity and 
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was not characterized by any high expressing gene. Subpopulation 5, which also 
decreased by 3 fold after PTEN k.d., appeared to be a proliferative subpopulation.  
 
Figure 2.3. Overview of Six HCC1954 Subpopulations. A) UMAP depicting single cells organized into six HCC1954 
subpopulations. B) Cell proportions of each HCC1954 subpopulation. Relative percentage of cells existing in each 
subpopulation relative to the total number of cells in a given cell line is noted in parentheses. C) Heatmap depicting 
most upregulated genes per subpopulation. 
As observed previously, the analyses of upregulated genes in each subpopulation 
provided limited perspective to the subpopulation level changes induced by k.d of PTEN. 
All differentially expressed genes for each subpopulation were analyzed to characterize 
changes to the subpopulations after PTEN k.d. (i.e. subpopulations 1, 4, and 5). 
Characterization of the remaining HCC194 subpopulations are described in Section 2.3.3. 
Since subpopulation 1 had the largest subpopulation level change after PTEN k.d., we 
sought to identify genes differentially expressed by subpopulation 1 by comparing the 
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genes expressed by subpopulation 1 with the genes collectively expressed by the 
remaining clusters. This approach revealed 1,537 genes differentially expressed by 
subpopulation 1 and 119 statistically significant gene sets (padj < 0.05). Of these gene 
sets, relevant gene sets included cytokine activity and response, macromolecule 
catabolic process, and DNA replication (padj < 0.05). The cytokine signaling gene sets 
were positively enriched by subpopulation 1, suggesting high expression of inflammatory 
genes. Cell metabolism and cell cycle gene sets were negatively enriched in 
subpopulation 1, suggesting this subpopulation exhibited quiescent properties. The low 
quantity of relevant gene sets between subpopulation 1 and the remaining HCC1954 
subpopulations suggested transcriptomic similarities between these two groups of cells, 
which would decrease the statistical power to identify statistically significant gene sets. 
Based on the heatmap shown in Figure 2.3, it appeared as though subpopulation 3 might 
co-express genes found in subpopulation 1. The presence of subpopulation 3 in the 
analyses might confound the gene expression differences between subpopulation 1 and 
the rest of the HCC1954 subpopulations, especially since subpopulation 1 exhibited intra-
subpopulation heterogeneity in gene expression. Subpopulation 3 was removed from the 
differential gene expression analysis of subpopulation 1 compared with the remaining 
HCC1954 subpopulation to improve the statistical power to characterize subpopulation 1.  
DGE analysis was performed again to identify key transcriptomic differences 
between HCC1954 subpopulation 1 and subpopulations 0-5 (without subpopulation 3). 
This analysis revealed 1,166 statistically significant differentially expressed genes (padj 
< 0.01). Of these 1,166 genes, 407 genes were expressed significantly higher and 759  
genes were expressed significantly lower in HCC1954 subpopulation 1 (padj < 0.01, 
Figure 2.4C). The top 20 statistically significant genes encoded proteins that are heavily 
involved in DNA synthesis and repair (polymerase I and transcript release factor, PTRF; 
aurora kinase B, AURKB; mitotic checkpoint, BUB3; and DNA replication complex 
member, GINS). Other top 20 statistically significant genes encoded nuclear proteins 
(GRLX and EPAS), proteins involved in cellular/nucleic acid metabolism (thymidine 
phosphorylase, TYMP; monoamine oxidase A, MAOA), and proteins that regulate 
inflammatory response (complement factors, CFB and C1R; chemokine induced, 
ZC3H12A; and TNF-α interacting protein 3, TNIP3). Despite the statistical significance of 
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these differentially expressed genes, the fold change in their expression by subpopulation 
1 was less than 2-fold (Figure 2.4C). It was possible for different subpopulations to exhibit 
similar expression of genes, especially ones that are critical to cellular function (i.e. 
metabolism and genes associated with the cell cycle), which consequentially, decrease 
the fold change in gene expression exhibited by cells of subpopulation 1.  
GSEA identified revealed 295 statistically significant gene sets for subpopulation 
1 (padj < 0.05). Of these 295 statistically significant gene sets, low enrichment in gene 
sets for DNA replication, and mitotic spindle were observed, suggesting an arrest from 
cell cycle (padj < 0.05, Figure 2.4D). Scrutiny of these gene sets revealed significant low 
expression of regulators of the cell cycle, such as ubiquitins, which coordinate the cell 
cycle by timely degradation of cyclins during distinct phases of the cell cycle.102,103 These 
genes were expressed 1.5 fold lower in subpopulation 1 compared to the remaining 
HCC1954 subpopulations. Interestingly, the mTOR pathway was negatively enriched in 
subpopulation 1 relative to the other subpopulations (Figure 2.4D). The mTOR pathway 
is one of the pathways downstream of PI3K/AKT that governs cell growth and quiescence 
through the regulation of protein synthesis, transcription of cell cycle genes, and 
translation of cell cycle proteins.104,105 Scrutiny of the mTOR gene set revealed reduced 
expression of cell cycle genes such as RRM2, TUBA4A, CDKN1A, and MAP2K3 in 
subpopulation 1. Low expression of these genes due to the downregulation of the mTOR 
pathway would result in a reduction of cell cycle proteins and quiescent characteristics 
for this subpopulation. Furthermore, the low expression of these genes in subpopulation 
1 suggested that deficiency of PTEN might not always translate to increased mTOR 
signaling as suggested by the literature.53,69 It also provided insight why mTOR inhibitors 
have been clinically ineffective in HER2+ breast cancer patients with PTEN loss, showing 
that PTEN deficiency in HER2+ breast cancer could result in unique patient cohorts that 
require treatment options beyond the PTEN/AKT/PI3K pathway inhibitors. GSEA also 
yielded a significant low enrichment in the Myc target gene set (Figure 2.4D). Analysis of 
the Myc target gene set revealed significantly low expression of genes encoding 
ribosomal subunits (RPLP0, RNPS1, RPB55), metabolic proteins (lactate dehydrogenase 
LDHA), and regulators of the cell cycle (mitotic checkpoint BUB3, G2/M-associated cyclin 
B1, and ubiquitin UBE2C). The lowered expression of these Myc targets by 1.3 – 1.7 fold 
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in subpopulation 1 suggested that this subpopulation exhibited quiescent properties due 
to reduced cell cycle activity, metabolism, and protein synthesis. From the gene sets for 
DNA replication, mitotic spindle, and Myc target genes, BUB3, UBE2C, PCNA, and 
GINS4 were expressed lowest in HCC1954 subpopulation 1 compared to the other 
subpopulations (padj < 0.0001, Figure 2.4E), which were expressed 1.3 – 1.6 fold lower 
in subpopulation 1. While these genes are lowly expressed in subpopulation 1, these 
genes and other cell cycle associated genes were expressed in 4-40% of HCC1954 
subpopulation 1 cells (padj < 0.0001), which highlighted the intra-subpopulation 
heterogeneity present in this subpopulation. This intra-subpopulation heterogeneity gave 
rise to two groups of cells within subpopulation 1: a proliferative group and a quiescent 
group. Furthermore, the quiescent features of subpopulation 1 revealed by GSEA was 
consistent with the GSEA findings from the comparative transcriptomic analyses of 
HCC1954 PTEN k.d. cells and parental HCC1954 because the latter findings suggested 
that HCC1954 with PTEN k.d. exhibited increased quiescence. Since HCC1954 
subpopulation 1 enriched after PTEN k.d., it was likely that this subpopulation contributed 
to the increase of quiescent features observed in cells with PTEN k.d. Taken together, 
PTEN k.d. in HCC1954 resulted in a 84-fold increase in subpopulation 1 that exhibited 





Figure 2.4. Characterization of HCC1954 Subpopulation 1 Revealed Quiescent Properties. A) UMAP depicting single 
cells organized into six HCC1954 subpopulations. B) Cell proportions of each HCC1954 subpopulation. Red box 
emphasizes subpopulation 1, which increased by 84 fold after PTEN k.d. C) Volcano plot of differentially expressed 
genes by HCC1954 subpopulation 1. Cells in red denotes statistically significant differentially expressed genes by 
HCC1954 subpopulation 1 (padj < 0.01). Top 20 statistically significant genes are labeled. D) Gene sets identified by 
GSEA. Gene sets upregulated are denoted by positive normalized enrichment score (NES). Statistically significance is 
denoted by p-value adjusted by Benjamini-Hochberg (BH) procedure (padj < 0.05). E) Most differentially expressed 
genes identified from D. **** padj < 0.0001. 
2.3.4. HCC1954 Subpopulation 1 was Characterized by Heterogeneous Cytokine 
Signaling and Altered Cytoskeletal Dynamics 
In addition to the relatively quiescent features revealed by GSEA, these analyses 
also showed a positive enrichment in 11 gene sets associated with inflammatory 
response, such as and cytokine signaling, interleukin signaling, TNF-α signaling, defense 
response, and chemotaxis (Figure 2.5A). Evaluation of these gene sets revealed a slightly 
higher yet significant expression of the CCL and CXCL families of chemokines (CCL2, 
CCL20, CXCL3, CXCL8, Figure 2.5). These chemokines were expressed in 10-40% of 
HCC1954 subpopulation 1 cells but were expressed 1.7 fold higher than the levels from 
the other HCC1954 subpopulations. Additionally, cytokine responsive proteins such as 
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NFκB inhibitor, NFκBIA; NFκB subunit 2, NFκB2; serum glycocortocoid kinase, SGK1; 
TNF interacting protein, TNFAIP3; AP-1 family transcription factor, JUNB, and BIRC3, 
were also detected. These cytokine responsive proteins were expressed in 4-24% of 
HCC1954 subpopulation 1 and expressed 1.1 – 1.3 fold higher than cells of 
subpopulations 2 – 5 (padj < 0.0001). These encoded proteins, specifically JUNB and 
BIRC3, have been shown to be induced by IL-1β.106–110 The induction of these cytokines 
is expected in HER2-overexpressing breast cancer because the upregulated HER2 
signaling has been shown to stimulate a pro-inflammatory response characterized by 
NFκB and STAT3 signaling.111,112 SGK1, which has been shown to be induced by IL-6, is 
also a known downstream effector of AKT and has been reported to be critical for breast 
cancer bone metastasis.113–115 Additionally, it has been reported that the increase of 
NFκB signaling via TNF-α signaling upregulates the expression of anti-apoptotic proteins 
that degrades inhibitors to NFκB signaling (i.e. NFκBIA) as a means to facilitate cell 
survival during cell cycle arrest.116 This phenomenon could explain the enhanced cytokine 
signaling and overall quiescent property of HCC1954 subpopulation 1. Conversely, the 
increase of cytokines has been shown to inhibit the growth of breast cancer cells by 
preventing the G0/G1 transition.97 The expression of cytokines and inflammatory genes 
in a subset of HCC1954 subpopulation 1 cells highlighted the extent of heterogeneity 
within HCC1954. This intratumoral heterogeneity was exemplified at the subpopulation 
level since only a fraction of subpopulation 1 cells expressed genes associated to 
inflammatory signaling, while the remaining cells of this enriched subpopulation did not 
express those cytokines as a response to k.d. of PTEN. Interestingly, 15% of the genes 
featured in the inflammatory response gene sets were cytoskeletal proteins (such as 
integrins, actin ACTG2, vimentin VIM, and fibronectin FN1) and cell adhesion proteins 
(such as claudin CLDN1 and laminin LAMB3). The detection of these encoded 
cytoskeletal proteins within the inflammatory response gene sets suggested the presence 
of cytokine-mediated changes to the cytoskeleton of cells within HCC1954 subpopulation 
1 (Figure 2.5). This phenomenon was further supported by the positive enrichment of cell 
motility and extracellular matrix remodeling as well as a negative enrichment of cell 
adhesion gene sets, which further suggested that subpopulation 1 exhibited weakening 
cell adhesion and gain of cell motility features (Figure 2.5A). Among the genes featured 
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in the cell motility and adhesion gene sets included chemokines (CXCL8, CCL20, CXCL3, 
and CCL2) and genes regulating cell motility dynamics (Figure 2.5B). Interestingly, genes 
expressed lowest in cell motility and cell adhesion gene sets were genes encoding 
regulators of cell adhesion, such as tetraspanin CD9, actin depolymerizing protein coflin 
CFL1, cell adhesion laminin LAMB3, and Rho GTPase regulator of cell adhesion117, 
RHOC. These encoded cell adhesion proteins, specifically CD9, LAMB3, and RHOC were 
expressed in 5-20% of HCC1954 subpopulation 1 cells and were expressed 1.3 fold lower 
in HCC1954 subpopulation 1, while actin depolymerizing protein cofilin was expressed in 
48% of subpopulation 1 and expressed 1.4 fold lower. The decreased expression of these 
cell adhesion regulators and high expression of chemokines in subpopulation 1 
suggested a deregulation of cell adhesion dynamics that was coordinated by increased 
cytokine signaling.  
 
Figure 2.5. Enrichment of Cytokine Signaling, Cell Motility, and Cell Adhesion Suggested Altered Cytoskeletal 
Dynamics in HCC1954 Subpopulation 1. A) Gene sets involved in inflammatory response, cell motility, and cell 
adhesion were identified by GSEA. Statistically significance is denoted by p-value adjusted by Benjamini-Hochberg 
(BH) procedure (padj < 0.05). B) Differentially expressed genes by subpopulation 1 identified by gene sets in A. Top 
chemokines and regulators of cell adhesion and cell motility dynamics are represented. * padj < 0.05, **** padj < 0.0001. 
2.3.5. HCC1954 Subpopulation 1 Exhibited Mixed Expression of Epithelial and 
Mesenchymal Markers, Hinting an Epithelial, Early EMT Phenotype 
This weakened cell adhesion due to the low expression of epithelial adhesion 
proteins and the positive enrichment of cell motility gene sets by GSEA suggested 
HCC1954 subpopulation 1 harbored an epithelial early EMT phenotype. The hallmark of 
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epithelial cells is cell-cell adhesion between epithelial cells, which is ensured by adherens 
junctions, tight junctions, and desmosomes in the cytoskeletons of epithelial cells.118,119 
Proteins belonging to the claudin family and occludins are critical for maintaining tight 
junctions.118–120 Cadherins, specifically E-cadherin (encoded by CDH1), is responsible for 
the integrity of adherens junctions.118–120 Lastly, desmoplakins are key proteins for 
maintaining the cell-cell adhesions via desmosomes.118–120 The epithelial cytoskeleton 
boasts of structural proteins known as keratins.118–121 Keratins constitute the filaments of 
the cytoskeletons of epithelial cells, which support the apico-basal polarity established by 
these cells.118–121 Together, these cytoskeletal components orchestrate the maintenance 
of the cell-cell adhesion between epithelial cells, and these epithelial characteristics are 
lost during EMT.118–120 In HCC1954, eepithelial cell adhesion molecule EPCAM and 
epithelial cadherin CDH1, were detected, but the expression of CDH1 was limited to a 
subset of subpopulation 1 cells (Figure 2.6A). In comparison to the other subpopulations, 
the expression of EPCAM and CDH1 was not significantly different from the levels 
expressed by the remaining HCC1954 subpopulations (Figure 2.6A). The reduction of 
these markers have been regarded as the initial molecular switch to a mesenchymal 
phenotype.120 Additionally, it has been reported that different epithelial markers are lost 
during distinct stages of EMT.120 Keratins KRT14, KRT5, and KRT8 are maintained until 
late stages of EMT, while EPCAM and E-cadherin have been reported to be lost during 
the early EMT stages.120 Consistent with the temporal parameter for EMT, epithelial 
keratins (KRT7, KRT8, KRT17, KRT18) were expressed in 41-63% of HCC1954 
subpopulation 1 and were expressed 1.2 fold lower in subpopulation 1 compared to 
remaining subpopulations (Figure 2.6A). Cell adhesion proteins such as claudins 
(CLDN1, CLDN4, and CLDN7) were detected in up to 32% of subpopulation 1 and were 
expressed 1.2 fold lower than subpopulations 2 – 5 (Figure 2.6A). Other structures critical 
for epithelial cell adhesion, such as tight junction proteins (TJP1, aka ZO-1, and TJP3) 
and syndecan (SDC4 and SDCBP2) were detected in less than 15% of subpopulation 1. 
Additional cell adhesion molecules, such as ICAM, CEACAM1, CEACAM6 and BCAM, 
were also detected in less than 10% of HCC1954 subpopulation 1, which emphasized 
that the majority of subpopulation 1 cells did not express these cell adhesion properties. 
Furthermore, the expression of transcription factors that regulate epithelial genes 
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(GRHL1-3 and OVOL-1) and known epithelial marker MUC1 were not detected in this cell 
line. The high expression of epithelial structural proteins and low expression of cell 
adhesion markers suggested subpopulation 1 cells exhibited an epithelial phenotype with 
weakening cell adhesion and therefore, an early EMT hybrid phenotype.  
To further support the epithelial early EMT hybrid phenotype, markers associated 
with EMT and the mesenchymal phenotype were investigated. Genes of interest included 
activators of EMT (such as MKI67, β-catennin, WNT signaling, and TGF-β signaling) and 
regulators of extracellular matrix interactions (such as fibronectin FN1, plasminogen 
activator PLAUR, tumor necrosis factor receptor TNFRSF12A, insulin growth factor 
binding protein IGFBP3, and S100 family protein S100A7).98,117–120,122–125 All of these 
proteins contribute to development of mesenchymal phenotype through the 
reorganization of the extracellular matrix, weakening of epithelial cell adhesion, an 
increase of cell motility, and an increase of invasion characteristics.98,117–120,122–125 These 
markers, specifically TNFRSF12A, FN1, PLAUR, IGFBP3, and MKI67 were expressed in 
7-36% of HCC1954 subpopulation 1, while S100A7 was expressed in 84% of HCC1954 
subpopulation 1 (Figure 2.6B). Interestingly, the expression of S100A7 has been reported 
to promote breast cancer progression through cytokine signaling and reported to correlate 
with HER2-overexpressing high grade tumors.124–128 Thus, the high expression of 
S100A7 might be a reflection of its compounding signaling cascades in HCC1954. In 
addition to S100A7, subpopulation 1 expressed other S100 proteins that have been 
shown to be involved in reorganization of the extracellular matrix, such as S100A4, 
S1008, and S100A9.124,129,130 TNF-α receptor superfamily member TNFRSF12A was 
detected in 16% of subpopulation 1 cells and expressed 1.5 fold higher than the cells of 
the other subpopulations (Figure 2.6B). Detection of this gene was particularly interesting 
because its expression level has been correlated with the overexpression of matrix 
metallopeptidase MMP9 in progressive breast cancer and thus been regarded as a 
prognostic marker for poor patient survival.98 Despite the expression of genes involved in 
regulating the epithelial cytoskeleton and signaling that facilitate EMT, classical EMT 
transcription factors, such as TWIST1/2, SNAIL, SLUG, ZEB1/2, were not detected. The 
lack of expression of these EMT transcription factors suggested that a full EMT program 
was not activated. Consistent with this insight, expression of mesenchymal-specific 
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cytoskeletal proteins, such as N-cadherin and vimentin, and proteins that facilitate 
extracellular matrix degradation (MMP9 and MMP19) were not detected. Taken together, 
the expression of epithelial cytoskeletal proteins, low expression of proteins that maintain  
epithelial cell adhesion, and the low expression of proteins that promote EMT suggested 
that subpopulation 1 represented epithelial cells with weakened cell adhesion and thus, 
harbored an epithelial early EMT hybrid phenotype.   
 
Figure 2.6. Mixed Expression of Epithelial and Mesenchymal Markers by HCC1954 Subpopulation 1. A) Epithelial 
markers and B) Mesenchymal markers detected in HCC1954 Subpopulation 1. Asterisks denote statistical significance 
of gene expression by subpopulation 1 cells relative to remaining HCC1954 subpopulations. *** padj < 0.001, **** padj 
< 0.0001. 
2.3.6. PTEN k.d. in HCC1954 Slightly Increased Heterogeneity in Expression of 
Select Epithelial and Mesenchymal Markers 
The scrutiny of epithelial and mesenchymal markers not only revealed an 
epithelial, early EMT phenotype for subpopulation 1, but also hinted that PTEN k.d. in 
HCC1954 introduced additional intratumoral heterogeneity for remaining subpopulations 
(Figure 2.7). PTEN k.d. did not cause significant changes in the expression of key 
epithelial markers, EPCAM and CDH1. In all of the subpopulations, the expression of 
epithelial keratins and claudins was lower in cells with PTEN k.d., but that difference was 
not statistically significant. In subpopulation 2, PTEN k.d. cells exhibited 1.4 fold lower 
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expression in CLDN1 compared to parental subpopulation 2 (Figure 2.7A). Additionally, 
subpopulation 4 PTEN k.d. cells expressed adhesion proteins, TJP1 and SDC4, 1.1 and 
1.4 folder lower than parental subpopulation 4, respectively (padj < 0.0001, Figure 2.7A). 
Interestingly, within subpopulations 2, 3, and 5, the expression of S100A7 was expressed 
1.2 – 1.3 fold higher in PTEN k.d. compared to the parental subpopulation (padj < 0.0001, 
Figure 2.7B). The expression of S100A7 has been linked to cell motility, invasion, loss of 
cell adhesion by stimulating pro-inflammatory response in breast cancer.125,126,128,129 
Furthermore, expression of various S100 proteins, including S100A7, have been 
correlated with poor overall survival and reduced relapse free survival in breast cancer 
patients.124,129 Additionally, PTEN k.d. cells in subpopulation 0 and 2 expressed 1.2 fold 
higher levels of FN1 (fibronectin) compared to parental subpopulations (Figure 2.7B). In 
subpopulation 5, PTEN k.d. cells also expressed FN1 1.2 fold higher than parental cells, 
but this difference was not statistically significant. Taken together, this data hinted that 
PTEN k.d. increased intratumoral heterogeneity due to the decreased expression of tight 
junction proteins and increased expression of select mesenchymal markers in PTEN k.d. 
cells compared to parental cells of certain subpopulations.  
 
Figure 2.7. PTEN k.d. Exerted Intra-Subpopulation Heterogeneity in Expression of Subset of Genes. A) Epithelial 
markers and B) Mesenchymal markers detected in HCC1954 subpopulation 1. Asterisks denote statistical significance 
of gene expression by subset of cells with PTEN k.d. relative to parental subpopulation. Italicized and underlined gene 
names are ones where gene expression was significant between PTEN k.d. cells compared with parental 
subpopulation. * padj < 0.05, *** padj < 0.001, **** padj < 0.0001. 
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2.3.7. PTEN k.d. Increased Intra-Subpopulation Heterogeneity of Remaining 
HCC1954 Subpopulations 
In addition to the changes to subpopulation 1, PTEN k.d. also altered relative 
subpopulation proportions of the remaining subpopulations. Namely, the relative 
subpopulation distribution of subpopulations 4 and 5 decreased by 3.2 fold after PTEN 
k.d. Characterization of these subpopulations by DGE and GSEA revealed both of these 
subpopulations were significantly enriched in cell adhesion, cell motility, and cytokine-
mediated cell motility gene sets (Figures 2.8 and 2.9). HCC1954 cells from subpopulation 
4 exhibited positive enrichment for cell adhesion gene sets and negative enrichment for 
cell motility gene sets (Figure 2.8A). Scrutiny of the cell adhesion gene sets revealed high 
expression of regulators of cell adhesion, such as CLDN8, NRP1, and FERMT1, which 
were expressed in 35-60% of subpopulation 4 cells. Interestingly, subpopulation 4 also 
revealed decreased expression of other known regulators of cell adhesion and epithelial 
polarity, such as ICAM1, AQP3, and DSC2. Furthermore, analyses of cell motility gene 
set revealed low expression of mediators of cell-extracellular matrix interactions, such as 
integrins (ITGB8 and ITGA2), collagen (COL16A1), fibroblast growth factor proteins 
(FGFBP2). In addition, the expression of chemokines (CXCL8, CXCL3, CXCL2, CXCL17) 
and cytokine modulators (SAA1 and SAA2) were low in subpopulation 4, suggesting the 
lack of cytokine-mediated cell motility within subpopulation 4 as a whole. Interestingly, 
within subpopulation 4, cells with PTEN k.d. exhibited higher cytokine signaling as 
evidenced in the significantly higher expression of chemokines and cytokine modulators 
(CXCL8, SAA1, SAA2; Figure 2.8B). Furthermore, subpopulation 4 PTEN k.d. cells also 
exhibited higher levels of integrins (ITGB8 and ITGA2) and collagen (COL16A1 and 
COL4A3BP) compared to parental subpopulation 4. The increased expression of these 
proteins suggested elevated cell-extracellular matrix interactions, which is an important 
prerequisite for gaining cell motility properties. Based on these observations, it appeared 
that PTEN k.d. in subpopulation 4 might facilitate the increase of cytokine expression and 
the acquisition of cell motility among the subset of subpopulation 4 cells with PTEN 
deficiency. Interestingly, certain epithelial adhesion protein, such as claudins (CLDN 7 
and CLDN8), aquaporin (AQP3), desmocolin (DSC2), were expressed 1.2 fold higher in 
PTEN k.d. cells compared to parental subpopulation 4. Moreover, PTEN k.d. cells 
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exhibited decreased expression of other known regulators of epithelial adhesion and 
polarity, such as SDC4, SDCBP, TSPAN1, ENAH, GSN, and ATP1B1, compared to 
parental subpopulation 4 (padj <0.05). PTEN k.d. in subpopulation 4 distinctively 
expressed survivin (BIRC5), which is linked to escaping apoptosis (padj < 0.0001, Figure 
2.8B). Other genes that were expressed selectively in the PTEN k.d. cells and not parental 
subpopulation 4 included PRC1 and matricellular protein CNN3 (Figure 2.8B). The slight 
but significant alterations in expression of these cell adhesion and cell motility proteins 
among subpopulation 4 cells with PTEN k.d. suggested a gain of cell motility properties 
as a result of PTEN k.d.  
 
Figure 2.8. HCC1954 Subpopulation 4 Exhibited Increased Heterogeneity with PTEN Deficiency. A) Statistically 
significant genes sets identified for subpopulation 4 by GSEA. Statistically significance is denoted by p-value adjusted 
by Benjamini-Hochberg (BH) procedure (padj < 0.05). B) Differentially expressed genes by subpopulation 4 identified 
by gene sets in A. Genes involved with cytokine signaling and cell growth are represented. Top: expression of genes 
shown for HCC1954 subpopulations with asterisk to denote statistical significance of gene expression in subpopulation 
4 relative to remaining HCC1954 subpopulations. Bottom: expression of genes evaluated in parental cells and PTEN 
k.d. cells of each subpopulation with asterisks to denote statistical difference in gene expression between subpopulation 
4 cells with PTEN k.d. compared to parental subpopulation 4. * padj < 0.05, **** padj < 0.0001. 
Besides subpopulation 4, subpopulation 5 also decreased by 3.2 fold after k.d. of 
PTEN. This subpopulation appeared to be largely quiescent due to the negative 
enrichment scores for gene sets for mitosis, DNA replication, and G1/S checkpoints, but 
consisted a subset of cycling cells (Figure 2.9A). The cycling phenotype of subpopulation 
5 was evidenced by the expression of relatively high expression of genes critical to the 
G2/M transition, such as WEE1, PCNA, MKI67, and ASPM. HCC1954 subpopulation 5 
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was also enriched in gene sets for cell adhesion, apical cell interactions, and extracellular 
matrix interactions (Figure 2.9A). Analysis of these gene sets revealed expression of 
proteins that mediate interactions with the extracellular matrix, such as ankryins 
(ANKRN36C and ANKYRN36), integrins (ITGB8, ITGB2), and fibronectin (FN1). These 
markers were expressed in greater than 70% of subpopulation 5 cells, which suggested 
the occurrence of cytoskeletal remodeling in these cells. Despite the expression of 
regulators of extracellular matrix interactions, genes encoding cell adhesion proteins 
(CLDN8, TJP3, BCAM, CEACAM) were also detected in 20-50% of subpopulation 5 cells. 
Analysis of consequences of PTEN k.d. in subpopulation 5 revealed enhanced cytokine 
signaling compared to parental subpopulation 5. Cells with PTEN k.d. exhibited 1.8 fold 
higher expression of cytokines (CCL20, CXC3CL1, CFB, NFKB2), although these 
markers were expressed in 10-20% of subpopulation 5 cells with PTEN k.d. Additionally, 
PTEN k.d. cells within subpopulation 5 also exhibited 1.3 and 1.8 fold increase in 
expression of integrins ITGB2 and ITGB8, respectively, when compared to parental 
subpopulation 5. Furthermore, PTEN k.d. resulted in a gain of quiescent features due to 
a 2 fold reduction in expression of cycling markers (PCNA, ACTN1, TUBB4B, Figure 
2.9B). These cycling markers were only detected in parental subpopulation 5 and not in 
the subset of subpopulation 5 cells with PTEN k.d (Figure 2.9B). Actins (ACTN1, 
ACTNG2, ACTR3, ATNR3C) were also reduced in subpopulation 5 PTEN k.d. compared 
to parental subpopulation 5, suggesting altered cytoskeletal actin dynamics. These 
changes to the cytoskeleton of subpopulation 5 PTEN k.d. cells coincides with the slight 
but significant increase in integrins and cytokines in these PTEN k.d. cells. It has been 
shown that these coupled changes cooperate to modulate actin dynamics and cell 
motility.96,100,101 Taken together, PTEN k.d in subpopulation 5 introduced intra-
subpopulation heterogeneity by increasing cytokine signaling and quiescence and by 




Figure 2.9. HCC1954 Subpopulation 5 Exhibited Increased Quiescence with PTEN Deficiency. A) Statistically 
significant genes sets identified for subpopulation 5 by GSEA. Statistically significance was denoted by p-value adjusted 
by Benjamini-Hochberg (BH) procedure (padj < 0.05). B) Differentially expressed genes by subpopulation 5 identified 
by gene sets in A. Genes involved with cell growth are represented. Top: expression of genes shown for HCC1954 
subpopulations with asterisk to denote statistical significance of gene expression in subpopulation 5 relative to 
remaining HCC1954 subpopulations. Bottom: expression of genes evaluated in parental cells and PTEN k.d. cells of 
each subpopulation with asterisks to denote statistical difference in gene expression between subpopulation 5 cells 
with PTEN k.d. compared to parental subpopulation 5. * padj < 0.05, ** padj < 0.01. 
Changes to the relative proportions of subpopulations 0, 2, and 3 were also 
observed, although those subpopulations changed by approximately 1.2 fold after k.d. of 
PTEN. While the changes in steady states of these subpopulations were not as dramatic 
as subpopulation 1, DGE analysis and GSEA that these subpopulations, particularly 2 
and 3, enriched inflammatory signaling (Figure 2.10). In subpopulation 2, enhanced 
inflammatory signaling was evident by the high expression of SERPINB3, S100 proteins, 
and S100A7, which was expressed in approximately 90% of subpopulation 2 cells and 
expressed 1.5 fold higher than cells from other HCC1954 subpopulations. In 
subpopulation 3, the increased cytokine signaling was shown by elevated expression (1.5 
– 3.5 fold) of inflammatory molecules (Figure 2.10). These inflammatory proteins included 
CCL2, CCL20, CXCL2, CXCL3, CXCL8, SERPINB3/4, S100 proteins, SAA1/2, NFKBIA, 
and IFI27, which were expressed in 50-90% of subpopulation 3 cells (Figures 2.8 and 
2.10). Between these two subpopulations, subpopulation 3 exhibited greater 
inflammatory signaling compared to subpopulation 2, which demonstrated by the higher 
expression (2 fold) of cytokines in subpopulation 3 compared to subpopulation 2 (CCL2, 
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CCL20, CXCL3, CXCL8; Figures 2.8 and 2.10). Interestingly, within subpopulations 2 and 
3, cells with PTEN k.d. expressed higher levels of cytokines compared to parental 
subpopulations 2 and 3 (Figure 2.10). Increased cytokine signaling in subpopulation 2 
PTEN k.d. cells was exemplified by the elevated expression of CCL2, CXCL2, CXCL3, 
SAA1/2, S100A7A, TNIP3, TNFSF10, and SERPINB3/4, which expressed 1.5 – 1.7 fold 
higher compared to parental subpopulation 2 (padj < 0.01). In subpopulation 3, increased 
cytokine signaling for PTEN k.d. cells relative to parental subpopulation 3 was validated 
with the slightly elevated expression of SERPINE2, CCL2, CCL5, CCL28, LBP, S100A7A, 
CXCL5, and IL22RA2 (padj < 0.01). Despite the significantly higher expression of 
cytokines PTEN k.d. cells from subpopulations 2 and 3, these cytokines were expressed 
in 10-40% of these cells (padj < 0.01), which highlighted the heterogeneity in inflammatory 
signaling introduced to subpopulations 2 and 3 as a result from k.d of PTEN. In addition 
to cytokine signaling, both subpopulations 2 and 3 were enriched in cell adhesion and cell 
motility gene sets (Figure 2.10). In subpopulation 2, genes governing epithelial cell 
adhesion were detected and included keratins, syndecans, claudins, and regulator of 
epithelial polarity ATP1B1 (padj < 0.01). Of these proteins, KRT15, SDC3, and ATP1B1 
were expressed approximately 1.3 fold higher in subpopulation 2 compared to the other 
subpopulations (padj < 0.01). Genes that regulate cell motility and interactions with the 
extracellular matrix were also detected in 60-90% of subpopulation 2 cells (padj < 0.01). 
These proteins included S100 proteins (S100A7, S100A8, S100A9, S100A11, S100P), 
collagen COL4A3BP, and insulin growth factor IGFBP3, which were expressed 1.2 – 2.2 
fold higher in subpopulation 2 compared to the other subpopulations (padj < 0.01). 
Subpopulation 2 cells with PTEN k.d. were also enriched in cell motility gene sets and 
had slightly increased expression of integrins (ITGB2 and ITGB6) and fibronectin (padj < 
0.01). Interestingly, the expression of FN1 and ITGB6 was detected only in PTEN k.d. 
cells of subpopulation 2 (padj < 0.01, Figures 2.8 and 2.10), which possibly hinted that 
PTEN k.d. enhances cell motility features through the expression of additional regulators 
of extracellular matrix interactions. Additionally, expression of ITGB6 was slightly yet 
significantly higher in subpopulation 3 than subpopulation 2 (padj < 0.0001, Figure 2.10B). 
Importantly, k.d. of PTEN in subpopulation 2 resulted in a slight but significant decrease 
in members of the claudin family (CLDN1 and CLDN8) by 1.4 and 1.2 fold, respectively, 
62 
 
compared to parental subpopulation 2, which suggested a decrease of epithelial 
character (padj < 0.01; Figure 2.8). For subpopulation 3, syndecans (SDCBP, SDCBP2, 
and SDC4), EPCAM, claudins (CLDN1, CLDN4, CLDN7), keratins (KRT7, KRT8, KRT17, 
and KRT18), and regulators of epithelial polarity (ATP1B1 and RHOC) were detected in 
60-90% of subpopulation 3 cells (padj < 0.01). Of these epithelial features, syndecans, 
ATP1B1, and RHOC were expressed 1.2 – 1.4 fold higher in subpopulation 3 compared 
to the other subpopulations (padj < 0.01). Additionally, subpopulation 3 cells also 
expressed markers of cell motility such as MGP, S100A1, S100A8, and S100A9 that 
were1.2 – 2 fold higher compared to other subpopulations (padj < 0.01). Analysis of PTEN 
k.d. in subpopulation 3 revealed slight changes to cell adhesion and cell motility markers, 
such as the 1.2 fold increase in expression of ITGB2 and ACTG2 compared to parental 
subpopulation 3 (padj < 0.01, Figure 2.10D). Tyrosine kinase NTRK2 was expressed in 
12% of subpopulation 3 PTEN k.d. cells and 1.1 fold higher compared to parental 
subpopulation 3 (padj < 0.01). Elevated expression of this protein has been shown to 
coordinate with PTEN deficiency to upregulate JAK and PI3K/AKT signaling in leukemia 
cells, which have some relevance in HER2-overexpressing breast cancer.131 Taken 
together, subpopulations 2 and 3 were characterized by relatively high cytokine signaling 
and expression of genes critical to regulating cell adhesion. Analysis of PTEN k.d. in these 
subpopulations revealed slightly higher cytokine signaling and deregulation of cell 
adhesion in PTEN k.d. cells compared to parental subpopulations 2 and 3. The collective 
expression of cytokine signaling and deregulated cell adhesion suggested increased 
levels of cytokines contribute to a feedback loop that altered cell adhesion dynamics. 
Based on the evaluation of subpopulation 2, subpopulation 3, and the effects of PTEN 
k.d. within these subpopulations, it appeared that PTEN deficiency enriched for 
phenotypes already present in these subpopulations (i.e. high cytokine signaling and 
deregulated cell adhesion). Lastly, subpopulation 0 was characterized by low cytokine 
signaling and modest levels of cell cycle genes. Analysis of effects of PTEN k.d. in 
subpopulation 0 did not reveal any significant gene set that distinguished subpopulation 




Figure 2.10. PTEN k.d. in Subpopulations 2 and 3 Stabilized Existing Phenotypes. Statistically significant genes sets 
identified for A) subpopulation 2 and C) subpopulation 3 by GSEA. Statistically significance was denoted by p-value 
adjusted by Benjamini-Hochberg (BH) procedure (padj < 0.05). Differentially expressed genes by B) subpopulation 2 
and D) subpopulation 3. Top: expression of genes shown for HCC1954 subpopulations with asterisk to denote statistical 
significance of gene expression in subpopulation 2 relative to remaining HCC1954 subpopulations. Gene expression 
differences between subpopulation 2 and 3 are also noted with asterisks. Bottom: expression of genes evaluated in 
parental cells and PTEN k.d. cells of each subpopulation with asterisks to denote statistical difference in gene 
expression between subpopulation 2 cells with PTEN k.d. compared to parental subpopulation 2. For subpopulation 3, 
on left, expression of genes shown for HCC1954 subpopulations with asterisk to denote statistical significance of gene 
expression in subpopulation 3 relative to remaining HCC1954 subpopulations. On right, expression of genes evaluated 
in parental cells and PTEN k.d. cells of each subpopulation with asterisks to denote statistical difference in gene 
expression between subpopulation 3 cells with PTEN k.d. compared to parental subpopulation 3. * padj < 0.05, ** padj 
< 0.01, *** padj < 0.001, **** padj < 0.0001. 
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2.3.8. PTEN k.d. in SKBR3 Resulted in Global Increase of Quiescent Properties 
Relative to Parental SKBR3 
The effects of PTEN k.d. were evaluated for SKBR3 using similar approaches as 
described for HCC1954. Similar to HCC1954, the SKBR3 cell line pair consisted of cells 
with comparable transcriptomic profiles, as evidenced by the overlap between the cells 
with SKBR3 PTEN k.d. cells and parental SKBR3 (Figure 2.11A). Also akin to HCC1954, 
SKBR3 harbored a subpopulation that was exclusively found in SKBR3 PTEN k.d. cells 
(circled in Figure 2.11A). DGE analysis identified 992 differentially expressed genes (padj 
< 0.01). Of these, 515 genes were higher, and 477 genes were lower in SKBR3 PTEN 
k.d. cells relative to parental SKBR3 (Figure 2.11B, padj < 0.01). GSEA of these 
differentially expressed genes revealed only 16 statistically significant gene sets, which 
included the cancer gene neighborhoods of cyclin A2 (CCNA2), cell-division protein 20 
(CDC20), and mitotic checkpoint gene encoding for BUB1B (padj < 0.01, Figure 2.11C). 
Despite the low quantity of statistically significant gene sets between parental SKBR3 and 
SKBR3 PTEN k.d. cells, the low expression of gene sets associated with the cell cycle 





Figure 2.11. Global Comparisons of Transcriptomic Composition of Parental SKBR3 and SKBR3 PTEN k.d. A) UMAP 
plot depicting parental SKBR3 (cyan) and SKBR3 PTEN k.d. (pink). Circled region denotes subpopulation enriched by 
PTEN k.d. cells. B) Volcano plot of differentially expressed genes by SKBR3 PTEN k.d. cells. Cells in red denotes 
statistically significant differentially expressed genes by SKBR3 PTEN k.d. cells (padj<0.01). Top 20 statistically 
significant genes are labeled. C) Gene sets identified by GSEA. Statistically significance is denoted by p-value adjusted 
by Benjamini-Hochberg (BH) procedure (padj < 0.01). 
2.3.9. PTEN Deficiency in SKBR3 Resulted in 120-Fold Enrichment of Quiescent, 
Early EMT Subpopulation 1 
Since GSEA suggested a global increase of quiescent properties resulting from 
PTEN deficiency, we analyzed the effects of PTEN k.d. on the subpopulations of SKBR3 
to reveal the phenotype PTEN deficiency favored. Nonlinear dimensionality reduction 
using UMAP revealed the intratumoral heterogeneity of SKBR3, which was manifested 
as six subpopulations (Figure 2.12A). Parental SKBR3 was distributed into 37% 
subpopulation 0, 0.3% subpopulation 1, 24% subpopulation 2, 12% subpopulation 3, 15% 
subpopulation 4, and 9% subpopulation 5 (Figure 2.12B). As shown in Figure 2.12B, 
PTEN in SKBR3 altered the cellular composition of the bulk cell line, resulting in 23% 
subpopulation 0 (1.5 fold decrease), 44% subpopulation 1 (120 fold increase), 23% 
subpopulation 2, 7.5% subpopulation 3 (1.6 fold decrease), 0.8% subpopulation 4 (18 fold 
decrease), and 0.4% subpopulation 5 (24 fold decrease). Interestingly, PTEN k.d. in 
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SKBR3 drastically enriched a minor subpopulation (i.e. subpopulation 1) akin to 
HCC1954. 
To elucidate the phenotype of SKBR3 subpopulation 1, DGE and GSEA was 
performed by comparing subpopulation 1 to the rest of the subpopulations. This analysis 
yielded 1,154 differentially expressed genes and 9 statistically significant gene sets, most 
of which were involved in the electron transport chain (padj < 0.05). The low quantity of 
statistically significant gene sets implied extensive transcriptomic similarities between the 
compared subpopulations, which limited the statistical power of GSEA to identify 
statistically significant gene sets. As an alternative method to characterize SKBR3 
subpopulation 1, we compared this subpopulation with subpopulations that were farthest 
on the UMAP plot (i.e. subpopulations where the transcriptomic difference between 
subpopulation 1 was greatest). By comparing these subpopulations (i.e. subpopulations 
0 and 3) with subpopulation 1, DGE analysis revealed 1,199 genes differentially 
expressed by subpopulation1, despite their low fold change in gene expression (Figure 
2.12C). Of these 1,199 differentially expressed genes, 440 genes were expressed higher, 
and 759 were expressed lower in subpopulation 1 (Figure 2.12C, padj < 0.01). Scrutiny 
of these genes by evaluating the top 20 statistically significant genes revealed 
commonalities (Figure 2.12C, padj < 0.01). The top 20 statistically significant genes 
encoded proteins that are critical for cell cycle (haus augmin like subunit 2, HAUS; BUB1B 
mitotic checkpoint serine/threonine kinase B, BUB1B; and replication factor C subunit 3, 
RFC3) and microtubule function (tubulin gamma 1, TUBG1; centromere protein J, 
CENPJ; establishment of sister chromatid cohesion N-acetyltrasferase, ESCO2; dual 
specificity protein kinase, TTK; and shugoshin like 1, SGOL1). Additionally, top 
statistically significant genes also encoded proteins involved in nucleic acid metabolism 
(non-SMC condensing matrix, NCAPG and cyclic nucleotide phosphodiesterase, CNP) 
and cellular metabolism (acetolactate synthase, ILVCL and carbonyl reductase, CBR3). 
These top 20 statistically significant genes were associated with cell cycle and were 
expressed in SKBR3 subpopulation 1, which hinted of a quiescent phenotype for this 
subpopulation. GSEA revealed 794 statistically significant gene sets for subpopulation 1 
(padj < 0.01). SKBR3 subpopulation 1 was negatively enriched in cell cycle associated 
gene sets, which further supported the quiescent phenotype suggested from the analysis 
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of the top statistically significant genes (Figure 2.12D and E). Additionally, GSEA 
suggested SKBR3 subpopulation 1 harbored an epithelial phenotype as evidenced by the 
positive enrichment of gene sets associated with biological adhesion (Figure 2.12D). 
Additionally, this subpopulation exhibited a positive enrichment in cytokine signaling, 
specifically TNF-α signaling. Scrutiny of the gene sets was performed to determine what 
genes contributed to these enrichment scores and to validate the quiescent epithelial 
phenotype of SKBR3 subpopulation 1 as suggested by GSEA.  
 
Figure 2.12. Single Cell Analysis of SKBR3 Subpopulations and Characterization of Subpopulation that Enriched After 
PTEN k.d. Subpopulation 1. A) UMAP plot depicting six SKBR3 subpopulations. Dots represent single cells. 
Subpopulations are organized by color. B) Cell Distribution using the same color scheme as shown in A. C) Volcano 
plot depicting genes differentially expressed by SKBR3 subpopulation 1. Grey dots represent genes with a log2FC that 
is not statistically significant. Red dots represent genes with a log2FC that is statistically significant. Statistical 
significance is denoted by p.adj < 0.01. C) Gene sets enriched by SKBR3 subpopulation 1. Normalized enrichment 
score (NES) and FDR (false discovery rate) adjusted p-values are displayed. FDR < 0.01 denotes statistical 
significance. D) Heatmap of gene sets from C. Colored scale represents normalized gene expression for each gene. 
To validate the quiescent phenotype, cell cycle associated gene sets identified by 
GSEA were scrutinized. These gene sets included DNA replication, DNA repair, G2/M 
checkpoints, chromatin binding, and DNA metabolism, which were all negatively enriched 
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by SKBR3 subpopulation 1 and supported the quiescent phenotype of subpopulation 1 
(Figure 2.13A). Furthermore, targets of E2F and the DREAM complex were also 
expressed lower in SKBR3 subpopulation 1, which supported the quiescent phenotype of 
this subpopulation since targets of E2F and the DREAM complex are repressed in 
quiescent cells.132–134 Analysis of the E2F and DREAM targets gene sets revealed 74 
genes expressed higher and 218 genes expressed lower in subpopulation 1. Among 
these high expressing genes was FOS, which was expressed in 31% of SKBR3 
subpopulation 1 and expressed 1.4 fold higher (Figure 2.13A, padj < 0.01). The other 
genes with elevated expression in subpopulation 1 were expressed in less than 10% of 
subpopulation 1 (padj < 0.01). Among genes that were expressed lower in subpopulation 
1 were genes associated with proliferation, such as helicase HELLS, MKI67, and geminin 
GMNN, which expressed in 7-31% of subpopulation 1 genes and expressed in 1.2 – 1.5 
fold lower in SKBR3 subpopulation 1 (Figure 2.13B, padj < 0.01). In addition, the analysis 
of these genes revealed members of the PRC2 complex, such as EZH2 and RbBP8, 
which were expressed in 20% and 85% of subpopulation 1, respectively (Figure 2.13B, 
padj < 0.01). EZH2 and RbBP8 were detected 1.2 and 1.3 fold lower in subpopulation 1 
compared to other SKBR3 cells (both padj < 0.0001). Decreased expression of PRC2 
members has been shown to result in quiescence135,136, which is consistent with the 
increase of quiescence observed from this subpopulation. Additionally, the median 
percent of cells that expressed genes cell cycle associated gene sets was 6%, which 
signified that, collectively, subpopulation 1 consisted of a quiescent group of cells. The 
global increase of quiescent properties revealed by the comparative analysis of parental 
SKBR3 and SKBR3 with PTEN k.d. cells might have stemmed from the 120 fold 
enrichment of subpopulation 1 (Figures 2.11 and 2.13). Together, the low expression of 
cell cycle gene sets observed in the collective SKBR3 PTEN k.d. cells and in SKBR3 
subpopulation 1 suggested that PTEN k.d. resulted in the overall increase of quiescent 




Figure 2.13. Quiescence Properties of SKBR3 Subpopulation 1. A) Cell cycle associated gene sets identified by GSEA. 
Statistically significance is denoted by p-value adjusted by Benjamini-Hochberg (BH) procedure (padj < 0.01). B) 
Differentially expressed genes identified from gene sets from A are depicted. **** padj <0.0001. 
Interestingly, 80 of 392 genes (20%) identified from the cell cycle associated gene 
sets were also identified in the drug binding gene set, which was another gene set 
enriched by subpopulation 1 (Figure 2.12). Of the genes identified from the drug binding 
gene set, 80 of 135 genes (59%) overlapped with the genes identified from the cell cycle 
associated gene sets. The extent of the overlap underscored how the mechanisms 
involved in drug binding could impair cell cycle progression by disrupting the proteins that 
regulate it. Genes unique to the drug binding gene set were among the higher expressed 
genes in subpopulation 1. These top genes were are involved in cellular or nucleotide 
metabolism; they included receptor-interacting serine/threonine kinase RIPKA4, 
glutamine-ammonia ligase GLUL, purine nucleoside phosphorylase PNP, peptidyl 
isomerase FKBP1A, PIK3CB, calcium-independent phospholipase PNPLA8, and casein 
kinase CSNK1A1. These genes were expressed in 13-25% of subpopulation 1 cells and 
expressed 1.3 fold higher in subpopulation 1 (padj < 0.01). Interestingly, multidrug 
resistance protein family members, such as ABCC2 and ABCG2, were identified in 
SKBR3 using the drug binding gene set but were lowly expressed in SKBR3 (padj < 0.01). 
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In addition, ABCG2 is the nominal breast cancer resistance protein and its overexpression 
has been reported to contribute to a drug resistant phenotype in breast cancer cells.137,138 
The low expression of these genes in subpopulation 1 and in bulk SKBR3 suggested that 
PTEN k.d. would not affect the anti-HER2 sensitivity based on ABC transporter 
superfamily expression levels. Furthermore, the scrutiny of the drug binding exposed a 
reduction in the expression of genes encoding kinesins by SKBR3 subpopulation 1 
compared to the other SKBR3 subpopulations (Figure 2.14). Kinesins (KIF) are a family 
of motor proteins that are known to coordinate the movement of spindle 
microtubules.139,140 However, their functions extend beyond mitosis and they are known 
to rely extensively on microtubules to move cellular vesicles, organelles, mRNA, and 
elements of the cytoskeleton, and thus, are regarded to play a key role in cell motility.139–
143 Importantly, these proteins have been regarded to disrupt the structures that maintain 
the integrity of cell-cell adhesion between epithelial cells (e.g. tight junctions and 
adherens junctions).141 Kinesins disrupt cell-cell adhesion by binding to the keratin 
filaments of the epithelial cytoskeleton to regulate the formation of contractile rings, which 
is a key step to dismantle tight junctions and adherens junctions present in epithelial 
monolayers.141 The loss of these cell-cell adhesion structures has been regarded as a 
key feature of the initiation of EMT, and thus, the downregulation of these kinesins in 
SKBR3 subpopulations 1 corroborates its epithelial phenotype (Figure 2.14). Additionally, 
cells with enhanced rates of kinesin-mediated intracellular transport have been shown to 
exhibit early apoptosis.144 Therefore, the reduced expression of kinesins and the 
concomitant decrease in kinesin activity in SKBR3 subpopulation 1 hinted of a possible 





Figure 2.14. Downregulation of Kinesins as a Possible Mechanism for Stress Response by SKBR3 Subpopulation 1. 
Violin plots depicting expression of known kinesins in SKBR3 subpopulation 1. Dots represent single cells expressing 
markers. Statistical significance was determined by comparing log2(fold change) of gene expression and differences 
in percentage of cells expressing genes between subpopulation 1 and subpopulations 0 and 3. **** padj < 0.0001. 
2.3.10. SKBR3 Subpopulation 1 Exhibited Mixed Expression of Epithelial 
Markers and Markers That Facilitate EMT 
In addition, SKBR3 expressed genes characteristic of epithelial phenotype, which 
included EPCAM, KRT19, and CLDN4 (Figure 2.15A). These encoded proteins are 
critical for maintaining the cell-cell junction and polarity between the epithelial cells.118–121 
As previously shown in Figure 2.14, SKBR3 subpopulation 1 express significantly low 
levels of kinesins, which contributed to its epithelial phenotype since the expression of 
these proteins have been shown to disrupt cell-cell adhesion.139–143 In addition to the 
expression of epithelial markers, SKBR3 subpopulation 1 cells expressed low levels of 
CD151, a tetraspanin protein that mediates integrin-dependent cell motility.145,146 Thus, 
the reduced expression of this protein could compromise the ability of the subpopulation 
1 cells to engage in cellular motility. Furthermore, SKBR3 subpopulation 1 cells exhibited 
decreased expression of ankryin G (encoded by ANK3), which is highly distributed in 
adherens junctions and critical for integrin signaling within the cytoskeleton.147–149 
Interestingly, ankryin 3 has been shown to interact with E-cadherin, and downregulation 
of ankryin 3 during EMT has been shown to interfere with the downstream signaling of E-
cadherin.147,150 While SKBR3 subpopulation 1 cells expressed a subset of epithelial-
specific markers, it exhibited low expression of proteins regulating tight junction and cell 
adhesion, such as ANK3, CDH1, SDC1, and DSP, which suggested weakening of cell-
cell adhesion and thus an early EMT phenotype (Figure 2.15A). Additionally, SKBR3 
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subpopulation 1 cells expressed markers associated with EMT. These markers included 
FN1, MKI67, S100A4, which is upregulated during EMT, metastasis, and regarded as 
crucial for the cytoskeletal remodeling during EMT (Figure 2.15B).118,119,123,151–153 FN1, 
MKI67, and S100A4 were expressed in 4%, 31%, and 40%, respectively, were expressed 
by subpopulation 1 (Figure 2.15B), which not only illustrated the expression of markers 
that promote cell motility and interactions with the extracellular matrix but also highlighted 
the heterogeneity in the expression of markers that govern EMT phenotype. However, 
SKBR3 subpopulation 1 cells did not express classical markers of mesenchymal 
phenotype, such as vimentin (VIM) nor N-cadherin (CDH2). Collectively, the expression 
of these markers suggested SKBR3 subpopulation 1 predominantly exhibited epithelial 
phenotype, but the lowered expression of critical epithelial markers (CDH1 and tight 
junction proteins) hinted that SKBR3 subpopulation harbored an epithelial, early EMT 
phenotype.  
 
Figure 2.15. Mixed Expression of Epithelial and Mesenchymal Markers by SKBR3 Subpopulation 1. A) Epithelial 
markers and B) mesenchymal markers detected in SKBR3 Subpopulation 1. Asterisks denote statistical significance of 
gene expression by subpopulation 1 cells relative to other subpopulations. **** padj < 0.0001. 
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2.3.11. PTEN k.d. in SKBR3 Slightly Increased Heterogeneity in Expression of 
Markers Associated with EMT 
In addition to analyzing the expression of epithelial and markers associated with 
EMT by SKBR3 subpopulation 1, the consequences of PTEN k.d. for each subpopulation 
was also analyzed for these markers. Similar to HCC1954, the expression of epithelial 
keratins, claudins, and tight junction proteins (TJP11 and TJP3) were not statistically 
different in the subset of SKBR3 cells with PTEN deficiency (Figure 2.16A). This is 
consistent with the literature about temporal dependence of the gained expression of EMT 
markers and decreased expression of epithelial markers; expression of keratins have 
been observed until the late stages of EMT.120 Furthermore, syndecan binding protein 2 
(SDCBP2), not SDC1, was detected in less than 20% of cells in each subpopulation (padj 
< 0.01), and PTEN k.d. cells of SKBR3 subpopulations 0, 2, and 3 exhibited a significantly 
lower expression of SDCBP2, which signified a decrease in cell adhesion based on the 
changes in expression of this gene (padj < 0.001). Interestingly, the expression of 
fibronectin (FN1) was slightly, but significantly higher in the subset of PTEN k.d. cells 
compared to parental SKBR3 for subpopulations 2 and 3 (padj < 0.01, Figure 2.16B). For 
subpopulation 0, the expression of fibronectin was slightly lower in PTEN k.d. cells 
compared to parental subpopulation 0 (padj < 0.01, Figure 2.16B). Taken together, PTEN 
k.d. in SKBR3 introduced intra-subpopulation heterogeneity by altering the expressing of 




Figure 2.16. PTEN k.d. in SKBR3 Exerted Intra-Subpopulation Heterogeneity in Expression of Subset of Genes. A) 
Epithelial markers and B) Mesenchymal markers detected in SKBR3 Subpopulation 1. Asterisks denote statistical 
significance of gene expression by subset of cells with PTEN k.d. relative to parental subpopulation. Italicized and 
underlined gene names (2) are ones where gene expression was significant between PTEN k.d. cells compared with 
parental subpopulation. **** padj < 0.0001. 
Taken together, the k.d. of PTEN in SKBR3 altered the subpopulation dynamics, 
which accompanied a 120 fold enrichment in quiescent, epithelial, early EMT 
subpopulation. This subpopulation also exhibited a kinesin-dependent mechanism to 
evade apoptosis induced by cellular stress. Analysis of expressed epithelial and markers 
associated with EMT revealed SKBR3 subpopulation 1 exhibit epithelial early EMT 
phenotype based on the expression of epithelial keratins, low expression of tight junction 
proteins, and expression of genes associated with cell motility for EMT such as FN1.  
2.3.12. PTEN k.d. in SKBR3 Increased the Intra-Subpopulation Heterogeneity 
of Remaining SKBR3 Subpopulations  
In addition to the increase of the relative SKBR3 subpopulations, PTEN k.d. also 
impacted other SKBR3 subpopulations (Figure 2.12). Besides subpopulation 1, the 
relative proportions of the remaining SKBR3 subpopulations decreased after the k.d. of 
PTEN relative to the parental subpopulations. Of the subpopulations that decreased, the 
relative proportions of subpopulations 4 and 5 decreased by the largest magnitudes (by 
18 fold and 24 fold, respectively) after the k.d. of PTEN (Figure 2.12). Subpopulation 4 
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was constituted of 15% of parental SKBR3 and decreased to 0.8% of SKBR3 with PTEN 
k.d (Figure 2.12). The characterization of subpopulation 4 by DGE and GSEA revealed 
significantly positive enrichment for gene sets involved in the cell cycle, mitotic spindle, 
G2/M gene sets, and DNA replication, suggesting that subpopulation 4 cells exhibited 
proliferative phenotype (Figure 2.17A, padj < 0.05). This phenotype was further supported 
by the high expression of proliferative markers, such as CENPF, SMC4, BRCA2, CKAP5, 
CENPE, TOP2A, and MKI67. All of these genes were expressed in 95-100% of SKBR3 
subpopulation 4 and expressed 1.5 – 2.3 fold higher in subpopulation 4 compared to other 
subpopulations. Additionally, subpopulation 4 was negatively enriched for inflammatory 
signaling, namely gene sets involved innate immune signaling, which was verified with 
the lowered expression of inflammatory molecules in subpopulation 4 compared to other 
subpopulations (Figure 2.17A, padj < 0.05). Inflammatory proteins that were lowly 
expressed in subpopulation 4 included S100 proteins, ILF2, NKFBIA, FTH1, DYNLL1, 
TNFAIP3, CCL2, CD58, and CXCL1 (Figure 2.17B, padj < 0.05); these genes were 
expressed 1.6-2.6 fold lower in subpopulation 4 compared to the remaining SKBR3 
subpopulations. Lastly, subpopulation 4 was enriched in gene sets germane to cell 
adhesion and extracellular matrix interactions (Figure 2.17A, padj < 0.05). Interestingly, 
the expression of CLDN3, KRT8 and ACTB were expressed 2 fold lower in subpopulation 
4 compared to the other subpopulations, suggesting subpopulation 4 might exhibit less 
epithelial phenotype compared to the other SKBR3 subpopulations (padj < 0.05). In 
addition, HSPB1 was identified from the cell adhesion gene set to be 3.5 fold lower in 
expression compared to the other SKBR3 subpopulations (padj < 0.05). This finding was 
interesting because the lowered expression of this heat shock protein has been shown to 
weaken cell adhesion and to increase cell motility in breast cancer cells.154 Scrutiny of the 
consequences of PTEN k.d. in this subpopulation revealed too few subpopulation 4 cells 
with PTEN k.d. (6 cells) relative to parental subpopulation 4 (83 cells). This low number 
of SKBR3 subpopulation 4 cells with PTEN k.d. hindered the identification of differentially 
expressed genes and significant gene sets to distinguish the subset of subpopulation 4 




Figure 2.17. SKBR3 Subpopulation 4 Cells were Characterized by High Cell Cycling and Cell Adhesion Properties. A) 
Statistically significant gene sets identified by GSEA for SKBR3 subpopulation 4. B) Genes identified from gene sets 
shown in A. Asterisks denote statistical significance of expression of gene in subpopulation 4 relative to expression in 
other subpopulations. *** pad j< 0.001, **** padj < 0.0001. 
In addition to subpopulation 4, SKBR3 subpopulation 5 was also affected by PTEN 
k.d.; this subpopulation constituted 10% of parental SKBR3 and was reduced by 24 fold 
to 0.4% in SKBR3 after k.d. of PTEN (Figure 2.12). We sought to characterize 
subpopulation 5 by DGE analysis and GSEA, but GSEA did not identify statistically 
significant gene sets for subpopulation 5 (padj > 0.05). Instead, genes differentially 
expressed by subpopulation 5 were analyzed. There were 926 differentially expressed 
genes by subpopulation 5. Among these genes were tropomyosin 1 (TPM1), which was 
expressed in 98% of subpopulation 5 and expressed 2.2 fold higher than cells of 
remaining SKBR3 subpopulations (padj < 0.05). Tropomyosin tightly regulates 
contraction in muscles and is known to regulate actin filaments found in the 
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cytoskeleton155, and thus, its high expression in this subpopulation suggested a role in 
governing cell motility in this subpopulation. Interestingly, the lowest differentially 
expressed genes in subpopulation 5 were epithelial cell adhesion proteins, such as 
CLDN4, CLDN7, LAMB3, and TIPIN, all of which were expressed 1.2 – 1.4 fold lower in 
subpopulation 5 compared to the other SKBR3 subpopulations (padj < 0.05). These 
encoded proteins are critical for epithelial cell adhesion and polarity, and their relatively 
low expression in subpopulation 5 suggested subpopulation 5 exhibited less epithelial 
characteristics compared to other subpopulations. Additionally, proteins that facilitate 
ECM interactions and ECM degradation were also identified among the differentially 
expressed genes of subpopulation 5, which included ADAM17, ITGB1, and ANKRD36. 
Taken together, this data suggested a dysregulation of the cytoskeletal dynamics and 
disruption of cell-cell adhesion among subpopulation 5 cells relative to other SKBR3 
subpopulations. Moreover, characterization of the subset of subpopulation 5 cells with 
PTEN k.d. by GSEA did not reveal significant gene sets that distinguished the subset of 
subpopulation 5 cells with PTEN k.d. from the parental subpopulation 5. Similarly to what 
was observed with the subpopulation 4 cells with PTEN k.d., the inability to distinguish 
parental subpopulation 5 from the cells with PTEN k.d. was due to the low number of 
subpopulation 5 cells with PTEN k.d. (3 cells) relative to the parental subpopulation 5 (54 
cells). With 5 cells with PTEN k.d. in SKBR3 subpopulation 5, comparative analyses 
between these groups of cells within subpopulation 5 could not have been performed 
reliably to yield statistically significant gene sets.  
Changes in SKBR3 subpopulations 0, 2, and 3 were also observed, although 
changes in the subpopulations were 1.5, 1.1, and 1.6, respectively after PTEN k.d (Figure 
2.12). Subpopulation 0 was characterized with a positive enrichment in cell cycle gene 
sets (DNA replication, base excision, G2/M checkpoints, and proliferation), suggesting 
SKBR3 subpopulation 0 represented highly proliferative cells (Figure 2.18A). Scrutiny of 
those gene sets validated this phenotype with the high expression of genes critical for cell 
cycle progression and proliferation, such as CDC6, CDK1, MCM2, TOP2A, PCNA, 
RRM2, and ATAD2 (Figure 2.18B, padj < 0.05). These genes were among the highest 
expressed genes of subpopulation 0, were expressed in 90-99% of subpopulation, and 
were expressed 1.5 – 2 fold higher in subpopulation 0 compared to cells of other SKBR3 
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subpopulations (padj < 0.05). Interestingly, this subpopulation was negatively enriched 
for inflammation signaling gene sets, such TNF-α signaling, immune system signaling, 
and interleukin signaling (Figure 2.18A). The negative enrichment of these inflammatory 
gene sets suggested low cytokine signaling, which was supported with the low expression 
of various cytokines in this subpopulation (i.e. IL18, CXCL3, CCL2, CCL20, TNFAIP8L1, 
padj < 0.05, Figure 2.18B). In addition to being characterized as proliferative and low in 
cytokine signaling, subpopulation 0 was also negatively enriched in cell adhesion and cell 
motility gene sets (Figure 2.18A). Evaluation of these collective gene sets revealed 
expression of epithelial markers such as EPCAM and ACTB in approximately 90% of 
subpopulation 0 cells (padj < 0.05). Interestingly, markers that correspond to EMT were 
expressed, though at low levels, in subpopulation 0. These EMT associated genes 
included ADAM17 (~42% of subpopulation 0), ITGB11 (73%), FN1 (57%), S100P (94%), 
S100A9 (100%), and TNFRS12A (80%) (padj < 0.05). The mixed expression of epithelial 
markers and markers that facilitate the interaction between the extracellular matrix 
suggested SKBR3 subpopulation 0 exhibited both epithelial features and features 
associated with cytoskeletal and extracellular matrix remodeling. Aside from 
characterizing subpopulation 0 as a whole, we also characterized the subset of 
subpopulation 0 cells with k.d. of PTEN. The subset of subpopulation 0 with PTEN k.d. 
enriched for gene sets associated with cell cycling (padj < 0.05). However, the genes that 
were upregulated in subpopulation 0 PTEN k.d. cells were different from cell cycle genes 
that characterized the collective subpopulation 0. Instead, the cell cycle associated genes 
identified from subpopulation 0 PTEN k.d. cells encoded helicases, such as RMI2 and 
DEAD box DDX20, and stress responsive DNA replication proteins, such as TIPIN and 
DDIT4 (padj < 0.05). Importantly, TIPIN is known to increase DNA replication as a 
response to cellular stress156, which suggested that PTEN k.d. in subpopulation 0 might 
engage additional mechanisms of DNA replication as a response to k.d. of PTEN. In 
addition, the subset of subpopulation 0 with PTEN k.d. also negatively enriched for 
inflammatory signaling, which was verified by the low expression of interleukins (IL18), 
chemokines (CXCL1), interferons (IFI27, IFIT1, and IFITM3), TNF-α interacting protein 
(TNFAIP3). In addition to expressing low cytokines, subpopulation 0 with PTEN k.d. also 
negatively enriched for cell adhesion gene sets, which mirrored the negative enrichment 
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of these gene sets in the collective subpopulation 0. Fibronectin (FN1) and BMP7 were 
detected in 15% of the subset of subpopulation 0 with k.d. of PTEN, which highlighted 
that PTEN k.d. resulted in a subset of SKBR3 subpopulation 0 cells exhibiting cell motility. 
Interestingly, canonical WNT ligand WNT7B was 1.1 fold higher in subpopulation 0 with 
PTEN k.d. compared to parental subpopulation 0, which revealed that PTEN k.d. altered 
the expression of distinct canonical WNT ligands that are critical to the EMT program. 
Additionally, WNT7B was identified at high expression levels in epithelial and epithelial-
mesenchymal hybrid cells derived from human mammary epithelial cell line (HMLER) 
xenografted into mice.157 Thus, the increased expression of WNT7B in subpopulation 0 
PTEN k.d. cells suggested that PTEN k.d. might have upregulated canonical WNT 
signaling via increased expression of WNT7B. Another gene that was differentially 
expressed by subpopulation 0 PTEN k.d. cells was FSCN1 (fascin1). Fascin1 has been 
shown to regulate actin cytoskeletal dynamics, and its overexpression has been 
correlated with metastasis and cell motility.158,159 FSCN1 was detected in parental 
subpopulation 0 and not in the subset of subpopulation 0 with PTEN k.d. cells (padj < 
0.0001, Figure 2.18B). In summary, subpopulation 0 was largely characterized by 
proliferative phenotype, low cytokine signaling, slight but statistically significant 
deregulated cell adhesion. While PTEN k.d. in subpopulation 0 cells mirrored the 
phenotype of the parental subpopulation 0, consequences of PTEN k.d. in this 




Figure 2.18. SKBR3 Subpopulation 0 Cells were Characterized by High Cell Cycling, Low Cytokine Signaling, and Low 
Cell Adhesion. A) Statistically significant gene sets identified by GSEA for SKBR3 subpopulation 0. B) Genes identified 
from gene sets shown in A. Asterisks denote statistical significance of expression of gene in subpopulation 0 relative 
to expression in other subpopulations. Split violin plots (WNT7B and FSCN1) shown to compare the expression of gene 
in PTEN k.d. cells (pink) and parental SKBR3 (cyan), and asterisks above subpopulation denote statistical significance 
of gene expression by subset of cells with PTEN k.d. relative to parental subpopulation. *** padj < 0.001, **** padj < 
0.0001. 
In contrast to subpopulation 0, SKBR3 subpopulation 2 exhibited low cell cycling 
genes, high cytokine signaling, TGF-β signaling, Myc targets, hypoxia, and regulators of 
cell adhesion. Scrutiny of these gene sets revealed comparably low expression of Myc 
target genes that are critical for cell proliferation and growth (ORC1, PCNA, CCB1, CDC6, 
BIRC5, TOP2A, MKI67; Figure 2.19). These genes were expressed in 1.4 – 2.3 fold lower 
by subpopulation 2 compared to other SKBR3 subpopulations (Figure 2.19B). Evaluation 
of cell adhesion gene sets revealed expression of both epithelial (EPCAM, KRT18, 
CLDN7, CLDN4, THBS, AQP3, ACTG1, ANK3, and HSPB1B1) and EMT promoting 
markers (MMP9, BMP7, TGFB, S100P, S100A11). The mixed expression of epithelial 
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and EMT promoting markers suggested subpopulation 2 exhibited an epithelial 
phenotype with cytoskeletal remodeling to possible acquire motile features that are critical 
for participation in EMT. Furthermore, SKBR3 subpopulation 2 also expressed 
inflammatory molecules (NFKBIA, JUNB, S100P, CD55, DES1, and FOS) in 60-90% of 
this subpopulation, which was expressed in 1.1 – 1.5 fold higher compared to other 
SKBR3 subpopulations (Figure 2.19B). Expression of these cytokines coincided with the 
mixed expression of cell adhesion and EMT associated markers because inflammatory 
signaling has been regarded to contribute to the activation of EMT. Furthermore, DGE 
analysis of the subset of subpopulation 2 with PTEN k.d. revealed 1.3 fold higher in gene 
expression of cleavage substrate of ADAM17, vasporsin (VASN), and WNT7B in 
subpopulation 2 with PTEN k.d. compared to parental subpopulation 2. This slight but 
significant increase in expression of these genes suggested that PTEN k.d. could 
increase the propensity of subpopulation 2 cells to propagate TGF-β and WNT signaling 




Figure 2.19. SKBR3 Subpopulation 2 Cells were Characterized by Low Cell Cycling, High Cytokine Signaling, and High 
Cell Adhesion. A) Statistically significant gene sets identified by GSEA for SKBR3 subpopulation 2. B) Genes identified 
from gene sets shown in A. Asterisks denote statistical significance of expression of gene in subpopulation 2 relative 
to expression in other subpopulations. Split violin plot for WNT7B shown to compare the expression of gene in PTEN 
k.d. cells (pink) and parental SKBR3 (cyan), and asterisks above subpopulation denote statistical significance of gene 
expression by subset of cells with PTEN k.d. relative to parental subpopulation. *** padj<0.001, **** padj < 0.0001. 
Lastly, subpopulation 3 was characterized using DGE analysis and GSEA. These 
analyses revealed that subpopulation 3 was enriched in gene sets critical for cell cycle 
and motor activity (Figure 2.20). This subpopulation was negatively enriched in cytokine 
signaling and cell adhesion gene sets. Analysis of these gene sets revealed high 
expression of cyclins, survivin (BIRC5), and proteins involved in DNA transcription and 
replication, which indicated that subpopulation 3 cells also consisted of cycling cells. Of 
these cell cycling genes, CENPE, CENPF, ASPM, AURKA, TOP2A, PLK1, and TTG1 
were among the most differentially expressed by subpopulation 3. These genes were 
expressed in 90% of subpopulation 3 and 2.5 – 3 fold higher in subpopulation 3 relative 
to other subpopulations (Figure 2.20B). SKBR3 subpopulation 3 was enriched in immune 
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system signaling, and thus, the following genes encoding inflammatory proteins were 
detected: S100P, JUNB, NFKBIA, IL6ST, TNFIP8L1, DYNLL1, CD58, ILF2, IFI35, 
S100A6, and CD55 (Figure 2.20B). However, the expression of the majority of these 
genes (S100P, JUNB, NFKBIA, IL6ST, TNFIP8L1, and CD58) were not differentially 
expressed by subpopulation 3, which suggested that cytokine signaling was not as strong 
characteristic of this subpopulation as compared to other SKBR3 subpopulations. In 
addition, subpopulation 3 was negatively enriched for cell adhesion gene sets and 
positively enriched for cell motility gene sets. Evaluation of these gene sets revealed 
expression of epithelial keratins (KRT18 and KRT19) and ANK3, which were expressed 
in 80% of subpopulation 3 cells. Furthermore, markers associated with EMT activation 
and cell motility such as matrix metalloproteinase MMP7 and MMP9 were detected in 
30% and 60%, respectively. Interestingly, the subset of subpopulation 3 with PTEN k.d. 
did not exhibit large transcriptomic differences compared to parental subpopulation 3. For 
example, the proliferative property of subpopulation 3 was retained after PTEN k.d. There 
was no statistically significant differences in the expression of cell cycle and cell 
proliferative genes (TOP2A, CENPE, CENPF, AURKA), which suggested that PTEN k.d. 
did not significantly alter the cell cycling properties of this subpopulation. Similarly, PTEN 
k.d. did not appear to alter the cytokine signaling because no significant differences in 
cytokines were observed between parental subpopulation 3 and the subset of 
subpopulation 3 with k.d. of PTEN. Interestingly, the scrutiny of the effects of PTEN k.d. 
in this subpopulation revealed a slight, but significant difference in the expression of cell 
adhesion and cell motility genes. Specifically, it revealed a slightly higher expression of 
gap junction proteins, such as connexin (CNST), ANK1, aquaporin (AQP3) in the subset 
of subpopulation 3 with PTEN k.d. relative to parental subpopulation 3, but the percentage 
of subpopulation 3 PTEN k.d. cells that expressed these genes was approximately 10% 
(padj < 0.0001). In addition, PTEN k.d. cells expressed syndecan binding protein 
SDCBP2 and WNT inhibitor DKK1 at levels that were 1.2 fold lower than parental 
subpopulation 3 and in less than 5% of subpopulation PTEN k.d. cells compared to the 
20% of parental subpopulations that expressed those genes. Furthermore, EMT 
promoting markers such as FN1 (shown in Figure 2.16), TNFAIP3, WNT9A, and FBLN5 
were also expressed 1.2 fold higher in the subset of subpopulation 3 with PTEN k.d. 
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compared to parental subpopulation 3. These slight yet significant changes that the k.d. 
of PTEN introduced to the subpopulation 3 increased the intra-subpopulation 
heterogeneity by altering the expression of key genes critical for cell cycle and cell 
adhesion.  
 
Figure 2.20. SKBR3 Subpopulation 3 Cells were Characterized by High Cell Cycling and Immune System Signaling. 
A) Statistically significant gene sets identified by GSEA for SKBR3 subpopulation 3. B) Genes identified from gene sets 
shown in A. Asterisks denote statistical significance of expression of gene in subpopulation 3 relative to expression in 
other subpopulations. **** padj < 0.0001. 
2.3.13. PTEN k.d. in BT474 Increased Overall Quiescent Properties 
To dissect the transcriptomic consequences of PTEN k.d. in BT474, global 
transcriptomic analyses were performed between parental BT474 and BT474 PTEN k.d. 
cells. These analyses revealed similar transcriptomic compositions for parental BT474 
and BT474 with PTEN k.d. as evidenced by the overlap of single cells from both cells 
lines (Figure 2.21A). DGE analysis was performed between parental BT474 and BT474 
PTEN k.d. cells and yielded 542 genes deregulated by BT474 PTEN k.d. cells (padj < 
0.01). Of these genes, 353 were higher and 189 were lower in BT474 PTEN k.d. cells. 
The top 20 statistically significant genes were analyzed and revealed to encode cation-
binding proteins (PCP4, C1orf101, and S100A8), proteins critical to epithelial cells 
(ODAM and CSTA), metabolic proteins (ATP13A5, CYP1A1, APOBE3A, and P2RY10), 
and proteins involved in chromosome maintenance (SMC1B and CNTLN). Interestingly, 
all of these 20 genes were expressed higher in PTEN k.d. cells, albeit by less than 2-fold 
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increase in expression (Figure 2.21B). The functions of the proteins encoded by the top 
20 statistically significant genes suggested that PTEN k.d. in BT474 resulted in changes 
in cellular metabolism and an increase in epithelial character to adapt to the deficiency of 
PTEN. 
To understand the functional consequences of the genes differentially expressed 
by BT474 PTEN k.d. cells, GSEA was performed and revealed 72 statistically significant 
gene sets enriched by BT474 PTEN k.d. cells (padj < 0.05). Of these, gene sets relevant 
to this study included genes enriched in cells with stem-like phenotypes (“Pece Stem Cell 
Up” from MSigDB) and genes involved in the innate immune signaling pathway (Figure 
2.21C and D). From the gene set upregulated by cells with stem-like properties, tubulin 
TUBB2A and metallothioneins (MT1X and MT1F) were the only genes that BT474 PTEN 
k.d. cells expressed with a statistically significant difference (1.5 fold upregulation, padj < 
0.01). Interestingly, TUBB2A has been reported to be significantly downregulated in 
breast cancer tissue compared to normal breast tissue and significantly upregulated in 
breast cancer tissue that responded to taxane compared to those that did not.160 
Additionally, 15 genes encoding ribosomal subunits were detected in BT474 PTEN k.d. 
cells, which constituted nearly 50% of this gene set. These ribosomal subunits were 
expressed in 90-100% of parental BT474 and BT474 with PTEN k.d., and thus, the 
expression of these genes were not significantly different between these two BT474 
groups. Interestingly, aberrantly high expression of ribosomal proteins, such as RPL13, 
RPL15, and RPL35, have been reported to facilitate metastasis in breast cancer 
patients.161 In addition to the enrichment of “stem cell up” gene set, BT474 PTEN k.d. 
cells were significantly enriched in genes involved in the innate immune signaling. High 
expressing genes detected from this gene set inflammatory-responsive cytoskeletal 
proteins and regulators of inflammatory response. Proteins regulating cytoskeletal 
activities and cell adhesion include GSN (padj < 0.0001) and RAB5C (padj < 0.01), which 
were both elevated by 1.4 fold in PTEN k.d. cells, despite being expressed in 28% and 
36% of BT474 PTEN k.d. cells, respectively. Additional cytoskeletal proteins that were 
expressed by BT474 PTEN k.d. cells included cofilin COFL1 and ACTG1, although the 
expression of these proteins were not significant. Cytoskeletal proteins such as GSN and 
COFL1 are actin depolymerizing proteins that unravel the actin filaments of the 
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cytoskeleton to expose ACTG1 to facilitate cell motility during inflammatory responses, 
which highlighted the impact of inflammatory signaling to the modulation of actin 
dynamics in BT474 by k.d. of PTEN.100,101,162,163 Regulators of innate immune signaling 
and inflammatory responses were elevated by 1.1 – 1.4 fold in BT474 PTEN k.d. cells, 
and these included DEGS1 (padj < 0.01), FOS (padj < 0.0001), POLR3K (padj < 0.0001), 
CALML5 (padj < 0.0001), GGH (padj < 0.0001), and DPP7 (padj < 0.0001). Among these 
regulators of the innate immune system were DEGS1, GGH, and DPP7, which encoded 
enzymes that modulate inflammatory responses via folate homeostasis and production 
of sphingolipid metabolites.164–167 Despite their statistically significant upregulation in 
BT474 PTEN k.d. cells, these genes were detected in 17-38% of BT474 PTEN k.d. cells 




Figure 2.21. PTEN k.d. in BT474 Revealed Global Decrease of Cell Cycling Properties. A) UMAP plot depicting parental 
BT474 (pink) and BT474 with PTEN k.d. (blue). Dots depict single cells from each cell line. B) Volcano plot depicting 
genes with significant fold changes in expression in BT474 PTEN k.d. cells. Genes with statistically significant fold 
changes in expression are depicted in red, and genes with non-statistically significant expression are depicted in grey. 
Top 20 statistically significant genes are labeled. Statistical significance was denoted by padj < 0.01. C) Gene sets 
enriched by BT474 PTEN k.d. cells. Gene sets were identified by GSEA. Normalized gene expression (NES) and false 
discovery rate p-value (FDR) are shown. Statistical significance was denoted by FDR < 0.01. 
2.3.14. PTEN k.d. in BT474 Induced Subpopulation Level Changes and 
Enriched Quiescent Subpopulation by 2 Fold 
 In addition to understanding the global transcriptomic changes resulting from 
PTEN k.d. in BT474, we analyzed how PTEN k.d. affected the steady state of BT474 
subpopulations (Figure 2.22A). Parental BT474 comprised of 4 subpopulations, where 
13.9% of parental BT474 was distributed into subpopulation 0, 33.0% in subpopulation 1, 
15.6% in subpopulation 2, 23.1% in subpopulation 3, and 14.4% in subpopulation 4. 
Knockdown of PTEN changed the subpopulation composition, where 33.6% of BT474 
PTEN k.d. cells were subpopulation 0 (2.4 fold increase), 24.5% were subpopulation 1 
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(1.3 fold decrease), 25.2% in subpopulation 2 (1.6 fold increase), 14.0% in subpopulation 
3 (1.7 fold decrease), and 2.7% in subpopulation 4 (5.3 fold decrease). Interestingly, two 
subpopulations increased in BT474 following PTEN k.d., despite a 1.6 fold and 2.4 fold 
increase for subpopulations 0 and 2 (Figure 2.22B). The magnitude of the subpopulation 
changes induced by k.d. of PTEN in BT474 contrasted the magnitude of subpopulation 
level changes observed in HCC1954 and SKBR3. In the latter cell lines, the k.d. of PTEN 
resulted in an 84 and 120 fold increase in a subpopulation, respectively. Additionally, the 
observation that two subpopulations enriched in BT474 could reflect the context-
dependent consequences of PTEN k.d. in these HER2+ breast cancer cell lines. Since 
subpopulation 0 and 2 both enriched in BT474, analyses were performed on those 
subpopulations.  
 Differential gene expression and GSEA was performed to characterize BT474 
subpopulation 0. Differential gene expression of subpopulation 0 identified 499 
statistically significant deregulated genes (padj < 0.01). Of these, 44 genes were higher, 
and 455 genes were lower in subpopulation 0 cells. The top 20 statistically significant 
genes of subpopulation 0 were associated with cell cycle, all of which were 2-4 fold lower 
in BT474 subpopulation 0 cells (padj < 0.01, Figure 2.22C). These genes encoded 
proteins involved in DNA replication (UBEC, CLSPN, H2AFZ, BRD8, TTF2, and TOP2A), 
chromatin organization (PRC1, HELLS, and SMC4), microtubule formation (MLF1IP, 
STMN1, TUBA1B, and ZWINT), and nucleic acid metabolism (TYMS, DUT, and RRM1). 
The low expression of these genes, which are heavily involved in different stages of the 
cell cycle, suggested BT474 subpopulation 0 exhibited a quiescent phenotype. 
Furthermore, this subpopulation’s quiescent phenotype and the enrichment of this 
subpopulation due to PTEN k.d. suggested BT474 cells entered a dormant state to adapt 
to the cellular stress imposed by the deficiency of the PTEN tumor suppressor.  
 Since these differentially expressed genes provided a limited perspective to the 
consequences of PTEN k.d. in BT474 subpopulation 0, GSEA was performed to dissect 
the functional consequences of these differentially expressed genes. GSEA of BT474 
subpopulation 0 revealed 849 gene sets (padj < 0.01). Among these gene sets, negative 
enrichment scores were observed for genes sets associated with cell cycle (padj < 0.01, 
Figures 2.22 and 2.23). The low expression of these gene sets was consistent with the 
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low expression of the top 20 statistically significant genes of BT474 subpopulation 0 
(Figures 2.22 and 2.23). The negative enrichment of cell cycle associated gene sets in 
BT474 subpopulation supported the overall increase of a quiescent phenotype that 
resulted in the PTEN k.d. cells. Additionally, genes that increase with EMT (i.e. genes 
involved in EMT and mesenchymal genes) were identified to be negatively enriched by 
GSEA (Figure 2.23D). Furthermore, GSEA revealed this subpopulation was not 
significantly enriched in the Hallmark of EMT gene set (MsigDB systematic name: M5930, 
padj > 0.05), which suggested that BT474 subpopulation 0 exhibited an epithelial 
phenotype rather than EMT or mesenchymal characteristics. Lastly, GSEA revealed a 
significant attenuation in expression of genes involved in drug binding (padj < 0.01, Figure 
2.22D). Together, GSEA revealed BT474 subpopulation exhibited quiescent features, 





Figure 2.22. Single Cell Analysis of BT474 Subpopulations and Characterization of Subpopulation That Enriched After 
PTEN k.d. Subpopulation 0. A) UMAP plot depicting five BT474 subpopulations. Dots represent single cells. 
Subpopulations are organized by color. B) Cell Distribution using the same color scheme as shown in A. C) Volcano 
plot depicting genes differentially expressed by BT474 subpopulation 0. Grey dots represent genes with a log2FC that 
is not statistically significant. Red dots represent genes with a log2FC that is statistically significant. Statistical 
significance was denoted by p.adj < 0.01. C) Gene sets enriched by BT474 subpopulation 0. Normalized enrichment 
score (NES) and FDR (false discovery rate) adjusted p-values are displayed. FDR < 0.01 denotes statistical 
significance. D) Heatmap of gene sets from C. Colored scale represents normalized gene expression for each gene. 
2.3.15. Decreased Cell Cycle Activity of BT474 Subpopulation 0 Coincided 
with Low Expression of Genes Critical for Drug Binding 
In addition to exhibiting a negative enrichment score for the cell cycle gene set, 
GSEA of BT474 revealed negative enrichment scores for additional gene sets that are 
linked to cell growth and proliferation. These additional gene sets included proliferation, 
transcription regulated by p53, DNA replication, chromatin binding, G2/M checkpoint, 
DNA metabolism, DNA repair, downstream targets of E2F and DREAM complex (Figure 
2.23A). Among the lowest expressed genes by BT474 subpopulation 0 were ones 
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encoding proteins involved in mitosis (CENPF, PRR11, ASPM, SMC4, TUB1A, and 
AURKA) and DNA replication (HMGB2 and TOP2A), which were expressed 2 – 3.2 fold 
lower in BT474 subpopulation 0 cells relative to other subpopulations (Figure 2.23B). Key 
proliferating genes (e.g. BIRC5, MKI67, and GMNN) were significantly lower in BT474 
subpopulation 0, and the low expression of these genes is characteristic of quiescent 
cells (Figure 2.23B).168–170 Interesting, epigenetic readers (EZH2 and PHF19) and non-
histone binders of heterochromatin (HP1BP3 and CBX5) were also detected among the 
lowest expressed genes of subpopulation 0. These epigenetic modulators were detected 
in 13 – 37% and 37 – 48% of BT474 subpopulation 0, respectively (Figure 2.23B). 
Downregulation of PRC2 repressive complex subunits, such as EZH2 and PHF19, has 
been shown to result in an increase of quiescence in cells.135,136 Further analysis of the 
genes lowly expressed by subpopulation 0 suggested that the quiescent property of 
BT474 subpopulation 0 could not only result from a decrease of cell cycle, but also from 
a decrease of regulatory proteins and transportation of cellular cargo between organelles. 
 Analysis of the genes identified from the cell cycle gene sets revealed an overlap 
of 53 genes between the cell cycle gene sets and the drug binding gene set for BT474 
subpopulation 0. These 53 genes constituted 16% of the collective cell cycle gene sets 
and 75% of the drug binding gene set, which highlighted the integral contribution of genes 
involved in the cell cycle to mechanisms of drug binding. Evaluation of the shared genes 
between cell cycle gene sets and drug binding gene set revealed significantly low 
expression of ubiquitin (UBE2C and UBE2I), proteins involved in cell division (TOP2A, 
SMC4, RFC4, SPAG5, ZWINT, and FEN1), and proteins that regulate the cell cycle G2/M 
transition (AURKA, CENPE, and CDK1). Interestingly, a subset of these genes, UBE2C, 
AURKA, SPAG5, ZWINT, and FEN1, along with HMGB2, TYMS, and RFC4, have been 
shown to be downregulated in HER2+ breast cancer cells after treatment with 
trastuzumab, pertuzumab, and in combination.22,171 This data highlighted how PTEN k.d. 
in BT474 mirrored a stress response induced by HER2-directed therapy. In addition, the 
genes unique to the drug binding gene set encoded specific members of ubiquitins 
(UBE2J2 and UBE2G1), participants of the mevalonate pathway (HMGCS1 and ACSF2), 
proteins involved in drug metabolism (ABCC3 and CYP4B1), metabolic proteins (GOT1, 
NME4, SUCLG2), proteins involved in DNA replication (EIF4A1 and ATAP1A1), histidyl-
92 
 
TRNA synthetase (HARS2), calcium-dependent kinase (CAMK2G), and nuclear 
phosphoserine protein (KIAA0232). These genes were detected in 5-30% of BT474 
subpopulation, while 25-70% of cells of remaining BT474 subpopulations expressed 
these genes (Figure 2.23B). All of these genes were unique to the drug binding, except 
HARS2, ATP13A5, CAK2G, and KIAA0232, and were lower in subpopulation 0 by 1-fold, 
and HARS2, ATP13A5, CAK2G, and KIAA0232 were expressed 1-fold higher in BT474 
subpopulation 0. Furthermore, this subpopulation exhibited a slightly lower, yet significant 
expression of proteins involved in drug resistance and drug metabolism, such as 
multidrug resistance protein ABCC3 and cytochrome P450 proteins CYP1A1 and 
CYP4B1. Additionally, only a few BT474 expressed these proteins as approximately 20% 
of BT474 subpopulation 0 expressed these proteins whereas approximately 45% of the 





Figure 2.23. Top Downregulated Genes Associated with Cell Cycle and Epigenetic Modulators in BT474 Subpopulation 
0. A) Cell cycle associated gene sets identified for BT474 Subpopulation 0. B) Violin plots depicting genes involved in 
cell cycle and epigenetic modulators of gene expression. Dots denote single cells. ** p < 0.01, *** p < 0.001, **** p <  
0.0001. 
2.3.16. BT474 Subpopulation 0 Exhibited Epithelial Early EMT Phenotype, and 
PTEN k.d. Did Not Introduce Intra-Subpopulation Heterogeneity 
In addition to the quiescent properties, GSEA of BT474 subpopulation 0 suggested 
this subpopulation harbored an epithelial phenotype. Scrutiny of the genes contributing 
to this phenotype revealed not only of an epithelial phenotype, but an epithelial early EMT 
phenotype, which was consistent with the subpopulations that enriched in HCC1954 and 
SKBR3. This subpopulation expressed transmembrane proteins that regulate cell 
adhesion in epithelial cells, such as EPCAM, CLDN4, and desmosomes DSP (Figure 
2.24).  Additionally, BT474 subpopulation 0 expressed low levels of other cell adhesion 
proteins such as tight junction protein (TJP1), syndecans (SDC1), and low levels of 
transcription factor that suppresses EMT (GRHL2). Epithelial cytoskeletal proteins such 
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as keratins were detected in BT474 subpopulation 0, and the expression of these keratins 
in subpopulation 0 was not statistically significant from other subpopulations (Figure 
2.24). Thus, the mixed expression of epithelial keratins and low expression of cell 
adhesion proteins suggested subpopulation 0 cells exhibited epithelial phenotype with a 
weakening of cell-cell adhesion. Furthermore, additional known markers of epithelial 
phenotype, such as E-cadherin (CDH1), keratin KRT5 and KRT14, occludin ZO1, and 
MUC1 were not detected in BT474 subpopulation 0. Despite the hints of an epithelial 
early EMT phenotype, BT474 subpopulation 0 cells did not express classical EMT 
markers such as EMT transcription factors (ZEB1/2, SNAIL, SLUG, or TWIST1/2), 
mesenchymal-specific cytoskeletal protein (VIM, FN1, or CDH2), which suggested that a 
full EMT program has not been activated in subpopulation 0. While classical EMT markers 
were not detected in BT474 subpopulation 0 cells, these cells expressed proteins that 
promote cytoskeletal remodeling, weaken cell-cell adhesion, and facilitate the interactions 
with the extracellular matrix, which included IGFBP2 and MGP. These proteins were 
expressed in approximately 20% of BT474 subpopulation 0 cells, which highlighted the 
heterogeneity in the expression of markers that govern the epithelial or the onset of an 
EMT program. Taken together, the mixed expression of epithelial markers, the mixed 
expression of cell-cell adhesion proteins, the lack of expression of classical EMT and 
mesenchymal markers, and the expression of proteins that promote matrix remodeling 
collectively suggested that BT474 subpopulation 0 exhibit an epithelial phenotype with 
weakened cell adhesion, and thus, an epithelial early EMT phenotype. Interestingly, the 
expression of these markers (presented in Figure 2.24) were not statistically significant 
between cells of the parental subpopulation and subset of cells with PTEN k.d. within 
each subpopulation. Expression of additional markers associated with cell motility and 
EMT (CTNNB1, WNT, BMP, and BMP7) were evaluated between parental and cells with 
PTEN k.d., but showed no significant difference in the expression of these genes between 
the parental cells and cells with PTEN k.d. within each subpopulation. Unlike HCC1954 
and SKBR3, intra-subpopulation heterogeneity based on the expression of these 
epithelial and EMT associated markers was not detected between parental and PTEN 
k.d. cells of BT474. Stated differently, PTEN k.d. in BT474 subpopulation 0 did not result 




Figure 2.24. Expression of Epithelial-Specific Markers and Markers That Promote EMT Suggested Epithelial Early EMT 
Phenotype for BT474 Subpopulation 0. Violin plots depicting expression of genes critical for A) epithelial phenotype 
and B) EMT and/or mesenchymal phenotype. Statistical significance was denoted by padj <0.05. **** p< 0.0001. 
Altogether, the data suggested that PTEN k.d. in BT474 resulted in a 2.4-fold 
enrichment of a quiescent, epithelial subpopulation exhibiting early EMT characteristics. 
However, the magnitude of PTEN k.d. in BT474 was not as large as previously observed 
in HCC1954 or SKBR3. Furthermore, a subset of the cell cycle genes that were 
significantly reduced in BT474 subpopulation 0 were identified to be critical for drug 
binding as well, suggesting that quiescence might be a means for these cells to evade 
cellular stress imposed by the k.d. of PTEN. This phenotype was supported by the lack 
of expression of genes involved in the cell cycle, mixed expression of epithelial cell 
adhesion markers, the lack of mesenchymal-specific markers, and the detection of genes 
involved with the weakening of epithelial cell adhesion. It is important to note that these 
genes, albeit their statistically significant fold changes, were expressed in a small subset 
of cells (7-50%), which further exemplified the consequences of intratumoral 
heterogeneity even within a subpopulation.  
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2.3.17. PTEN k.d. in BT474 Enriched for Proliferative, Mesenchymal 
Subpopulation by 1.6 Fold  
In addition to the enrichment of subpopulation 0, BT474 also exhibited an increase 
in subpopulation 2 after k.d. of PTEN. Subpopulation 2 constituted 15.6% of parental 
BT474, and after PTEN k.d., this subpopulation consisted of 25% of BT474, which 
corresponded to a 1.6 fold increase in this subpopulation (Figure 2.25A). To characterize 
this subpopulation and gain insight on how PTEN k.d. affected BT474 subpopulation 2, 
we performed DGE analysis to identify significantly dysregulated genes by BT474 
subpopulation 2, which revealed 237 differentially expressed genes (padj < 0.01). Of 
these genes, 203 genes were higher in subpopulation 2, and 34 genes were lower by 
subpopulation 2 relative to the other BT474 subpopulations. The top 20 statistically 
significant genes all contributed to the cell cycle, all of which were expressed 2-4 fold 
higher in subpopulation relative to the other subpopulations. Among the top 20 statistically 
significant genes are genes associated with DNA replication (proliferating cell nuclear 
antigen, PCNA; POLD3, DNA polymerase delta catalytic subunit; CCNE2, cyclin-
dependent kinase 2; and DNMT1, DNA methyltransferase 1-associated protein). Also 
among the top 20 statistically significant genes were genes encoding nucleic acid 
metabolism enzymes (RRM2, ribonucleoside-diphosphate reductase subunit M2; TYMS, 
thymidylate synthase; and TK1, thymidine kinase), regulators of microtubules (TUBA1B, 
tubulin alpha 1B and STMN1, stathmin), and regulators of chromatin organization (DEK 
and centromere protein MLF1IP). Based the analysis of the top 20 statistically significant 
genes, the 2-4 fold upregulation of genes associated with the cell cycle suggested BT474 
subpopulation 2 consisted of highly proliferative cells (Figure 2.25).  
GSEA was performed to evaluate the functional consequences of the genes 
differentially expressed by subpopulation 2 (padj < 0.01, Figure 2.25C). This analysis 
confirmed the high expression of genes involved in the cell cycle, which reflected 
proliferative phenotype suggested by the top 20 statistically significant genes expressed 
by subpopulation 2. Furthermore, BT474 subpopulation 2 exhibited a significant 
upregulation of genes involved in EMT and a significant downregulation of genes that 
when EMT is activated (i.e. epithelial genes), which suggested BT474 subpopulation 2 
exhibited a mesenchymal phenotype. Interestingly, this subpopulation was not 
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significantly enriched for Hallmark of EMT gene set, implying this subpopulation might not 
exhibit full EMT program or a complete mesenchymal phenotype. Lastly, BT474 
subpopulation 2 was significantly enriched for genes involved in drug binding. 
Interestingly, the gene sets enriched by BT474 subpopulation 2 starkly contrasted the 
gene sets enriched by BT474 subpopulation 0, implying PTEN k.d. in BT474 resulted in 
an enrichment of distinct subpopulations. 
 
Figure 2.25. Characterization of BT474 Subpopulation 2 Revealed Proliferative Mesenchymal Properties. A) UMAP 
plot depicts relative distribution of parental BT474 and resultant distribution of BT474 following k.d. of PTEN. 
Subpopulation 2 is emphasized for clarity. B) Volcano plot depicting statistically significant genes expressed by BT474 
subpopulation 2. C) Gene sets enriched by subpopulation 2. D) Heatmap of gene sets identified in C. Color scale 
represents normalized expression of gene. 
After the general phenotype of BT474 subpopulation 2 was explored with GSEA, 
these gene sets evaluated to characterize subpopulation 2. This additional analysis 
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revealed significant upregulation in genes involved in proliferation, cell cycle checkpoints, 
DNA metabolism, chromatin binding, DNA replication, DNA repair, and targets of the 
DREAM complex (Figure 2.26A and B). Interestingly, this subpopulation showed a 
significant downregulation of ERK signaling. Analysis of these gene sets revealed 
extensive overlap between them, which was expected since they all play an integral part 
in the cell cycle. Between these gene sets, 174 genes were significantly expressed by 
subpopulation 2. The top highly expressed genes in BT474 subpopulation 2 encoded 
proteins involved in DNA replication (PCNA, ATAD2, HMGB2, and POLD3), DNA 
metabolism (DUT, RRM2, and TYMS), and regulation of G1/S phase transition (CCNE2 
and CLSPN). These genes were expressed in 70-90% of BT474 subpopulation 2, while 
25-60% of cells from remaining BT474 subpopulations expressed these genes (padj < 
0.01, Figure 2.26C). These genes were expressed 2.3 – 3.8 fold higher in subpopulation 
2 compared to cells of the remaining subpopulations (padj < 0.01). Among the top 10 
highest expressed genes by subpopulation 2, FAM111B (family with sequence similarity 
111 B) was the highest expressed gene and was expressed 3.8 fold higher in BT474 
subpopulation 2 compared to the cells from the remaining subpopulations (p < 0.01, 
Figure 2.26C). Interestingly, the protein interactions that this encoded protein makes and 
its function remains to be explored.172,173 Thus, this gene represented a potentially novel 
biomarker relevant to HER2+ breast cancer with deficiency in PTEN. Additionally, 
ATAD2, TYMS, and HMGB2 were also identified from the drug binding gene set (Figure 
2.26C). Scrutiny of this drug binding gene set revealed that all the statistically significant 
genes were involved in the cell cycle, and thus, were already identified by the collective 
cell cycle gene sets. The intersection of the drug binding and cell cycle gene sets 
highlighted the interconnections between the effects of drug binding and its 
consequences to the cell cycle. Furthermore, since subpopulation 2 exhibited proliferative 
properties, as exhibited by the high expression of genes involved in the cell cycle, this 
subpopulation might represent one that can be targeted by anti-HER2 therapies, such as 
trastuzumab, pertuzumab, T-DM1, and the newly approved trastuzumab deruxtecan. The 
latter two HER2-directed therapies are antibody drug conjugates of trastuzumab and 
topoisomerase I inhibitor and tubulin inhibitor, respectively, and both target actively 
proliferating HER2-overexpressing cells. Taken together, this data highlighted the 
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proliferative phenotype of BT474 subpopulation 2, which starkly contrasted with the 
quiescent subpopulation 0.  
 
Figure 2.26. Analysis of Proliferative Properties of Subpopulation 2. A) Gene sets identified by GSEA that supports the 
proliferative phenotype of BT474 subpopulation 2. B) Heatmap of gene sets identified in A. C) Differentially expressed 
genes identified by gene sets in A. **** padj< 0.0001. 
 GSEA also suggested BT474 subpopulation 2 harbored a mesenchymal 
proliferative phenotype as evidenced by the upregulation of genes that increases during 
EMT (i.e. mesenchymal genes) and a downregulation of genes that decrease with EMT 
(i.e. epithelial genes). Interesting, GSEA of this subpopulation also showed a significant 
downregulation of genes critical for cell adhesion and cell motility, suggesting that 
subpopulation 2 might not be fully mesenchymal. Additionally, GSEA showed slight 
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enrichment in “Hallmark of EMT”, but that enrichment was not statistically significant (padj 
> 0.05). Analysis of genes expressed by this subpopulation revealed expression of 
epithelial adhesion proteins, such as EPCAM, E-cadherin, claudins (CLDN7 and CLDN4), 
tight junction protein (TJP1), and desmoplackin (DSP) in BT474 subpopulation 2, but the 
fold change in expression was not statistically significant relative to other subpopulations 
(Figure 2.27A). Furthermore, BT474 subpopulation 2 expressed structural proteins found 
in cytoskeleton of epithelial cells such as keratins (KRT7, KRT8, KRT18, and KRT19, 
expressed in 80-99% of subpopulation 2 cells). Certain keratins, such as KRT8 and KRT 
19, were 1.3 fold lower in expression in BT474 subpopulation 2 compared to the rest of 
the subpopulations (pad j< 0.01, Figure 2.27A). Interestingly, subpopulation 2 did not 
express significantly high levels of transcription factor, GRHL2, which is known to 
suppress EMT in breast cancer cells by inhibiting ZEB1.122,174–177 Aside from the 
expression of epithelial markers, a portion of BT474 subpopulation 2 cells exhibited 
proteins that are increased with EMT, such as β-catenin (encoded by CTNNB1, 
expressed in 36% of BT474 subpopulation 2); β-catenin is known to activate EMT 
transcription factor ZEB1 by binding to its promoter.123,178 A subset of this subpopulation 
expressed genes needed to degrade the extracellular matrix and facilitate cell invasion, 
such as MGP (expressed in 70% of BT474 subpopulation 2), BMP7 (expressed in 63% 
of BT474 subpopulation 2), and MMP16 (expressed in 16% of BT474 subpopulation 2). 
Consistent with the expression of extracellular matrix remodeling genes and β-catenin, 
the expression of MKI67, a proliferation marker associated with EMT and invasion, was 
1.6 fold higher in BT474 subpopulation 2 compared with the rest of the subpopulations 
(Figure 2.27B). MKI67 was expressed in 54% of BT474 subpopulation 2 cells. 
Interestingly, only 12% of BT474 subpopulation 2 expressed mesenchymal-specific 
marker vimentin (Figure 2.27B). Despite the expression of proteins that facilitate EMT, 
subpopulation 2 did not fully exhibit mesenchymal properties, which was supported by 
the lack of expression in classical EMT transcription factors (TWIST, SNAIL, SLUG, or 
ZEB1/2) or mesenchymal-specific marker (FN1, LOX, MMP9, MMP19, or CDH2). Rather, 
subpopulation 2 expressed a combination of epithelial markers and proteins involved in 
EMT suggested an epithelial, early EMT state. Relative to BT474 subpopulation 0, 
subpopulation 2 might represent an early EMT state that is later than the state BT474 
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subpopulation manifested based on the comparison of markers expressed by these two 
subpopulations.  
 
Figure 2.27. Epithelial Early EMT (but Later than BT474 Subpopulation 0) for BT474 Subpopulation 2. Violin plots 
depicting A) epithelial markers and B) markers that promote EMT or mesenchymal markers. **** denotes pad j< 0.0001. 
2.4. Concluding Remarks 
In this chapter, we presented the characterization of PTEN k.d. in 3 HER2+ breast 
cancer cell line pairs (HCC1954, SKBR3, and BT474) using the single cell transcriptomics 
approach, Drop-seq. This approach allowed us to dissect the single cell transcriptomes 
of subpopulations constituting these parental and corresponding shPTEN cell lines. 
Analyses using this approach provided insight about the functional consequences of 
PTEN deficiency in HER2+ breast cancer in vitro. Single cell transcriptomic profiling of 
these cell line pairs yielded information about the intra- and intertumoral consequences 
of PTEN deficiency in HER2+ breast cancer in vitro. We studied the consequences of 
intratumoral heterogeneity on PTEN deficiency by evaluating the effects of PTEN k.d. on 
subpopulations of a given cell line. We also studied the intertumoral heterogeneity of 
PTEN deficiency by comparing the phenotypic effects of PTEN deficiency between these 
HER2+ breast cancer cell lines. The elucidation of the intratumoral consequences of 
PTEN k.d. showed that PTEN k.d. in HER2+ breast cancer cell lines resulted in an 
enrichment in a subpopulation characterized by quiescent properties and an epithelial, 
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early EMT phenotype. This subpopulation increased by 84 fold, 120 fold, and 2.4 fold 
after k.d. of PTEN in these cell lines in HCC1954, SKBR3, and BT474, respectively. In 
addition, k.d. of PTEN introduced intra-subpopulation heterogeneity by altering the 
expression of cell cycle, cytokines, cell adhesion, and EMT genes in cells with shPTEN 
compared to parental cells of a given subpopulation in HCC1954 and SKBR3 but not in 
BT474. Taken together, it appeared that PTEN deficiency in these cell lines resulted an 
increase in aggressive cancer phenotype due to the enrichment of a quiescent, epithelial, 
early EMT subpopulation and the introduction of intra-subpopulation heterogeneity.  
By evaluating the resultant consequences of PTEN deficiency between these cell 
lines, it appeared that the consequences of PTEN deficiency was similar in HCC1954 and 
SKBR3 based on the magnitude of subpopulation level changes and the introduction of 
intra-subpopulation heterogeneity. By these metrics, it appeared that BT474 might have 
represented a unique case for studying PTEN deficiency in HER2+ breast cancer in vitro 
because PTEN k.d. did not produce a substantial change in the subpopulation dynamics 
nor did it introduce substantial intra-subpopulation heterogeneity. Comparative analyses 
of the consequences of PTEN deficiency between these HER2+ breast cancer cell lines 
suggested an extent of context dependent effects of PTEN deficiency, which could reflect 
the context dependent effects of PTEN loss observed in the clinic. Altogether, our findings 
suggested that PTEN deficiency enhances an aggressive cancer phenotype through the 
enrichment of a quiescent, epithelial, early EMT subpopulation and introduction of intra-
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Chapter 3: Preliminary Findings of Treatment Studies with Trastuzumab in HER2+ 
Breast Cancer Cells BT474 and MDA-MB-361 
 
Abstract 
Acquired resistance to trastuzumab is a frequent barrier to overall survival in HER2+ 
breast cancer patients with metastatic disease. The reduction in expression of the PTEN 
tumor suppressor has been hypothesized to be linked to trastuzumab resistance, but its 
exact contribution to the development of trastuzumab resistance remains controversial. 
To gain insight on the consequences of PTEN status on trastuzumab sensitivity in HER2+ 
breast cancer cell lines, we used single cell transcriptomics to ascertain whether the pre-
existing transcriptomic alterations due to knockdown of PTEN in HER2+ breast cancer 
cell lines, BT474 and MDA-MB-361, affect trastuzumab response. We cultured BT474 
and MDA-MB-361 (parental and shPTEN cell lines) in the presence of 10 µg/mL for 1 
month prior to generating single cell transcriptomic libraries via the Drop-seq pipeline. 
Untreated BT474 and MDA-MB-361 (parental and shPTEN cell lines) were cultured 
simultaneously to serve an untreated controls for treatment studies. With BT474, 
successfully sequenced transcriptomic libraries included parental BT474, BT474 
shPTEN, and BT474 shPTEN+treatment. Global transcriptomic analyses between 
treated and untreated BT474 shPTEN revealed that treated BT474 shPTEN significantly 
downregulated genes critical for cell growth (padj < 0.01). However, the distribution of 
BT474 subpopulations between parental BT474, BT474 shPTEN, and BT474 
shPTEN+treatment remained constant and did not reproduce the 2 fold increase in the 
quiescent subpopulation as observed from a previous biological replicate. With MDA-MB-
361, successfully sequenced transcriptomic libraries included MDA-MB-361 (+ treatment) 
and MDA-MB-361 shPTEN. Comparative transcriptomic analyses between parental 
MDA-MB-361 and MDA-MB-361 shPTEN revealed no statistically significant gene sets
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based on PTEN status. Treatment of parental MDA-MB-361 revealed significant 
downregulation of gene sets critical for cell growth relative to untreated parental MDA-
MB-361 (padj < 0.05). Due to the insufficient number of treatment controls from both 
BT474 and MDA-MB-361, no conclusions were made from these treatment studies. It is 
possible that BT474 and MDA-MB-361 might not represent appropriate models for 
combined analyses of PTEN knockdown and trastuzumab treatment because the 
magnitude of changes resulting in PTEN knockdown might be too small. It might be more 
appropriate to consider alternative HER2+ breast cancer cell line models, such as 
HCC1954 and SKBR3, for studying how PTEN deficiency affects trastuzumab response.  
3.1. Introduction 
 Trastuzumab resistance among HER2-overexpressing (HER2+) breast cancer 
remains a barrier to patient survival and outcome.36–39 Resistance to anti-HER2 therapies 
is prevalent among patients with advanced, metastatic disease and less common among 
early stage HER2+ breast cancer patients.28,34,35 There are many mechanisms 
hypothesized to governed the onset of trastuzumab resistance, such as proteolytic 
cleavage of the extracellular domain of HER2; the overexpression of tyrosine kinases, 
such as HER3, IGFR, and c-MET; and aberrant PI3K/AKT signaling due to PTEN 
deficiency.23,26,38,43  
 PTEN is a tumor suppressor that regulates the PI3K/AKT signaling pathway 
through the dephosphorylation of PIP3 → PIP2 and thus controls cell survival, cell 
metabolism, and tumorigenesis.25,50,52,53 Aberrant downregulation due epigenetic 
silencing or loss of heterozygosity has been shown to result in constitutive activation of 
PI3K/AKT and its effector proteins such as FOXO, mTOR, and GSK-β.54,56–59 Deficiency 
of PTEN occurs in 40% of HER2+ breast cancer patients and is significantly correlated 
with decreased survival rates among these patients.42,48,60,61 The role of PTEN deficiency 
and its contribution to trastuzumab resistance remains controversial.20,42,45,48,179 In vitro 
studies with HER2+ breast cancer cells with PTEN knockdown (k.d.) indicated that 
trastuzumab treatment resulted in the development of an aggressive mesenchymal 
phenotype.112 Furthermore, previous single cell colony formation studies from the Sun 
Lab demonstrated that HER2+ breast cancer cells with PTEN k.d. generated 
mesenchymal colonies at a higher frequency compared to parental colonies. 
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Furthermore, trastuzumab treatment of these colonies with PTEN k.d. further increased 
the formation of mesenchymal colonies (unpublished data). Despite being phenotypically 
different from the parental cells, the subset of HER2+ breast cancer cells with PTEN k.d. 
that increased mesenchymal colonies were unable to be characterized by traditional stem 
cell markers, such as CD44, CD24, and ALDH, which exemplified the limitation of these 
assays in classifying these aggressive colonies that resulted from PTEN k.d. and 
trastuzumab treatment. These previous findings emphasized the need for alternative, 
unbiased strategies to characterizing these aggressive colonies that were enriched by 
PTEN k.d. and trastuzumab treatment. These previous findings suggested that PTEN 
deficiency in patients could worsen the patient outcome when they are treated with 
trastuzumab. Despite these implied consequences of PTEN deficiency in HER2+ breast 
cancer, PTEN is not routinely assessed for HER2+ breast cancer patients, and HER2+ 
breast cancer patients are treated with trastuzumab-based therapy regardless of PTEN 
status.  
There is a critical need to elucidate the mechanisms by which HER2+ breast 
cancer cells with PTEN deficiency responds to trastuzumab to generate a cancer 
phenotype with increased aggressiveness. Furthermore, it is critical to determine how the 
phenotype that result from PTEN deficiency and trastuzumab treatment ultimately impact 
the long term response to trastuzumab. This insight could guide the discovery of effective, 
alternative therapeutic solutions for HER2+ metastatic breast cancer who experience 
trastuzumab resistance. Deeper knowledge about how PTEN deficiency impacts 
trastuzumab sensitivity could have clinical significance since PTEN deficiency occurs in 
40% of HER2+ breast cancer patients. Additionally, understanding the relationship 
between PTEN deficiency and trastuzumab treatment could reveal characteristics of 
subsets of HER2+ breast cancer patients who are predisposed to respond poorly to 
trastuzumab-based therapies based on PTEN deficiency. Ideally, those patients could be 
identified at the beginning of their cancer management journey and could be treated with 
alternative therapies. Herein, we described preliminary findings using single cell RNA-seq 
to scrutinize the transcriptomic alterations that arise in HER2+ breast cancer cells with 
PTEN deficiency when treated with trastuzumab.  
120 
 
3.2. Materials and Methods 
3.2.1. Cell Culture 
Cells with silenced PTEN were generated by lentiviral infection to introduce short 
hairpin RNA of PTEN. To target the human PTEN gene for silencing, the pLentilox 3.7 
vector containing shPTEN was used to generate “PTEN k.d.” cell lines. As a control for 
lentiviral infection, pLentilox 3.7 vector containing fluorescent dye DsRed, which resulted 
in the wild type (wt) PTEN cell line derivative. Knockdown studies were performed by Dr. 
Joseph Burnett as previously described by Korkaya and coworkers to yield HER2+ breast 
cancer cell line pairs based on PTEN status.77,82,83 
The following HER2+ breast cancer cell lines with wild type (WT) PTEN and PTEN 
knockdown (“PTEN k.d.” derivative) were used during the course of this study: BT474 
and MDA-MB-361. BT474 cell line derivatives were maintained in DMEM/F-12 50:50 and 
supplemented with 10% FBS, 1% Pen-Strep, and 1% of 2mM L-Glutamine. MDA-MB-361 
cell line derivatives were maintained in DMEM supplemented with 1% anti-anti (Gibco 
cat. no. 15240062) and 20% FBS. MDA-MB-361 and BT474 were cultured with 10 µg/mL 
trastuzumab in complete media for 4 weeks prior to use for Drop-seq experiments. 
Complete media with trastuzumab was prepared fresh by reconstituting trastuzumab 
powder into complete media to a final concentration of 10 µg/mL. All concentrations noted 
are final concentrations in media. Cells were cultured in an incubator at 37°C and 
humidified with 5% CO2.  
3.2.2. Drop-seq Experiments 
Drop-seq experiments were performed in accordance to the online protocol from 
the McCarroll lab (version 3.1, 2015).85 Barcoded Bead SeqB beads were ordered from 
Chemgenes and will be referred as Drop-seq beads. Microfluidics devices used were 
generous gifts from Dr. Michael Brooks from Dr. Max Wicha’s group. For these devices, 
treatment with Aquapel was performed using instructions from the McCarroll lab to ensure 
a hydrophobic surface through the microfluidics devices. To ensure high-quality droplets 
and maintain consistency between Drop-seq experiments, microfluidics devices were 




3.2.3. Sequencing of cDNA libraries 
Single transcriptomic libraries generated from each cell line pair (BT474 and MDA-
MB-361) were sequenced by Next-seq (150 cycle, MO) at the Advanced Genomics 
Center at the University of Michigan. Approximately 7M reads/sample (75K reads/cell) 
were desired for sequencing runs. The following read lengths were used for Next-seq: 
read 1 length: 20 bp (26 cycles), read 2 length: 50 bp (96 cycles), and index read length: 
8 bp. Illumina adapters (i7) were used to discriminate single cell transcriptomic libraries 
derived from parental from shPTEN cell lines. The following i7 adapters (and adapter 
sequences) were used to prepare sequencing libraries: N701 (TCGCCTTA), N702 
(CTAGTACG), N703 (TTCTGCCT), and N704 (GTTGGACA). Transcriptomic libraries 
pooled by equal molar pooling of cell lines and ensured equal sequencing coverage per 
cell line.  
3.2.4. Read Alignment and Generation of Digital Expression Data 
Read alignment and the generation of the digital expression data matrix was 
performed by Dr. Joe Burnett and in accordance to the Drop-seq Computational 
Cookbook.86 Reads were de-multiplexed to separate reads corresponding to parental and 
shPTEN cell line based on i7 index adapters. Reads were aligned to the reference human 
genome (GRCh38.p13) to derive the cDNA from each read. Mapped reads were then 
organized into a digital count matrix based on the unique molecular identifier, which 
enabled the quantification of gene expression per gene for each cell represented from the 
single cell transcriptomic library.  
3.2.5. Unsupervised Dimensionality Reduction and Clustering 
Digital count matrices were imported into R for analysis using the Seurat package 
(version 3.1.2). The gene expression for treatment conditions of the parental and shPTEN 
cell lines were normalized using the NormalizeData function, which normalizes the feature 
(gene expression) counts of each cell relative to the total features of that cell. These 
normalized feature counts were then transformed using a natural log transformation. In 
order to perform downstream analyses with the metadata for each cell line pair, the 
metadata corresponding to the parental cell line and the shPTEN cell line were integrated. 
Integration of these metadata was performed by identifying integration anchors 
(FindIntegrationAnchors) with the dims and k.filter argument set to default settings. 
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Metadata was integrated using the IntegrateData function. Cell cycle heterogeneity was 
minimized by regressing the difference in the expression of G2/M and S phase genes. 
Analyses were also performed in absence of cell cycle regression, where the data 
changed minimally compared to using cell cycle regression. Analyses presented in this 
dissertation represent data where cell cycle regression was performed. Subpopulation 
clusters were resolved by using principal component analysis (PCA) and Uniform 
Manifold Approximation and Projection (UMAP). The resolution argument within the 
FindClusters function was optimized for each cell line pair by clustering the metadata at 
each clustering resolution from 0 – 1 in increments of 0.1. The multi-resolution clusterings 
were evaluated using the R package clustree, which guided the selection of the optimal 
clustering resolution.87  
3.2.6. Differential Gene Expression Analysis 
Differential gene expression was performed using FindMarkers function to 
evaluate differentially expressed genes between cell line pairs and subpopulations using 
the wilcox test. This analysis was performed to scrutinize the global transcriptomic 
differences between parental and shPTEN cell line by specifying ident.1 as the shPTEN 
cell line. Similarly, this analysis was performed to compare transcriptomes of treated and 
corresponding untreated condition. Additionally, differential gene expression analyses 
were performed to identify characteristic gene expressed by each subpopulation by 
specifying ident.1 as the subpopulation of interest. The FindMarkers function was used 
to evaluate the gene expression of PTEN and HER2 in all cell lines and between each 
subpopulation. Genes identified from the FindMarkers output were considered as 
statistically significant if p_adj < 0.01, where p_adj accounted for the bonferroni 
correction.  
3.2.7. Gene Set Enrichment Analysis (GSEA) 
 After differential gene expression was performed to assess the genes differentially 
expressed by a subpopulation of cells, gene set enrichment analyses was used to 
elucidate the functional consequences of those differentially expressed genes. GSEA was 
performed using the R package fgsea.88,89 In order to perform gsea using the fgsea 
package, a rank ordered list of genes from the set of differentially expressed genes was 
generated based on the log_avgFC of a given gene. This rank ordered list was used as 
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the stats argument within the fgsea function. The minimum gene set size was set to 10, 
and the maximum gene set size to test was 500. The number of permutations to run using 
the fgsea function was 1M. The rank ordered list of genes was compared a priori to the 
gene sets downloaded from MSigDb (msigdb.v7.0.symbols.gmt, accessed from 
https://data.broadinstitute.org/gsea-msigdb/msigdb/release/7.0/). Gene sets with p_adj < 
0.05 were considered statistically significant, where p_adj is the p_val adjusted using the 
Benjamini-Hochberg (BH) procedure. Gene sets that were identified to be statistically 
significant were downloaded from MSigDb and imported into R. Genes from the imported 
gene sets were intersected with the genes from our metadata using the Reduce function 
and the intersect function from the dplyr package; this enabled the identification of genes 
from statistically significant gene sets that contributed to the enrichment score of those 
gene sets. The output of the intersected list of genes were scrutinized based on 
avg_logFC, p_adj, pct.1, and pct.2, where avg_logFC is the natural log fold change in 
expression of a given gene from one subpopulation relative to another subpopulation. 
The p_val adjusted for BH correction and is noted as p_adj. The percentage of cells from 
the subpopulation of interest that expressed the gene of interest is quantified by pct.1, 
and the percentage of cells from the compared subpopulation that expressed the gene of 
interest is quantified as pct.2.  
3.3. Results and Discussion 
 To elucidate how PTEN k.d. affected the sensitivity of HER2+ breast cancer cells 
to trastuzumab, we performed single cell RNA-seq using the Drop-seq pipeline with two 
HER2+ breast cancer cell lines, BT474 and MDA-MB-361. With the treatment studies 
using these cell lines, we aimed to understand how the transcriptomic profiles of parental 
HER2+ breast cancer cells and the PTEN k.d. cells were altered when treated with 
trastuzumab. Findings from these in vitro studies could reveal how transcriptomes shaped 
by pre-existing PTEN deficiency affects the response of HER2+ breast cancer to 
trastuzumab.  
 For these treatment studies, both BT474 and MDA-MB-361 were previously 
treated for 3 months to develop trastuzumab resistance and provided to me as a gift for 
additional 1 month treatment with trastuzumab prior to sequencing. We integrated 
previous data for BT474 (data presented in Ch. 2, referred here as “batch 1”, noted with 
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“2” at end of sample name designations in this chapter) into the current treatment data. 
Data from the treatment studies belong to batch 2 and are referred as “BT474 wt” and 
“BT474 shPTEN,” respectively. Among the treatment set for BT474, we aimed to 
sequence parental and BT474 PTEN k.d. in the presence and absence of trastuzumab 
treatment (i.e. 4 treatment conditions in total). However, we were only able to sequence 
parental BT474 (no treatment), BT474 shPTEN (no treatment), and shPTEN (with 
treatment). Thus, with BT474, we were only able to glean insight about transcriptomic 
changes arising from trastuzumab treatment using BT474 shPTEN in the presence and 
absence of trastuzumab. Additionally, we used the second biological replicate of BT474 
wt 2 and BT474 shPTEN shPTEN to validate the 2 fold increase of a quiescence 
subpopulation after k.d. of PTEN. A similar experimental limitation was observed for the 
treatment studies using MDA-MB-361. We sought to sequence 4 treatment conditions 
using MDA-MB-361 (parental MDA-MB-361 and PTEN k.d., in presence and absence of 
trastuzumab). However, only parental MDA-MB-361 (+ treatment) and MDA-MB-361 
PTEN k.d. (no treatment) were successfully sequenced. Thus, treatment-induced 
changes could only be derived from the parental cell lines. Elucidation of the 
consequences of PTEN k.d. in MDA-MB-361 were also afforded using this cell line. Only 
preliminary observations will be presented in this chapter, and observations will need to 
be validated using the proper number of controls per cell line.  
3.3.1. Preliminary Findings for Treatment Studies Using Parental BT474 and 
BT474 PTEN k.d. Cells 
 Prior to downstream analyses, we verified protein expression levels of HER2 and 
PTEN between the three treatment conditions and within each subpopulation. As 
expected for BT474, the three treatment conditions of BT474 (denoted as “BT474 wt,” 
“BT474 shPTEN,” and “BT474 shPTEN + tx” from batch 2) expressed similarly high 
protein levels of HER2, which were not statistically significant between treatment 
conditions. The protein expression level of PTEN was significantly higher in parental 
BT474 compared to BT474 shPTEN (+ treatment, padj < 0.0001), although more cells 
were detected in both PTEN k.d. conditions compared to parental cell line. Between each 
of the BT474 subpopulations, the expression levels of HER2 and PTEN exhibited 
statistically significant differences. The expression of HER2 in subpopulations 0 (padj < 
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0.01) and 2 (padj < 0.0001) was significantly lower compared to other subpopulations 
(Figure 3.1A). In addition, the expression of HER2 in subpopulations 1 and 5 were 
significantly higher compared to other subpopulations (padj < 0.0001, Figure 3.1A). The 
expression of HER2 within each subpopulation was not statistically different between the 
treatment groups. The expression of PTEN was significantly lower in subpopulations 0 
and 4 compared to the other subpopulations (padj < 0.0001), while the expression of 
PTEN was significantly higher in subpopulation 5 compared to the other subpopulations 
(padj < 0.0001, Figure 3.1B).  
 
Figure 3.1. Evaluation of Expression Levels of HER2 and PTEN in BT474 (Batch 2) Revealed Heterogeneous 
Expression. Expression levels of A) HER2 and B) PTEN between treatment groups (left) and between subpopulations 
(right). Dots represent single cells from each treatment group, and the expression levels are normalized log transformed 
values. Asterisks above subpopulations denote statistical significance of HER2 or PTEN expression between 
subpopulations by Wilcox test. ** p < 0.01, **** p < 0.0001. 
 After relative levels of HER2 and PTEN were verified between treatment groups of 
BT474, between subpopulations, and within subpopulations, we evaluated how 
trastuzumab treatment induced global transcriptomic changes. The global transcriptomic 
profiles of parental BT474, BT474 shPTEN, and and BT474 shPTEN with treatment were 
analyzed using differential gene expression and GSEA. First, we sought to replicate the 
global transcriptomic differences that we previously observed by GSEA using parental 
BT474 and BT474 shPTEN (batch 2). This analysis yielded 36 significant gene sets and 
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revealed opposite phenotypes than what we previously observed for the global 
transcriptomic comparison between parental BT474 and BT474 shPTEN (padj < 0.01, 
Table 3.1). As detailed in Ch. 2, we previously observed an enrichment in innate immune 
signaling and stem cell gene sets by BT474 shPTEN. However, those gene sets were 
negatively enriched in BT474 shPTEN from batch 2 (padj < 0.01, Table 3.1).  
 The global transcriptomic comparisons between BT474 shPTEN and BT474 
shPTEN+treatment revealed 175 significant gene sets. Relative to BT474 shPTEN, 
BT474 shPTEN+treatment was negatively enriched DREAM complex targets, E2F 
targets, cycling genes, mitotic spindle, and cell division (padj < 0.01, Table 3.1), which 
suggested that trastuzumab treatment of BT474 PTEN k.d. cells reduced proliferation and 
cell growth. This treatment-induced reduction of cell growth was expected because it was 
consistent with the cytostatic effect of trastuzumab treatment.43,180,181  
Table 3.1. Gene Sets Identified from Comparative Transcriptomic Analyses of Parental BT474, BT474 shPTEN, and 
BT474 shPTEN+Treatment (Batch 2). pval represents unadjusted pval. padj represents the pval adjusted with BH 
correction. NES signifies the normalized enrichment score of the gene sets. Gene sets considered to be statistically 
significant if padj < 0.01. 
 
 Next, we aimed to verify our previous findings that PTEN k.d. in BT474 resulted in 
changes in the relative subpopulation proportions. Specifically, we wanted to verify the 2 
fold increase in a quiescent early EMT subpopulation, the 1.6 fold increase of a 
proliferative subpopulation, and the 5 fold decrease of a quiescent subpopulation marked 
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by high expression levels of HER2 and NEAT1. In order to make these comparisons 
between the experimental batches of BT474, we needed to determine how the 
subpopulations corresponded to each other across experimental batches. After 
integrating BT474 (batch 1) with the newly sequenced data (batch 2), we used different 
clustering parameters to accommodate the entire integrated BT474 dataset, which 
identified 6 subpopulations for both batch 1 and batch 2. Integrating the collective BT474 
datasets normalized the data relative to each other and lessened the batch variation 
between experiments. To characterize the subpopulations from this integrated dataset 
relative to BT474 wt 2 and BT474 shPTEN 2 from batch 1, we identified top differentially 
expressed genes for each subpopulation for each experimental batch (Figure 3.2). By 
using the differentially expressed genes from each subpopulation, we would be able to 
verify the previously observed subpopulation changes induced by k.d. of PTEN, and we 
would be able to evaluate what subpopulation level changes arose from trastuzumab 
treatment. As shown in Figure 3.2, the subpopulation identified between the two batches 
were fairly conserved, except for subpopulation 0 and 1. Based on the expression of 
PCNA, DUT, PRR11, PTTG1, SMC4, UBE2C, ARI61P1, TUBA1B, and HMGB2, 
subpopulation 0 from batch 1 corresponded to subpopulation 1 from batch 2. We 
previously observed subpopulation 0 (batch 1) increased by 2 fold after k.d. of PTEN. 
Additionally, subpopulation 1 from batch 1 corresponded to subpopulation 0 of batch 2 
based on the expression of those markers as well. Subpopulations 2 and 3 from both 
batches have the same respective subpopulation designation. Subpopulation 4 from 
batch 2 appeared to be quiescent due to the low and heterogeneous expression of a 
mixture of genes. Lastly, subpopulation 5 from batch 2 corresponded to subpopulation 4 
from batch 1 of BT474 due to the characteristically high expression levels of NEAT1 and 
HER2. Now that the subpopulations between the experimental batches have been 
identified, we can proceed to verify subpopulation level changes induced by PTEN k.d. 
(no treatment) and scrutinize how trastuzumab treatment altered the transcriptomic 




Figure 3.2. Comparison of BT474 Subpopulations Between Experimental Batch 1 and 2. Heatmap depicting 
differentially expressed markers for each BT474 subpopulation in A) batch 1 (data presented in Chapter 2) and B) batch 
2 (consisting of treatment studies) of BT474. 
 Firstly, we were unable to verify the previously observed changed induced by k.d. 
of PTEN in BT474 wt and BT474 shPTEN from batch 2. Specifically, we sought to verify 
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the 2 fold increase of the quiescent subpopulation 1 in batch 2 (corresponded to 
subpopulation 0 of batch 1), the 1.6 fold increase of the proliferative subpopulation 2, and 
the 4 fold decrease in subpopulation 5 (corresponded to subpopulation 4 from batch 1). 
However, the magnitude of these subpopulation changes were not reproduced in batch 
2 for subpopulations 1 and 5 (corresponded to subpopulations 0 and 4 from batch 1, 
Figure 3.3). Interestingly, subpopulation 2 from batch exhibited a 1.5 fold increase after 
k.d. of PTEN relative to parental subpopulation 2, which mirrored the 1.6 fold increase of 
subpopulation 2 after PTEN k.d. in BT474 from batch 1 (Figure 3.3). Using the biological 
replicates for parental BT474 and BT474 with PTEN k.d. from batch 1 and 2, we only 
reproduced the 1.5 fold increase of the proliferative subpopulation 2 after PTEN k.d. 
relative to parental BT474. We were unable to detect a 2 fold increase in the quiescence 
epithelial, early EMT subpopulation 1. Furthermore, we were unable to reproduce the 4 
fold decrease of the quiescent subpopulation marked by high expression of HER2 and 
NEAT1.  
 Despite the inconsistencies between experimental batches, we also made 
preliminary assessments of subpopulation level changes using comparative analyses of 
BT474 shPTEN and BT474 shPTEN+treatment. Based on the relative distribution of 
subpopulations, trastuzumab treatment appeared to increase subpopulation 5 by 1.7 fold. 
Since the previously observed subpopulation level changes induced by k.d. of PTEN were 
not fully observed in BT474 shPTEN (batch 2), the treatment induced changes to 
subpopulation 5 can only be regarded as a preliminary observation. For BT474, it is 
possible that the additive effects of trastuzumab treatment to PTEN deficiency could not 
be assessed due to the relatively small magnitude of transcriptomic change that PTEN 
k.d. induced in this cell line compared to others (i.e. HCC1954 and SKBR3). Thus, it is 
critical to repeat the treatment studies using those cell lines sine the magnitude of PTEN 
k.d. was larger in order to study how the consequences of PTEN deficiency in the 
presence of trastuzumab treatment. Choosing an appropriate cell line is critical to 
ascertaining whether PTEN deficiency primes the HER2+ breast cancer to respond poorly 




Figure 3.3. Single Cell Characterization of BT474 Datasets (Batch 1 and Batch 2). A) The left UMAP plot depicts single 
cells of each treatment group. Sample name followed with “2” denotes data from batch 1 (presented in Chapter 2). The 
right UMAP plot depicts single cells categorized into five BT474 subpopulations. B) Relative cell distribution of each 
treatment group/cell line into five BT474 subpopulations. Subpopulations colored using the same color scheme as right 
UMAP plot in A. Subpopulations are noted in bold and relative percentage of cells in given subpopulation relative to 
entire cell line is noted in parentheses. 
3.3.2. Preliminary Observations from Treatment Studies Using MDA-MB-361 
Similar to the treatment studies with BT474, preliminary observations were only 
made with MDA-MB-361 due to the insufficient number of controls. Treatment studies 
using MDA-MB-361 featured 3 treatment conditions: parental MDA-MB-361 (+ treatment) 
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and MDA-MB-361 shPTEN (no treatment). In this cell line, comparative analyses were 
performed with parental MDA-MB-361 and MDA-MB-361 with PTEN k.d. to ascertain how 
PTEN k.d. altered the transcriptome of MDA-MB-361. Additionally, we sought to 
determine how trastuzumab treatment induced transcriptomic alterations by comparing 
parental MDA-MB-361 in the presence and absence of trastuzumab treatment.  
We first verified the protein expression levels of HER2 and PTEN levels between 
the treatment groups, between subpopulations, and within a subpopulation. Cells from 
each treatment group exhibited high expression levels of HER2, which were not 
significantly different between the groups (Figure 3.4). Furthermore, HER2 was 
expressed in all five of the subpopulations that comprised MDA-MB-361 and within each 
subpopulation. The expression levels of HER2 was not significantly different between 
each of the treatment group (Figure 3.4). Regarding PTEN, the expression of PTEN was 
low in this cell line, and the expression levels of PTEN were not significantly different 
between each treatment group (Figure 3.4). Within each subpopulation, the levels of 
PTEN was not significant between the treatment groups (Figure 3.4). Lack of significant 
difference in PTEN expression levels might reflect the low levels of PTEN in this cell line 
and this difference in PTEN expression levels might be too low for Drop-seq to 
discriminate between parental MDA-MB-361 and MDA-MB-361 with PTEN k.d.  
 
Figure 3.4. Evaluation of Expression Levels of HER2 and PTEN in MDA-MB-361. Expression levels of A) HER2 and 
B) PTEN between treatment groups (left) and between subpopulations (right). Dots represent single cells from each 
treatment group, and the expression levels are normalized log transformed values. Asterisks above subpopulations 
denote statistical significance of HER2 or PTEN expression between subpopulations by Wilcox test. 
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Due to the insufficient number of controls for the treatment studies of MDA-MB-
361, we only presented preliminary observations, which require further follow-up studies 
for validation. We used DGE analysis and GSEA to evaluate the global transcriptomic 
differences between parental MDA-MB-361 and PTEN k.d. cells. GSEA identified 139 
gene sets (padj < 0.01), which included negative enrichment scores for drug binding and 
drug responses gene sets (Table 3.2). Furthermore, MDA-MB-361 shPTEN were also 
negatively enriched for cell motility and cell adhesion gene sets (Table 3.2). In addition, 
MDA-MB-361 PTEN k.d. cells were positively enriched for cell cycle gene sets, such as 
nuclear division, regulation of cell cycle, and cell cycle transition (Table 3.2), which 
suggested these cells actively progress through the cell cycle. Interestingly, MDA-MB-
361 PTEN k.d. cells were positively enriched in p53 signaling pathway (Table 3.2). 
Comparative analyses of parental MDA-MB-361 and MDA-MB-361 with PTEN k.d. 
revealed global transcriptomic differences. The reduction in PTEN expression increased 
cell cycling and p53 pathway relative to parental MDA-MB-361.  
Differential gene expression and GSEA was also used to assess the global 
transcriptomic alternations due to trastuzumab treatment using parental MDA-MB-361. 
These comparative analyses were performed using pval < 0.01 rather than padj < 0.01 
or padj < 0.05 as the parameter for statistical significance because 0 and 5 statistically 
significant gene sets were identified using the latter statistical significance cut offs, 
respectively. Previously, only BH-adjusted (Benjamini-Hochberg) p-values (padj) were 
used to determine statistical significance of gene sets because padj considers the gene 
set size and multiple hypothesis treating and thus represented a more stringent parameter 
for statistical significance cut offs. Only negative enrichment for cycling genes and vesicle 
mediated cell transport, hinting that treatment of parental cells reduced cell activity, which 
is consistent with the cytostatic mechanism of trastuzumab (padj < 0.05).43,180,181 Using 
the less stringent pval < 0.01 rather than padj as the parameter for statistical significance, 
GSEA revealed 313 gene sets (pval < 0.01). At this level of statistical significance, 
negative enrichment scores were identified for drug responses and drug binding gene 
sets. Furthermore, treated parental cells were also negatively enriched in cell cycle gene 
sets, such as cell division, cycling genes, proliferation, mitotic spindle, and chromosome 
remodeling. Taken together, trastuzumab treatment did not appear to result in significant 
133 
 
transcriptomic changes between the treated parental and untreated parental MDA-Mb-
361 as evidenced by the low number of significant gene sets (padj < 0.05) and the need 
to use the less stringent statistical significance parameter (pval < 0.01).  
Table 3.2. Gene Sets Identified from Comparative Transcriptomic Analyses of Parental MDA-MB-361, MDA-MB-361 
shPTEN, and Parental MDA-MB-361 +Treatment. pval represents unadjusted pval. padj represents the pval adjusted 
with BH correction. NES signifies the normalized enrichment score of the gene sets. Gene sets considered to be 
statistically significant if padj < 0.01. 
 
After the evaluation of the global transcriptomic composition of the untreated, 
treated parental, and PTEN k.d. of MDA-MB-361, we evaluated the steady state 
subpopulations of each treatment condition for MDA-MB-361. We observed minimal 
differences in all of the subpopulations between the three treatment groups. Each 
treatment group consisted of the following subpopulation composition: 34-40% of 
subpopulation 0, 21-28% of subpopulation 1, 11-17% of subpopulation 2, 12-15% of 
subpopulation 3, and 8-11% of subpopulation 4 (Figure 3.5). Based on the relative 
distribution of MDA-MB-361 cells in each subpopulation, no significant change in the 
subpopulations were observed between untreated parental and MDA-MB-361 with PTEN 
k.d., which implied that PTEN k.d. might not induce observable changes at the 
subpopulation levels in this cell line. While GSEA revealed that PTEN k.d. in MDA-MB-
361 expressed more cell cycling genes, the reduction of PTEN did not result in changes 
to the subpopulation steady state of MDA-MB-361. In HER2+ breast cancer cell lines, it 
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is possible that PTEN k.d. causes a global increase of quiescent features, and this global 
increase in quiescent features cause noticeable subpopulation level changes within the 
bulk cell line.  If this is the case, it is possible that the subpopulation composition of MDA-
MB-361 did not change as a result of PTEN k.d. because PTEN k.d. caused a global 
increase of cell cycling gene expression, rather than a global increase of quiescent 
features. Similarly, treatment induced changes were also not detected between the 
treated and untreated parental MDA-MB-361 at the subpopulation level. Thus, 
downstream analyses and the characterization of MDA-MB-361 subpopulations were not 
performed using this cell line due to the lack of subpopulation level changes resulting 




Figure 3.5. Single Cell Characterization of MDA-MB-361. A) UMAP plot depicting single cells of each treatment group 
(left) and single cells categorized into five MDA-MB-361 subpopulations (right). B) Relative cell distribution of each 
treatment group/cell line into five MDA-MB-361 subpopulations. Subpopulations colored using the same color scheme 
as UMAP plot in A. Subpopulations are noted in bold and relative percentage of cells in given subpopulation relative to 
entire cell line is noted in parentheses. 
3.4. Concluding Remarks 
Treatment studies yielded inconclusive results from both BT474 and MDA-MB-
361. In BT474, the previously observed 2 fold increase of the quiescent early EMT 
subpopulation was not reproduced in the current datasets. Furthermore, the 4 fold 
decrease of the quiescent subpopulation characterized by high expression of HER2 and 
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NEAT1 were also not reproduced using the biological replicate of parental BT474 and 
BT474 shPTEN from the treatment studies (BT474 batch 2). Regarding MDA-MB-361, 
similar observations were made after analyzing the effects of PTEN k.d. and trastuzumab 
treatment. While GSEA revealed that MDA-MB-361 with PTEN k.d. exhibited more cell 
cycling features, k.d. of PTEN did not result in changes to the subpopulation level steady 
states. In addition, GSEA of treated parental and untreated parental only suggested that 
treated parental cells exhibited less cell cycling compared to untreated parental MDA-
MB-361, which is reflective of the cytostatic mechanism of trastuzumab.43,180,181 
Furthermore, trastuzumab treatment did not induce changes at the subpopulation level of 
MDA-MB-361 as the subpopulation distribution remained constant regardless of PTEN 
status and trastuzumab treatment.  
It is possible that BT474 and MDA-MB-361 represented inappropriate models to 
observe subpopulation level changes that result from PTEN k.d. and trastuzumab 
treatment. For BT474, changes of 2-4 fold were observed in the subpopulations once, 
whereas, in other cell lines, such as HCC1954 and SKBR3, the subpopulations changed 
by a magnitude of 80 and 120 fold after k.d. of PTEN in those cell lines. Thus, the 
magnitude of change induced by PTEN k.d. in BT474 might be too small to be reliably 
observed and thus, this cell line might represent an inappropriate model for studying the 
consequences of PTEN k.d. at the subpopulation level. Instead, alternative HER2+ breast 
cancer cell lines such as HCC1954 or SKBR3 might reliably capture the functional 
consequences of PTEN k.d. on a subpopulation level and thus might be more appropriate 
models to scrutinize the added effect of trastuzumab treatment in the context of HER2+ 
breast cancer with PTEN deficiency. The differences in the global transcriptomic changes 
and the magnitude of subpopulation level changes that resulted from k.d. of PTEN also 
highlighted the context-dependency of PTEN deficiency. These context-dependent 
consequences of PTEN deficiency might mirror the intertumoral heterogeneity faced in 
the clinical management of HER2+ breast cancer among patients. Thus, these context-
dependent effects of PTEN deficiency might suggest that some patients with PTEN 
deficiency might be unaffected by PTEN deficiency as modeled by our preliminary 
findings using MDA-MB-361, whereas in other patients, the deficiency of PTEN might 
enrich for a quiescent epithelial early EMT subpopulation as suggested our findings from 
137 
 
Chapter 2 using HCC1954 and SKBR3. Taken together, the preliminary findings from the 
treatment studies using BT474 and MDA-MB-361 highlighted the inter- and intratumoral 
heterogeneity elicited by PTEN k.d. alone and hinted at the need for methods to subset 
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Chapter 4: Concluding Remarks 
 
4.1. Summary of Findings 
In this dissertation, we presented the characterization of PTEN deficiency and 
preliminary observations of trastuzumab treatment studies in HER2+ breast cancer cell 
lines using single cell transcriptomics. We uncovered consequences of intra- and 
intertumoral heterogeneity by dissecting the effects of PTEN deficiency in HER2+ breast 
cancer cell lines. Studies towards unraveling how PTEN deficiency affected intratumoral 
heterogeneity were performed using comparative transcriptomics analyses of 
subpopulations in parental and shPTEN cell lines. Insights about the intertumoral 
consequences of PTEN deficiency were extracted from comparative transcriptomic 
analyses between cell lines. At a single cell resolution, we found that PTEN k.d. increased 
the global quiescent properties compared to the parental cell line as evidenced by the 
decreased cell cycle activity. Furthermore, PTEN k.d. expanded a quiescent, epithelial 
early EMT subpopulation by 84 fold, 120 fold, and 2.4 fold in HCC1954, SKBR3, and 
BT474, respectively. The phenotype of these expanded subpopulations was 
characterized as epithelial, early EMT because these expanded subpopulations 
expressed epithelial keratins, claudins, and EPCAM. However, they expressed low levels 
of E-cadherin, a critical cell adhesion protein found specifically on the surface of epithelial 
cells.119,120,123,157 In addition, they expressed markers that facilitate EMT, such as S100 
proteins, MKI67, FN1, and TNFSFR12A.119,120,123–126,128–130,157 However, expression of 
traditional mesenchymal markers, such as vimentin and N-cadherin, were not detected 
by the subpopulations that expanded after PTEN k.d.119,120,123,157 Interestingly, PTEN k.d. 
was shown to slightly increase intra-subpopulation heterogeneity by altering the 
expression of select genes that were critical for the phenotype of the subpopulation, such 
as cell cycling genes and cell adhesion proteins in HCC1954 and SKBR3 but not BT474. 
Comparative analyses between cell lines revealed context dependent consequences of 
PTEN deficiency in HER2+ breast cancer in vitro. Altogether, the characterization of
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PTEN deficiency in HER2+ breast cancer revealed important clinical implications for 
cancer management for the subset of HER2+ breast cancer patients with a deficiency in 
the PTEN tumor suppressor.  
In addition, treatment studies were performed to evaluate how the pre-existing 
transcriptomic profiles shaped by PTEN deficiency in HER2+ breast cancer cell lines 
would be altered in the presence of trastuzumab. We aimed to gain insight on how 
reduction of PTEN expression impacted the response of the HER2+ breast cancer cells 
to trastuzumab. Based on our characterization of the functional consequences of PTEN 
deficiency, we hypothesized that PTEN k.d. would enrich a quiescent subpopulation with 
epithelial early EMT characteristics and thus, this subpopulation would exhibit resistance 
to trastuzumab therapy. Using BT474 and MDA-MB-361, we were unable to observe 
substantial transcriptomic differences based on trastuzumab treatment. In treatment 
studies with BT474, we observed small subpopulation level changes between parental 
and PTEN k.d. cells, and treatment of BT474 PTEN k.d. cells appeared to elicit small 
subpopulation level changes, but those observations require further studies to yield 
conclusive results. Furthermore, we did not observe transcriptomic differences in MDA-
MB-361 regardless of PTEN status or trastuzumab treatment. Limitations of our treatment 
studies included the insufficient number of treatment controls and the use of a cell line 
with a relatively small transcriptomic changes as a result of k.d. of PTEN (i.e. BT474). It 
is possible that the observations from our treatment studies with BT474 and MDA-MB-
361 represented different behaviors of the cancer in response to treatment. In order to 
evaluate how the PTEN deficiency shapes the response to trastuzumab, it is critical to 
perform the treatment studies using HER2+ breast cancer cell lines where the 
transcriptomic changes resulting from k.d. of PTEN is larger than 2-4 fold. We believe 
appropriate cell lines for treatment studies include HCC1954 and SKBR3 because the 
transcriptomic changes that resulted from PTEN k.d. were 84 and 120 fold. Therefore, 
these cell lines represent more appropriate models to study the effect of PTEN loss on 
trastuzumab response. At this time, we are unable to conclude about the findings from 
our treatment studies.  
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4.2. Thoughts for Future Studies 
Since PTEN deficiency shows clinical relevance to HER2+ breast cancer in the 
literature and our data suggested that PTEN deficiency could increase the aggressive 
cancer phenotype, we propose future studies that could provide more comprehensive 
characterization of the resultant cancer phenotype after k.d. of PTEN. These studies 
include additional treatment studies using cell lines that show observable functional 
consequences arising from k.d. of PTEN, such as HCC1954 and SKBR3. We proposed 
the use of these cell lines for our treatment analyses because they would be appropriate 
models to study the effects of PTEN deficiency on trastuzumab response. Our data 
suggested that those cell lines were very sensitive to k.d. of PTEN as suggested by the 
large magnitude of subpopulation level changes and the introduction of intra-
subpopulation heterogeneity arising in PTEN k.d. cells. Since large, observable effects 
were found from these cell lines, we inferred that we would be able to observe additional 
transcriptomic changes after treatment of those cell lines with trastuzumab. These 
treatment studies are critical steps to understanding how PTEN loss in the 12-40% of 
HER2+ breast cancer patients affects these patients’ inherent ability to respond to 
trastuzumab. 
In addition to understanding how PTEN deficiency shapes the transcriptome to 
respond to trastuzumab, we are interested in leveraging insight about the consequences 
of PTEN deficiency to identify biomarkers that could predict trastuzumab response. Our 
central hypothesis for this work is that PTEN deficiency induces an aggressive cancer 
phenotype by enriching quiescent, epithelial, early EMT subpopulations and by 
introducing intra-subpopulation heterogeneity. Thus, it would be very valuable to pursue 
the identification of biomarkers that could effectively subset HER2+ breast cancer 
patients based on pre-existing transcriptomic signatures that characterize patients who 
would inherently respond poorly to therapy or even predict aggressive cancer. The use 
of biomarkers to subset patients based on pre-existing transcriptomes and to inform about 
patient response to HER2-directed therapy would help improve personalized medicine 
strategies for these patients and possibly improve patient outcome. Thus, we strongly 
believe future studies should include the biological and clinical validation of the 
subpopulations that were enriched by k.d. of PTEN in order to work towards the discovery 
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of biomarkers that could detect aggressive subpopulations of HER2+ breast cancer cells 
in patients. It is important to assess whether the group of HER2+ breast cancer patients 
with poor patient outcome and aggressive cancer phenotype is linked to the introduction 
of intra-subpopulation heterogeneity and/or the expansion of a quiescent, early EMT 
subpopulation, as suggested by our data. It would be ideal if the enriched quiescent early 
EMT subpopulations could be purified so that their functional properties could be 
analyzed. Identification of methods for purification of the subpopulation enriched by PTEN 
k.d. is a critical step prior to performing functional studies. In our studies, we found that 
subpopulation-specific markers for this quiescent early EMT phenotype was difficult to 
identify mainly due to its quiescent phenotype and the heterogeneous expression of 
various genes by this subpopulation. It appeared as though using markers for the 
subpopulations that did not enrich after PTEN k.d. as negative selection markers for the 
enriched subpopulations would be the most realistic approach. Alternatively, other routes 
to identifying biomarkers includes the use BioPortal to leverage RNA-seq data from 
previously sequenced HER2+ breast cancer tumor data to identify clinically relevant 
markers that are correlated with PTEN expression status and/or survival of HER2+ breast 
cancer patients. With the data leveraged from cBioPortal, we could apply a reverse 
approach where we identify clinically relevant markers to HER2+ breast cancer with 
PTEN deficiency to identify markers that characterize the enriched subpopulation in our 
single cell transcriptomics data. In summary, the identification of markers that could 
enable the purification of the enriched subpopulation that resulted from PTEN k.d. would 
be critical to working towards the goal of understanding how PTEN deficiency influences 
trastuzumab response and facilitating the discovery of alternative therapeutic strategies 
for patients who acquire resistance.  
Aside from purifying the quiescent early EMT subpopulation, future studies should 
include functional studies to test whether or not the enriched subpopulations by PTEN 
k.d. would undergo additional enrichment and exhibit resistant phenotype. These 
functional studies include the assessment of the sensitivity of the enriched subpopulation 
to trastuzumab in cell viability assays (e.g. MTT assays and annexin V assay) to confirm 
if the enriched subpopulation are resistant to trastuzumab since quiescence and EMT 
programs are known to be linked to therapy resistance. Cell proliferation studies are 
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expected to reveal constant cell viability in the presence of trastuzumab treatment, which 
would support the resistance phenotype of the subpopulations that enriched after PTEN 
k.d. Additionally, we are interested in evaluating the invasive potential of the enriched 
subpopulations using matrigel invasion assays. Based on our data, we hypothesize that 
enriched subpopulations would exhibit invasion characteristics via migrating through the 
experimental membranes in invasion assay experiments. We also hypothesize that the 
enriched subpopulations would exhibit greater invasive potential compared to 
subpopulations that did not enrich after PTEN k.d. and/or the bulk parental cell line. Lastly, 
we are interested in investigating the tumorigenic potential of these cells using mice 
xenograft models. In the literature, use of NOD/SCID mice xenografts have been used to 
assess consequences of PTEN deficiency in HER2+ breast cancer and thus would be 
appropriate for our studies.82 In these proposed xenograft studies, subpopulations that 
were enriched following PTEN k.d. are expected to exhibit greater tumorigenicity 
compared to parental cells and/or subpopulations that were not enriched by k.d. of PTEN. 
Enhanced tumorigenicity is expected to be observed by larger tumor size, volumes, and 
faster growth compared to tumors corresponding to parental cells or cells from 
subpopulations that were not enriched by PTEN deficiency. Moreover, isolated enriched 
subpopulations treated with trastuzumab are expected to form larger and faster tumors 
mice xenograft models compared to the isolated and untreated enriched subpopulations. 
Collectively, these functional studies of the enriched subpopulations following PTEN k.d. 
would unequivocally confirm that enriched subpopulations resulting from PTEN deficiency 
give rise to trastuzumab resistance.  
4.3. Clinical Implications of Findings 
The cell line models we used aimed to capture the gradual loss of expression of 
PTEN during the progression of HER2+ breast cancer, which is reflective of real life 
scenarios of PTEN expression dynamics in HER2+ breast cancer.55 Ebbesen and 
coworkers (2015) reported that PTEN loss occurs less at the onset of HER2+ breast 
cancer but is associated with tumor progression.55 Thus, the enrichment of a quiescent, 
epithelial, early EMT subpopulation, as suggested by our findings, is consistent with the 
resultant cancer phenotype after PTEN loss in HER2+ breast cancer. Importantly, the 
enrichment of these quiescent, epithelial, early EMT subpopulations hinted that PTEN 
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deficiency enhances the aggressive cancer phenotype in HER2+ breast cancer that might 
be linked to trastuzumab resistance. In this dissertation, all of the subpopulations 
analyzed expressed high levels of HER2, even the subpopulations enriched after PTEN 
k.d., which suggested that the enriched subpopulations could be targeted by current 
standard therapies used for HER2+ breast cancer patients. However, based on the 
phenotype of these enriched subpopulation as suggested by our data, the enriched 
subpopulations could exhibit resistance to HER2-directed therapy due to the quiescent, 
early EMT phenotype. Current HER2-targeted therapies (trastuzumab, pertuzumab, 
trastuzumab drug conjugates) target HER2-overexpressing, proliferative cancer cells and 
elicits cytostatic effects on those cells or release toxic anti-mitotic payloads to those cells 
to arrest the cell growth of the HER2-overexpressing cells. Given the mechanism of the 
HER2-directed therapies, it suggests that the enriched subpopulations by PTEN 
deficiency would be targeted by HER2-directed therapies but would resist the cytostatic 
of the first line therapies (trastuzumab and pertuzumab). Additionally, the enriched 
subpopulations are hypothesized to escape the cytotoxic effects second line therapies 
and derivatives (trastuzumab emtansine and trastuzumab deruxtecan) since those 
trastuzumab drug conjugates release anti-mitotic payload, which would be toxic to 
proliferative cells but not quiescent cells. Thus, as stated above, the identification of 
markers to isolate these enriched subpopulations from the bulk HER2+ breast cancer cell 
lines is a critical step to unravelling the consequences of PTEN deficiency and its impact 
on trastuzumab treatment. In addition to being valuable for technical and functional 
validation of the enriched subpopulations, the identification of markers could have clinical 
relevance since it would provide avenues to screen patients for their predicted response 
to HER2-directed therapies based on their pre-existing transcriptomes rather than solely 
on the expression of HER2. Effective subset of HER2+ breast cancer patients is 
necessary for cancer management, especially for metastatic HER2+ breast cancer 
patients, because the vast majority do not respond to HER2-directed therapies and the 
fraction of metastatic patients who respond to trastuzumab ultimately acquire resistance 
within 2 years of treatment. Thus, the use of markers to predict patient response to 
frontline therapy could improve patient outcome and survival at earlier stages of cancer 
management for patients with metastatic disease.  
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It is important to note limitations of our data that derived from our HER2+ breast 
cancer models, which aims to capture the consequences of PTEN deficiency in HER2 
breast cancer. While elucidating the role of PTEN deficiency in HER2+ breast cancer 
subpopulations is an important feat, it is also possible that PTEN deficiency is a molecular 
byproduct of oncogenic aberrations such as genetic mutations or epigenetic silencing that 
is not adequately captured in our data. Thus, it is possible that by studying the 
consequences of PTEN deficiency, we are not dissecting the primary contribution of the 
aggressive cancer phenotype or frequent cases of trastuzumab resistance. However, 
despite these limitations, there have been extensive controversy about the prognostic 
value of PTEN expression in HER2+ breast cancer. This work presented in this 
dissertation addresses the controversial role of PTEN and its prognostic value. We 
showed the inherent heterogeneity that exists within HER2+ breast cancer and that the 
reduction of PTEN expression could increase intratumoral heterogeneity by changing 
gene expression programs that governs the phenotype of cancer cells. Collectively, our 
data provided insight on the dynamic changes of the intratumoral heterogeneity that exists 
within a given HER2+ breast cancer, which is a critical element to leverage in future 
cancer management as the clinical importance of intra and intertumoral heterogeneity 
continues to grow in the field. In sum, our work has great potential to contribute shaping 
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Appendix: Towards the Identification of Small Molecule Inhibitors of the 
Interaction Between Myc and WDR5 
 
Abstract 
In approximately 50% of all human cancers, the expression and transcriptional activity of 
Myc is dysregulated and is closely linked to the onset of tumorigenesis. There have been 
numerous studies that aimed to inhibit Myc and eradicate its oncogenic activities. 
Inhibitors resulting from these past studies suffered from poor bioavailability and low 
target site engagement. A recently discovered interaction between Myc and WDR5 was 
reported, which showed that the interaction of Myc and WDR5 is critical for Myc to activate 
the transcription of target genes. The interaction of Myc and WDR5 provided new 
opportunities for targeting Myc, which we leveraged for our studies. Herein, we describe 
the use of high throughput screening and fragment based drug discovery identify small 
molecules and scaffolds with the potential of inhibiting Myc by targeting the interaction 
between Myc and WDR5. Using fragment based screening, we screened 1,500 fragments 
and identified 2 candidate fragments. In our high throughput screening campaign, we 
screened 25,000 small molecules (Z’ = 0.61). Small molecule hits were triaged using a 
negative selection MLL-WDR5 fluorescence polarization based binding assay. Site 
specificity for the Myc-WDR5 site was evaluated by a Myc-WDR5 fluorescence 
polarization based binding assay (Z’ = 0.68), which yielded 2 small molecules with the 
potential to engage at the Myc-WDR5 site. Co-crystal studies of validated fragments and 
small molecules with recombinant WDR5 revealed that none of the fragments nor 
molecules engaged at the Myc-WDR5 site.  
A.1. Introduction 
 In various cancers, oncogenic c-Myc (hereafter simply referred as Myc) has been 
linked to the many hallmarks of cancer and has been reported to be dysregulated in 
approximately 50% of all human cancers.182–186 Myc is a basic helix loop helix leucine
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 zipper transcription factor that requires its dimerization with obligate binding partner, 
Max, in order to influence transcription of target genes.183,187 It is normally expressed at 
low levels, and its expression is limited to highly proliferating cells.182–186 In cancers, the 
oncogenic potential of Myc is linked to its function as a transcription factor and drives 
tumorigenesis by increasing the transcription that is essential to proliferation, metabolism, 
and biosynthetic pathways.182–186  
 Because Myc plays a critical part to tumorigenesis, there have been numerous 
efforts to inhibit Myc.188–194 Both direct and indirect approaches have been pursued. Direct 
approaches targeting processes that impair the gene expression of Myc, which included 
the stabilization of G-quadruplex structures proximal to the promoter of Myc gene.188–191 
The stabilization of these G-quadruplex structures consequently repress the transcription 
of Myc genes.188–191 Other direct approaches to targeting Myc includes impairing the co-
localization of Myc on chromatin and inhibiting its heterodimerization with its binding 
partner Max.192–194 These approaches yielded small molecule inhibitors that had poor 
tumor accumulation, poor bioavailability, and poor target site engagement, and thus, had 
limited clinical success.195 Indirect approaches to targeting Myc included interfering with 
the protein translation of the Myc mRNA and stabilization of the Myc protein.195,196 Despite 
these various approaches to target Myc, many of them have been unsuccessful in 
producing an efficacious inhibitor with high bioavailability profiles.184,195 The crux of this 
problem is due to the intrinsic disordered structure of Myc; it takes on various and 
transient secondary structures and does not have any discernible pockets amendable for 
drug discovery.197–199 Because of these physical properties, Myc has been long deemed 
an “undruggable” target.197–199 
 Interestingly, Tansey and Fesik laboratories proposed a new model regarding the 
recruitment of Myc to chromatin.200,201 They showed that the activity of Myc is mediated 
by WD40 protein, WDR5, which functions as a transcriptional activator in various protein 
complexes, such as MLL, RbBP5, KANSL1, and KANSL2.200,202–204 In regards to Myc, it 
facilitates recruits Myc to the promoter region of target genes and activate the 
transcription of those genes.200 Biochemical and in vivo studies from Tansey and 
coworkers demonstrated that Myc associates with a groove on the surface of WDR5 
through key hydrogen bonds and electrostatic interactions.200 Scrutiny of the publically 
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available protein structure of WDR5 and the Myc peptide (PDB: 4Y7R) revealed key 
resides on WDR5 near the Myc interacting site (e.g. K52, K220, H178 and F263), which 
could be leveraged to generate high affinity chemical probes or small molecule inhibitors 
targeting the Myc-WDR5 site. Thus, the interaction of Myc and WDR5 presented a new 
opportunity for targeting Myc by targeting a druggable protein-protein interaction. 
 Herein, we described our approach to identifying small molecule inhibitors for the 
interaction of Myc and WDR5 by using high throughput screening and fragment based 
drug discovery campaigns. Both campaigns yielded 2-5 small molecules and fragments 
after screening and validation. However, none of the small molecules and scaffolds 
identified in our screens were shown to engage at the Myc-WDR5 interface by co-crystal 
studies.  
A.2. Materials and Methods 
A.2.1. Fragment-Based Screening of ChemDiv and Life893 Fragment Libraries 
Against WDR5 
Plates consisting of fragments at 1 mM in DMSO were removed from -20°C 
freezer, equilibrated to room temperature, and centrifuged at 1500 rpm for 2 min prior to 
addition of fragments to 384 well plates. To screen 1,350 fragments from the ChemDiv 
and Life893 fragment libraries against recombinant N-terminal truncated WDR5Δ23 
(residues 24-334), 1 μL of DMSO or 1 mM fragment in DMSO was added to 384 well 
plates, followed by the addition of 9 μL of 6.67 μM WDR5 and 10 μL of 2X Sypro Orange 
dye from Protein Thermal Shift™ Dye Kit (Thermo Fischer cat. no. 461146). The final 
concentrations for this assay were 3 μM WDR5, 1X Sypro Orange, and 50 μM of each 
fragment in 50 mM HEPES. Plates were centrifuged using a benchtop centrifuge for 1 
min prior to the assay. Total concentration of DMSO was 5% (v/v). The negative control 
used was 3 μM of WDR5 and 1X Sypro Orange (“WDR5+Sypro Orange control”). “Active 
fragments” were defined as fragments that increased the melting temperature of WDR5 
by 2°C relative to the melting temperature (Tm) of WDR5 in absence of the fragment, 
resulting in 10 fragments. To increase the quantity of “active fragments,” fragments were 
then selected if they induced an increase in the melting temperature of 2 standard 
deviations relative to the negative control. To screen fragments in the presence of MM-
401, a final concentration of 5 μM of MM-401 was used. To determine if these were non-
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specific binders, we performed the dose-dependent thermal shift assays using different 
concentrations of the fragments to assess whether concentration-dependent changes in 
the Tm of WDR5 occurred in the presence and absence of the WDR5-MLL inhibitor. Plates 
were assayed using Applied Biosystems ViiA7 Real-Time PCR system. Plates were 
heated from 25 – 95°C with a heating rate of 0.5°C/min Measurements were made in with 
excitation and emission wavelengths set at 580 nm and 623 nm, respectively. 
A.2.2. Multiplexed High-Throughput Screening of Small Molecules Against WDR5 
Multiplexed high-throughput screening of compounds deposited at the Center of 
Chemical Genomics of the University of Michigan was performed in collaboration with Dr. 
Aaron Robida. Libraries screened included LOPAC, Prestwick, and MB 24K. All thermal 
stability assays of recombinant ΔN1-23 WDR5 were performed using Applied Biosystems 
ViiA7 Real-Time PCR system. Plates were heated from 25 – 95°C with a heating rate of 
0.5°C/min. Measurements were made in with excitation and emission wavelengths set at 
580 nm and 623 nm, respectively. The thermal unfolding of WDR5 was monitored using 
Sypro Orange dye from Protein Thermal Shift™ Dye Kit (Thermo Fisher cat. no. 4461146) 
or using SYPRO™ Orange Protein Gel Stain 5000X Concentrate in DMSO (Thermo 
Fischer cat. no. S6650). Assays were performed using Applied Biosystems™ 
MicroAmp™ Optical 384-Well Reaction Plate with Barcode (Fisher Scientific cat. no. 
4309849). For these assays, 5 μL of 50 mM HEPES were added to the wells reserved for 
the negative control and multiplexed compounds (4 compounds per well). The 
combination of compounds to be multiplexed was predetermined by personnel at the 
Center of Chemical Genomics. To wells reserved for 4-plex was added 50 μL of selected 
compounds for a total of 200 nL of 4-plexed compounds per well. Compounds were added 
using Sciclone ALH3000 pintool (Perkin Elmer). To negative and positive control wells 
was added 1 μL of 20% DMSO (v/v). Following, to entire plate was added 14 μL of the 
master mix consisting of 15 μM of WDR5 in 50 mM HEPES and 2X Sypro Orange or 10X 
SYPRO Orange dye in 50 mM HEPES. The master mix consisting of 15 μM WDR5 and 
2X Sypro Orange or 10X SYPRO Orange was prepared fresh prior to each assay and 
was placed on the shaker for 10 minutes prior to addition. Plate was covered with Applied 
Biosystems™ MicroAmp™ Optical Adhesive Film (Fisher Scientific cat. no. 43-119-71), 
centrifuged at 1500 rpm for 2 min, and then, the thermal stability assay was performed. 
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The total concentration of DMSO was 1% (v/v). Final concentrations were 3 μM WDR5, 
1X Sypro Orange or 5X SYPRO Orange dye, and 10 – 25 μM of each compound in 50 
mM HEPES or 10 μM Myc peptide (sequence: H-DEEEIDVVSV-NH2). The negative 
control for this assay was 3 μM WDR5 + 1X Sypro Orange or 5X SYPRO Orange dye, 
and the positive control was 3 μM WDR5 + 1X Sypro Orange control (or 5X SYPRO 
Orange) + 10 μM Myc peptide. “Active wells” were defined as wells that showed an 
increase in the melting temperature by 3 standard deviations relative to the negative 
control. Deconvolution of 4-plexed “hits” were performed as dose-dependent thermal 
stability assays using Mosquito X1 (TTP Labtech) to select compounds from “active wells” 
and deliver to 384-well plate to provide a final concentration of 2-5 μM in DMSO. 
Measurements for deconvolution studies were performed as duplicates and thermal 
stability assays were performed using the Applied Biosystems ViiA7 Real-Time PCR 
system as noted above.  
A.2.3. Quality Control Studies for Ordered “Hit” Compounds Identified by HTS 
Ordered compounds (49) were analyzed for purity using ESI-MS dissolved in 1:1 
acetonitile:water, and peaks corresponding to M+H+ were analyzed. Activity of ordered 
compounds were analyzed using Thermal Shift Assay with same parameters as noted 
above to confirm that these compounds induce a change in Tm that is greater than 3 
standard deviations relative to the Tm of WDR5 alone. Assay conditions of “retest” studies 
were identical to conditions used for HTS.  
A.2.4. MLL-WDR5 Fluorescence Polarization Assay (Negative Selection) 
MLL-WDR5 competition assay was performed as previously described with some 
modifications, which were detailed here.202 To 15 mL Falcon tube was added 3.8 mL of 
8.42 nM of recombinant WDR5 in FP buffer and 3.8 mL of 1.26 nM MLL probe in FP 
buffer. Mixture was equilibrated at RT for 3 hours in dark with agitation. After 3 hours, 
aliquots of 3x20 µL were used to assess formation of WDR5-MLL probe complex. 
Fluorescence polarization values of complex were approximately 91 + 9.9. Following the 
evaluation of WDR5-MLL probe complex, competitive binding assay was prepared. To a 
black 384 well plate was added 19 µL of WDR5-MLL probe complex solution and 1 µL of 
either 20 mM, 10 mM, 5 mM, or 2.5 mM of HTS compound in DMSO. To wells 
corresponding to probe only positive controls was added 9.5 µL of 1.26 nM of MLL probe 
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in FP buffer, 9.5 µL of FP buffer, and 1 µL of DMSO. To wells corresponding to MM-401 
positive controls was added 19 µL of WDR5-MLL probe complex solution and 1 µL 
DMSO. To wells corresponding to WDR5-MLL probe negative controls was added 19 µL 
WDR5-MLL probe complex solution and 1 µL DMSO. Final assay conditions were 4 nM 
WDR5, 0.6 nM MLL probe, 5 µM MM-40l, and one of the following concentrations of HTS 
compounds: 1 mM, 500 µM, 250 µM, or 125 µM. Final volume of competitive binding 
assay per well was 20 µL. Competitive binding assays was incubated for 12 hours at RT 
in dark to ensure complete competition between HTS compounds and MLL probe. 
Titrations of HTS compounds were performed using the following concentrations of 
working solutions: 20 mM, 10 mM, 5 mM, 2.5 mM, 1.25 mM, 62.5 µM, 31.3 µM, and 15.65 
µM. Final assay concentrations for HTS compounds in titrations were 1 mM, 500 µM, 250 
µM, 125 µM, 62.5 µM, 31.3 µM, 15.65 µM, and 7.8 µM. Fluorescence polarization was 
read using the following spectrophotometric parameters: λex = 485 nm and λem = 528 nm. 
FP buffer was prepared fresh prior to each assay and had final pH = 6.5. Henderson–
Hasselbalch equation (below) was used to determine amounts of sodium phosphate 
(monobasic and dibasic) for buffer. For 15 mL of FP buffer, 121 mg NaH2PO4 and 68 mg 
Na2HPO4 and 215 µL of Triton X-100 was mixed in MilliQ water. Competitive assay was 
performed with 4 technical replicates and 2 biological replicates.  
𝑝𝑝𝑝𝑝 = 𝑝𝑝𝐾𝐾𝑎𝑎 + 𝑙𝑙𝑙𝑙𝑙𝑙 [𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑][𝑚𝑚𝑙𝑙𝑚𝑚𝑙𝑙𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑] 
In Henderson-Hasselbalch equation, pKa was 6.82, dibasic corresponds to Na2HPO4, and 
monobasic corresponds to NaH2PO4.  
A.2.5. Myc-WDR5 Fluorescence Polarization Assay 
To 5 mL Eppendorf tube was added 1.57 mL of 111.11 µM of recombinant WDR5 
in FP buffer and 875 µL of Myc probe in FP buffer. Binding of WDR5 and Myc probe was 
equilibrated for 4 hours at RT in dark with agitation. After 4 hours, fluorescence 
polarization readings were obtained to ensure formation of WDR5-Myc probe complex. 
Fluorescence polarization readings for WDR5-Myc peptide complex was 80+9.6 and free 
Myc probe was 23.7+6.5. To a black 384 well plate was added 14 µL of WDR5-Myc probe 
complex solution, 5 µL of FP buffer, and 1 µL of HTS compound in DMSO. Final 
concentrations of HTS compounds were 1 mM, 500 µM, 250 µM, or 125 µM. To wells 
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corresponding to Myc probe positive control was added 20 µL of probe master mix (135 
µL of FP buffer and 75 µL of 400 nM Myc probe solution). To wells corresponding to Myc 
peptide positive control was added 14 µL of WDR5-Myc probe complex solution and 6 µL 
of 647 µM Myc solution in FP buffer. Follow-up studies of the quick titration of the HTS 
compounds was performed using an extended titration with the following final 
concentrations of HTS compounds: 750 µM, 375 µM, 187.5 µM, 93.75 µM, and 46.87 µM 
in DMSO. Concentrations for the follow-up studies were as noted for the quick titration. 
For each well, the following assay conditions were used 9 µL of 100 µM recombinant 
WDR5, 5 µL of 400 nM Myc probe solution, 1 µL of compound in DMSO, and 5 µL of FP 
buffer (final volume 20 µL). Final assay concentrations were 45 µM WDR5, 40 nM Myc 
probe, 200 µM Myc peptide, and the final concentrations for the HTS compounds were 
noted above. Fluorescence polarization was read using the following spectrophotometric 
parameters: λex = 485 nm and λem = 528 nm. FP buffer was prepared fresh prior to each 
assay and based on the buffer used to study the interaction of WDR5 and KANSL2, which 
also is an overlapping interaction at the Myc-WDR5 site.204 The FP buffer for the Myc-
WDR5 FP assay consisted of 20 mM Tris and 200 mM NaCl (pH 7.0). For 15 mL of FP 
buffer, 34 mg of Tris base and 177 mg NaCl was combined in 15 mL of MilliQ water. 
Resultant pH was acidified using 162 µL of 1M HCl to pH 7.0.  
A.2.6. Peptide Synthesis of Myc Probes 
Peptides were synthesized manually using NovaRink resin (loading capacity 0.44 
mmol/g). To sealed vessel was added 227 mg NovaRink (0.1 mmol) in 10 mL of NMP. In 
a separate vessel was added Fmoc-AA (Fmoc protected amino acid, 0.5 mmol) in 2.6 nL 
NMP and 87 µL of DIPEA (0.5 mmol). Basic amino acid mixture was mixed at RT until 
clear and yellow in color. Then, 54 mg of HOAT (0.4 mmol) and 152 mg of HATU (0.4 
mmol) were added to basic amino acid mixture and sonicated until reaction mixture was 
clear. Activated Fmoc-AA mixture was added to NovaRink resin. Coupling reaction 
proceeded at RT for 1 hour with agitation. Double coupling was performed for bulky 
aliphatic amino acids, such as Fmoc-Val, Fmoc-Ile, and Fmoc-Ahx. Following coupling 
reaction, reaction supernatant was decanted, washed with 3x10 mL NMP, 3x10 mL DCM, 
and 3x10 mL NMP. Deprotection of Fmoc was performed using 20% piperidine/NMP (in 
XS) for 30 min at RT with agitation. Sample of deprotected resin was removed and added 
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to ninhydrin stain to assess complete deprotection prior to the start of the subsequent 
coupling step. Final unlabeled Myc peptide consisted of following amino acid sequence: 
Fmoc-Ahx-DEEEDIDVVSV-NH2 (M+H = 1466.68 Da).  
Bioconjugation of Myc peptides was performed using 5/6-FAM-NHS (Thermo cat. 
# 44610). To scintillation vial was added 100 mg of 5/6-FAM-NHS (0.1 mmol, 3 eq) in 4 
mL NMP and 70 µL of DIPEA (0.4 mmol, 4 eq). Mixture was swirled to afford a bright red, 
clear mixture. Mixture was added to resin. Labeling reaction proceeded for 12 hours at 
RT in dark and with agitation. Following 12 hours, resin was washed with 3x10 mL NMP, 
3x10 mL DCM, and 3x10 mL NMP. Global deprotection and resin cleavage was 
performed in TFA/H2O (9.5: 0.5, v/v) for 1 hour at RT with agitation. TFA was removed in 
vacuo. Azeotrope of DCM and TFA was used to quicken evaporation of TFA. Peptide was 
precipitated using 10 mL Et2O at 0°C for 1 hour, which yielded white, cloudy mixture with 
precipitate. Precipitate was filtered using Hirsch funnel, retained, and dried in desiccator 
for 3 hours. Crude peptide (2 mg) was used for reverse phase (C18) purification using 
HPLC. Crude peptide was dissolved in 0.1 M NH4HCO3 (aq) to yield a clear, bright green 
solution. Crude peptide solution was filtered by syringe (25 µm filter) prior to injecting onto 
HPLC for purification. Optimized purification method was the following: 20% ACN/H2O 
(isocratic for first 15 minutes), 20-40% ACN/H2O for 20 minutes, 40-75% ACN/H2O for 15 
minutes, and finally 40-75% ACN/H2O for final 5 minutes. Fractions of purified peptide 
eluted at 40% ACN/H2O and were detected with λ = 210 nm and λ = 254 nm. Peptide 
fractions were combined and solvent was removed in vacuo. Peptides were then 
resuspended in 3 mL of water, frozen in -80°C for 3 days, and lyophilized for 3 days.  
A.3. Results and Discussion 
For this drug discovery project, we used a high throughput screening (HTS) 
approach to screen libraries consisting of small molecules with drug-like properties and 
contain pharmacophores that have been selected by medicinal chemists for their 
structural diversity and bioactivity. The affinities of small molecule “hits” from the HTS 
screening campaign are typically in the micromolar range. We also used a fragment-
based drug discovery (FBDD) approach. Molecules from fragment libraries are smaller 
than small molecules and thus, bind to the protein with affinities ranging from micromolar 
to millimolar.205 However, due to their small size, these fragments are able to overcome 
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the entropic barrier to binding and can make “high quality interactions,” which permits 
their binding to be detected.205,206 Thus, screening fragments would facilitate the 
discovery of chemical scaffolds that are essential to the interaction with the target protein. 
These two screening approaches are summarized in Figure A.1. By using both of these 
libraries, we were able to sample a larger chemical space to search for molecules capable 
of binding to WDR5 so that it could be a candidate for blocking the interaction of Myc and 
WDR5.  
 
Figure A.1. Complementary Approaches to Drug Discovery Approaches: High Throughput Screening and Fragment-
Based Screening. 
A.3.1. Fragment Based Drug Discovery for Scaffolds That Interact with WDR5 
 In order to screen compounds against WDR5, we used the Thermal Shift assay, 
which is an assay based on differential scanning fluorimetry.207 This assay measures the 
melting temperature (Tm) of WDR5 in the presence of a hydrophobic dye (commercially 
available Thermal Shift assay kit can be used or SYPRO Orange can also be used).208 
The quantum yield of this dye is very low in aqueous buffers, but as the thermal shift 
assay progresses, WDR5 heats and undergoes thermal denaturation, which exposes the 
hydrophobic core of the protein.208 When the hydrophobic dye interacts with the 
hydrophobic core of WDR5, the quantum yield increases and facilitates the measurement 
of the Tm, which is the temperature at which half of the population of the protein is 
denatured and half remains properly folded.208 In the presence of a small molecule that 
binds to the protein, protein receives additional stabilization from the interaction with the 
small molecule, which shifts the Tm to higher temperature (Figure A.2).208 The shift in Tm 
facilitates the identification of compounds or fragments with binding activity. This general 
thermal shift assay was used as the screening method in this project due to the lack of 
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availability of an effective direct binding assay between Myc and WDR5. Thomas and 
coworkers developed a fluorescent polarization (FP) competitive assay for the 
WDR5/Myc interface using a FP probe constructed from consisting of a 10mer amino acid 
sequence of Myc that interacts with WDR5 and labeled with fluorescein (FAM).200 
However, the narrow dynamic range of this assay prevents its use as a screening method 
and therefore, we elected to perform a general screen of fragments and small molecules 
against WDR5, which were followed by validation studies to substantiate the binding of 
those “hit” molecules and to evaluate the site-specificity of those “hits.”  
 
Figure A.2. Cartoon of Thermal Shift Assay Using Sypro Orange for Fragment-Based Drug Discovery Approach. 
 Prior to screening experiments using fragment libraries or small molecule libraries, 
optimal conditions were screened. Parameters for assay conditions were: optimal 
WDR5:thermal shift dye ratio, buffer, DMSO concentration, and detergent concentration. 
We also determined the optimal concentration of MLL-WDR5 inhibitor so that it could be 
used as a positive control for binding. We performed cross-titration of the thermal shift 
dye (1:500, 1:1000) and WDR5 (1 µM, 3 µM, 5 µM) to determine the pair of the 
concentration of the thermal shift dye and WDR5 that provided a melt curve with a distinct 
sigmoidal shape, a S/N = 10, and the variance around the calculated Tm. From this cross-
titration, we found that the use of 3 µM WDR5 and 1:1000 Sypro Orange dye was optimal 
and resulted in a baseline Tm for WDR5 as 57 degs. Following, we screened for the 
optimal buffer (1X PBS, 50 mM Tris, 50 mM HEPES) and selected 50 mM HEPES as the 
buffer for this assay. Tris contains a primary amine, and thus, was not selected as the 
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assay buffer for its potential to participate in solvolysis with electrophilic small molecules 
or fragments in the screen. The detergent screen showed that the presence of detergents 
(Triton X-100 and Tween-20) resulted in high background through the putative 
interactions of the detergents with the aromatic framework of the Sypro Orange dye, and 
therefore, detergents were excluded from the assay conditions. Lastly, we determined the 
optimal concentration of dimethyl sulfoxide (DMSO) to be included in the assay conditions 
so that it could assist in the solubilization of organic fragments and compounds. From this 
DMSO screen, I determined that the optimal concentration of DMSO was 5% (v/v); higher 
concentrations of DMSO decreases the Tm, which is associated with a destabilization of 
WDR5 at these concentrations. From these studies, we determined the optimal conditions 
for fragment and small molecule screening campaigns using the thermal shift assay.  
 Fragments screened against WDR5 were obtained from Dr. Shaomeng Wang’s 
laboratory at the University of Michigan; these fragments came from the ChemDiv and 
Life Chemical fragment libraries. Fragments from these libraries have been certified to 
abide by the “Rule of 3,” which is similar to Lipinski’s “Rule of 5” for small molecules.209,210 
This property is a defining characteristic of fragment libraries because they provide control 
over the physiochemical properties during the optimization of the “hit” fragment to a 
molecule with more drug-like properties (Rule of 5). 209,210 The initial design for the 
fragment screens is to perform the thermal shift assay in the presence of a MLL-WDR5 
inhibitor to occlude the MLL-WDR5 site and thus, to maximize the discovery of fragments 
capable of interacting at the Myc-WDR5 site. However, due to the low-throughput nature 
of this assay set-up, we elected to identify fragments that increased the Tm of WDR5 in 
absence of the MLL-WDR5 inhibitor and validate the identified fragment for its ability to 
induce an additional increase in the Tm of WDR5 in the presence of the MLL-WDR5 
inhibitor. In order to identify “hit” fragments from these libraries, we screened these 
fragments at 50 µM against 3 µM of WDR5 and 1:1000 Sypro Orange dye in 50 mM 
HEPES buffer with 5% DMSO (v/v), and “hit” fragments were defined as fragments that 
increased the baseline Tm of WDR5 by 2°C to identify highly tight binders of WDR5 (Figure 
A.3). Fragments fitting these criteria were then validated in a dose-dependent thermal 
shift assay, which resulted in 10 fragments displaying a dose-dependent increase in the 
baseline Tm of WDR5 (Figure A.3B). In order to further substantiate the binding of these 
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fragments, we assayed them in a dose-dependent thermal shift assay in the presence of 
5 µM of an MLL-WDR5 inhibitor, LC-045 (provided by Dr. Yangbing Li from Dr. Shaomeng 
Wang’s lab). By including the MLL-WDR5 inhibitor, the new baseline Tm for WDR5 was 
72 degs, and fragments that were considered as “real binders” of WDR5 were ones that 
increased the Tm of WDR5 beyond 72 degs, which resulted in 2 fragments. The increase 
in Tm caused by LS.6.4.3 is likely to be caused by aggregation of WDR5 since only flat 
melt curves were observed for WDR5 in the presence of LS.6.4.3 and LC-045 (Figure 
A.3C). Two of the 10 fragments, LS.3.6.3 and LS.7.8.2 (Figure A.3C and D) were sent to 
the Center of Chemical Genomics at the University of Michigan for co-crystal studies, but 
these studies revealed that these fragments do not bind near the WDR5/Myc interface 
(data not shown). After performing this round of fragment screening, we realized that the 
use of a 2 deg shift as the selection criteria might have been too stringent and thus, 
hindered the opportunity to identify scaffolds that truly bind to WDR5 albeit with lower 




Figure A.3. Fragment Based Screening Approach to Identify Inhibitors of Myc-WDR5 Protein Interaction. A) Campaign 
view of thermal shift screen of 1,500 fragments against recombinant WDR5 depicting the change in melting temperature 
(Tm) of WDR5. X-axis depicts all of compounds by library identifier. B) Dose dependent thermal shift assay for 
fragments that elicited a change in Tm ≥ 2°C. Structures of fragments shown on right. C) Dose dependent thermal shift 
assay for fragments shown in B. Assay conducted in presence of MLL-WDR5 inhibitor, LC-045. Change in Tm of WDR5 
in presence of LC-045 and fragment depicted on graph. Structures of framgents that elicited additional change in Tm 
in WDR5 shown on right. D) Cartoon depicting the interactions between WDR5 and MLL and WDR5 and Myc peptide. 
Aim of fragment based screen was to identify fragments that occupy near the interaction between WDR5 and Myc. 
Protein structure of WDR5 interacting with Myc peptide obtained from PDB (4Y7R). 
 To continue with the quest to identify potential fragment binders, we reanalyzed 
the thermal shift data (completed in absence of the MLL-WDR5 inhibitor, LC-045) for 
fragments that increased the Tm of WDR5 by 2 standard deviations (SD) relative to the 
Tm of WDR5 alone, which is commonly used in FBDD. The use of 2SD as the selection 
parameter resulted in 68 fragments and after assaying those 68 fragments in a dose-
dependent thermal shift assay, 35 fragments exhibited a dose-dependent increase in the 
Tm of WDR5 (Figure A.4). Akin to the validation approach previously described, we 
screened the 35 fragments against WDR5 in the presence of MLL-WDR5 inhibitor, MM-
401, for their ability to provide an additional thermal stability and determined that 17 of 
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these fragments increased the Tm of WDR5 from 0.6 – 3°, depending on the concentration 
of the fragment used (Figure A.4). These 17 fragments have been identified from the 
primary screening campaign of Life Chemicals and Chem Div fragment libraries as true 
potential binders of WDR5 and will require further validation using co-crystal studies to 
ascertain the location and binding modes of these fragments to the surface of WDR5.  
 
Figure A.4. Validation of Fragments Identified From Fragment Based Screening. A) Campaign view of dose-dependent 
thermal shift assay of 35 fragments that increased Tm of WDR5 ≥ 2 standard deviations. B) Campaign view of dose-
dependent thermal shift of WDR5 in presence of 35 fragments shown in A and WDR5-MLL inhibitor, MM-401. C) 
Structures of fragments that increased Tm of WDR5 ≥ 2 standard deviations even in presence of MM-401. 
 At the end of the fragment-based screening campaign, 4 fragments were identified 
using the thermal shift assay. These fragments increased the Tm of WDR5, even in the 
presence of a MLL-WDR5 inhibitor, suggesting these fragments could be real binders of 
WDR5. These fragments were sent to the Center of Structural Biology at the University 
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of Michigan for crystallization studies to elucidate the site-specificity of these fragments. 
From the crystallization and crystal soaking studies performed by Dr. Jeanne Stuckey 
from the Center of Structural Biology, these fragments were found to bind to WDR5 on 
the face opposite of the WDR5-Myc interaction (data not shown). Based on this finding, 
these fragments were not proceeded to further analyses, such as structural-activity 
relationship (SAR) analyses or chemical modifications to improve binding potency. 
Additional fragment libraries could be screened to continue the discovery of chemical 
scaffolds capable of interacting near the interface of WDR5 and Myc.  
A.3.2. High Throughput Screening of Drug-Like Compounds Against WDR5 
In addition to using the fragment-based approach to identify novel inhibitors for the 
interaction between WDR5 and Myc, we also performed multiplexed high throughput 
screening. This approach is complementary to the fragment-based approach because 
unlike the fragment-based approach, HTS features small molecules, which are much 
larger than fragments and harbor more moieties and atoms that could interact with WDR5. 
Thus, compounds identified from HTS would have a higher binding affinity than fragments 
identified from fragment-based screening. Despite this advantage, compounds identified 
from HTS could be promiscuous binders, that is, compounds that bind to an array of 
proteins with little specificity.211 This limitation was minimized in this study because the 
assayed compounds were selected from commercially available libraries of drug-like 
compounds that have been curated to exclude these promiscuous ligands and assay 
interfering compounds (e.g. PAINS, pan-assay interference compounds211). Compounds 
assayed in this high throughput screening campaign were from the LOPAC, Prestwick, 
and Maybridge 24K libraries. The LOPAC library feature compounds with 
pharmacologically active compounds. The Prestwick library is a collection of FDA 
approved drugs and small molecules that were selected for their pharmacological 
diversity and verified bioavailability in humans. Lastly, the Maybridge 24K library features 
chemically diverse compounds and scaffolds. From these libraries yielded 25,000 small 
molecules for the HTS screening campaign, which was performed in collaboration with 
the Center of Chemical Genomics at the University of Michigan.  
The Thermal Shift screening assay was used to screen the 25,000 compounds in a 
384-well plate format, where each well consisted of recombinant WDR5 proteins, Sypro 
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Orange dye, and 4 drug-like compounds. Prior to the HTS, it was imperative to perform 
quality control studies to optimize the dynamic range of the assay and minimize the assay 
variability, especially since 80-100% of all initial “hits” (i.e. compounds that exhibit activity 
during a screening assay) could result from artefacts if controls and assay parameters 
are unoptimized.211 The Z’ score is a statistical parameter used to assess the dynamic 
range of the assay and the assay variability and is expressed as the following: 
𝑍𝑍′ =  1 − 3𝑆𝑆𝑆𝑆𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐,𝑐𝑐𝑛𝑛𝑛𝑛 +  3𝑆𝑆𝑆𝑆𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐,𝑝𝑝𝑐𝑐𝑝𝑝
�𝑚𝑚𝑚𝑚𝑑𝑑𝑚𝑚𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐,𝑐𝑐𝑛𝑛𝑛𝑛 −  𝑚𝑚𝑚𝑚𝑑𝑑𝑚𝑚𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐,𝑝𝑝𝑐𝑐𝑝𝑝� 
Thus, an assay with a wide dynamic range and minimal variability would exhibit a Z-factor 
> 0.5.212 This statistic is based on the assumption that all of the activities in a chemical 
library during a HTS campaign will exhibit a normal distribution, where the vast majority 
of the compounds will exhibit little to no biological activity.212 Thus, the threshold for 
identifying “hits” (i.e. compounds that exhibit significant activity in a HTS campaign) has 
been widely accepted to be 3 standard deviations from the average signal of the 
controls.212  
For these studies, quality control screening experiments yielded a Z’ score of 0.6, 
which confirmed that the HTS conditions yielded a wide dynamic range between the 
positive and negative controls as well as minimal assay variation. The positive control 
used in this HTS campaign consists of WDR5, Sypro Orange dye, and a 10mer peptide 
of Myc that consists of the amino acids that interact with WDR5. The negative control 
used in this HTS campaign consists of WDR5 and the Sypro Orange dye. Using the 
conditions optimized for HTS during the quality control studies, multiplexed (4-plex) HTS 
was performed to screen 25,000 compounds against WDR5 at a single concentration (1-
20 µM, Figure A.5). The threshold of 3SD relative to the negative control (i.e. WDR5 with 
Sypro Orange) yielded 581 active wells, which corresponded to 2,324 compounds (9.5% 




Figure A.5. Campaign View of HTS of 25,000 Compounds Against WDR5. Signals were normalized to signal of positive 
control (100%, red dots) and negative control (0%, blue dots). Signal from WDR5 in presence of multiplexed compounds 
are denoted in green and are normalized to the controls. Red line denotes 3 standard deviations (SD) above the 
negative control. Primary screen resulted in 581 active wells (9.5% “hit” rate). Z’ score for HTS primary screen: 0.61. 
Image retrieved from MScreen. 
Since the HTS campaign was performed in a multiplexed format (4-plex), it was 
necessary to perform a deconvolution step to determine which one of the 4 multiplexed 
compounds that raised the Tm of WDR5 by more than 3SD relative to the negative control 
(Figure A.6). For the deconvolution studies, compounds in active wells were screened 
individually at a concentration of 10 µM against WDR5. Due to the large number of active 
wells from the initial screen, the top 1,000 compounds were prioritized for deconvolution 
screening studies, which identified 207 active compounds. These 207 active compounds 
underwent additional filtering steps, which involved removal of compounds predicted to 
exhibit reactive chemical functionality (i.e. exhibits behaviors of PAINS211) and lack of 
drug-like properties. Specifically, active compounds that were considered to be 
promiscuous binders, defined as a “hit” in more than 10 assays recorded on MScreen213, 
were removed. Additionally, compounds with chemical structures predicted to be reactive 
as defined by NIH Molecular Libraries Small Molecule Repository and compounds with 
chemical structures predicted to be cytotoxic in biological assays were also removed from 
further studies. The resultant quantity of active compounds from the deconvolution screen 




Figure A.6. Campaign View of HTS Deconvolution of Active Compounds. Signals were normalized to signal of positive 
control (100%, red dots) and negative control (0%, blue dots). Signal from WDR5 in presence of multiplexed compounds 
are denoted in green and are normalized to the controls. Red line denotes 3 standard deviations (SD) above the 
negative control. Deconvolution studies resulted in 207 active compounds (8.7% “hit” rate). Z’ score for HTS 
deconvolution screen: 0.64. Image retrieved from MScreen. 
 Active compounds identified from the deconvolution studies were processed using 
concentration dependent thermal shift assays. Compounds considered “hits” from HTS 
were those that induced dose dependent changes in the Tm of WDR5. Concentration 
dependent thermal shift studies resulted in 49 compounds. These compounds resulted in 
a change in Tm that ranged from 0.5° to greater than 5°. Following the HTS of 25,000 
small molecules against WDR5, 49 were considered “hits,” which corresponded to a “hit” 
rate of 0.2%. These 49 compounds were ordered and retested in singleton using identical 
conditions as the primary screen to confirm their activity. This retest assay identified 7 
compounds that did not increase the Tm of WDR5 and therefore were removed from 
downstream studies. The final number of compounds that proceeded to downstream 
studies was 42.  
 After confirming the activity of the 42 compounds in the retest assay, we next 
evaluated the site specificity of these compounds. We leveraged the previously 
characterized protein-protein interaction of WDR5 and MLL to eliminate compounds that 
engage at the WDR5-MLL site via negative selection.202,214,215 In collaboration with the 
Wang Lab at the University of Michigan, we employed a competitive fluorescence 
polarization based assay targeting the protein-protein interaction of WDR5 and MLL for 
negative selection. Fluorescence polarization is a chemical technique that relies on the 
fluorescence properties of a fluorophore to evaluate protein-ligand binding.216–218 
Fluorescence polarization can be calculated from the following equation218:  
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𝑃𝑃 =  𝐹𝐹|| −  𝐹𝐹⊥
𝐹𝐹|| +  𝐹𝐹⊥ 
In the equation shown above, F|| denotes the parallel fluorescence intensity, and F⊥ 
denotes the perpendicular fluorescence intensity.218 Both parallel and perpendicular 
fluorescence intensity contribute the polarization of light.216–218 Therefore, a fluorescence 
polarization based assay leverages the polarizability of a chemical probe, which is a small 
(10mer) peptide labeled with a fluorophore.216–218 Upon excitation with polarized light, a 
free probe (i.e. a probe not interacting with any protein) tumbles rapidly in solution, which 
results in the depolarization of both the perpendicular and parallel fluorescence intensity 
and thus, ultimately results in a low polarization signal.216–218 In contrast, if the probe binds 
to a protein (which is larger in molecular weight than the probe), the probe-protein 
complex will tumble slowly in solution and thus, retain the polarized light and results in a 
high polarization signal.216–218 In context of the negative selection MLL-WDR5 assay, we 
used this assay as an approach to eliminate compounds that reduce the polarization of 
MLL-WDR5 complex (Figure A.7A). Such compounds compete with the MLL probe for 
the MLL-WDR5 interaction site and thus would be deprioritized (Figure A.7A). Since some 
of the 42 compounds identified from the HTS campaign have conjugated systems and 
have the potential to exhibit fluorescence, these 42 compounds were screened for auto-
fluorescence. The auto-fluorescence screen identified 9 compounds that exhibited 
intrinsic fluorescence at concentrations greater than 50 µM, which overlapped with the 
concentration range used for the negative selection assay. The remaining 33 compounds 
were screened in the negative selection assay were initially evaluated in the MLL-WDR5 
FP assay at 500 µM and 1 mM (Figure A.7B). These concentrations were selected 
because the binding affinity of WDR5 to the MLL probe was 100 nM, and therefore, high 
concentrations of the HTS compounds were required to evaluate any displacement of the 
MLL probe. Compounds that competed with the MLL probe for WDR5 at 500 µM and 1 
mM were analyzed in a follow-up study using a concentration range of 7 µM to 1 mM 
(Figure A.7C). This negative selection assay identified 2 compounds that displaced the 
MLL probe in a concentration-dependent manner, suggesting they interacted near the 
site of MLL-WDR5 rather than Myc-WDR5. These 2 compounds were removed from 




Figure A.7. Negative Selection of HTS Compounds Using MLL-WDR5 Competitive Binding Assay. A) Cartoon of 
competitive binding assay to eliminate compounds that engage at MLL-WDR5 site. KD of MLL probe and WDR5 is 100 
nM. Amino acid sequence of MLL probe is Ac-ARTEVHLRKS-Ahx-Ahx-K(5-FAM)-NH2.. Protein structure of WDR5 
obtained from PDB (4Y7R). B) Identification of binders at the MLL-WDR5 site by screening HTS compounds at 500 µM 
and 1 mM. C) Concentration dependent binding assay to validate competitors of MLL probe. Structures of compounds 
that displaced MLL probe in concentration dependent manner are shown. 
 After triaging the compounds using MLL-WDR5 assay as a negative selection tool, 
we sought to evaluate if these compound engaged at the WDR5-Myc interaction site. 
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Since our ultimate goal was to identify small molecule inhibitors of the protein-protein 
interaction of WDR5 and Myc, determining if these compounds interact with WDR5 at the 
Myc interacting site was a critical step to discovering potential WDR5-Myc inhibitors. To 
assess whether these compounds engaged at the WDR5-Myc site, we used a 
fluorescence polarization based competition assay using the previously published amino 
acid sequence of Myc that interacts with WDR5.200 The binding affinity of the Myc probe 
to recombinant WDR5 was 10 µM.200 We synthesized the Myc probe, reevaluated this 
binding affinity, and obtained a comparable binding affinity (KD = 13 µM, Figure SA.1). 
We attempted to rationally design and synthesize Myc probes with higher binding affinity 
to WDR5 by maximizing π stacking interactions between V264 of the Myc peptide and 
nearby aromatic residues of WDR5 to improve the dynamic range of the Myc/WDR5 FP 
assay (Figure SA.1). However, we were unable to rationally design a Myc probe with a 
stronger binding affinity than 10 µM. Therefore, we leveraged the previously published 
amino acid sequence of Myc for the fluorescence polarization based competitive binding 
assay. The goal of using the competitive Myc/WDR5 assay was to identify compounds 
that competed with the Myc probe to displace it from WDR5 in a concentration-dependent 
manner (Figure A.8A). The 31 compounds were initially screened at 125 µM and 250 µM 
or 500 µM and 1 mM, depending on the solubility of those compounds (Figure A.8B). 
Again, these concentrations were selected because they were approximately 10KD of 
Myc-WDR5 and therefore were deemed appropriate concentrations for the HTS 
compounds to displace the Myc probe. Under the assay conditions for the Myc-WDR5 
competitive binding assay, 6 compounds were exhibited solubility issues which were 
evidenced by high scattering of light by the colloids of those compounds. Thus, those 6 
compounds were removed from the Myc-WDR5 competitive binding assay and left 25 
compounds for site specificity analyses. Screening these 25 compounds at 125 µM, 250 
µM, 500 µM, or 1 mM identified 3 compounds that displaced the Myc probe from WDR5. 
The inhibitory activities of these 3 compounds were screened from a range of 50 µM – 1 
mM (5KD – 100KD), which confirmed the concentration-dependent displacement of the 
Myc probe for 2 compounds (Figure A.8C). Concentration-dependent displacement of the 
Myc probe suggested these two compounds engaged at/near the Myc-WDR5 interaction 




Figure A.8. Site Specificity Evaluation of HTS Compounds Using Myc-WDR5 Competitive Binding Assay. A) Cartoon 
of competitive binding assay to evaluate site specificity of HTS binding to WDR5 in presence of Myc peptide probe. KD 
of Myc probe and WDR5 is 13 µM. Amino acid sequence of Myc probe is FAM-Ahx-DEEEIDVVSV-NH2..Protein 
structure of WDR5 obtained from PDB (4Y7R). Z’ of Myc-WDR5 FP assay was 0.68. B) Identification of binders at the 
Myc-WDR5 site by screening HTS compounds at 125 µM, 250 µM, 500 µM, and 1 mM. C) Concentration dependent 
binding assay to validate competitors of Myc probe. Structures of compounds that displaced Myc probe in concentration 
dependent manner are shown. 
 Co-crystallization studies were performed in collaboration with Dr. Jeanne Stuckey 
at the Center of Structural Biology to determine if these 2 compounds exhibited site-
specifity for the WDR5-Myc interaction site. These co-crystallization studies revealed 
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neither 2928 nor 2778 interacted with WDR5 since the solved structure of WDR5 did not 
include neither of these compounds.  
A.4. Concluding Remarks 
The protein-protein interaction of Myc and WDR5 is a critical driver to early 
tumorigenesis events. There have been numerous reports aiming to inhibit Myc for Myc-
driven cancers.184,195,219–221 However, these efforts had limited success for clinical 
applicability, and only therapeutics that indirectly target Myc (i.e. to inhibit Myc translation 
and targeting via immunotherapy) have been approved.220,221 To overcome previously 
reported shortcomings in targeting Myc, we pursued a drug discovery program targeting 
the Myc-WDR5 protein-protein interaction using HTS and FBDD as a means to directly 
target Myc. These two screening approaches are complementary and were intended to 
facilitate the discovery of diverse compounds and scaffolds that could serve as parent 
compounds to future inhibitors of the interaction of Myc and WDR5.  
Both approaches identified 2-5 compounds/fragments at the end of the screening 
and validation stages. However, structural elucidation of these compounds and fragments 
using co-crystallization studies revealed that none of those compounds and fragments 
targeted the Myc-WDR5 site. Recently, nanomolar inhibitors of the interaction between 
Myc and WDR5 were identified by Fesik and coworkers.222,223 These potent inhibitors 
were identified through a NMR-based fragment based screen of libraries containing 
14,000 fragments and a FP based HTS campaign of 250,000 small molecules.222,223 
Simon and coworkers leveraged characterized chemical shifts from 15N labeled apo 
WDR5 and 15N labeled WDR5 with a peptide of Myc that engages with WDR5.222 In our 
studies, we were unable to leverage characterized chemical shifts of 15N labeled WDR5 
with Myc, which would have been needed as a critical positive control to screen for 
fragments or small molecules. The lack of this positive control hindered our pursuit of 
NMR studies for our primary screens because we would not have had a reference for 
chemical shifts that signified engagement with WDR5 at the Myc binding site. MacDonald 
and coworkers from the Fesik Lab also identified potent leads using their FP based Myc-
WDR5 competitive binding assay as their HTS screen.221 Both of these reports from the 
Fesik Lab emphasized the importance of leveraging structure-based screens to guide the 
discovery of fragment hits and small molecule hits. In our studies, our hypothesis was 
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based on the discovery of weak binders to the largely hydrophobic cleft where WDR5 
interacts with Myc and thus used thermal shift as the primary screen for both our fragment 
based screen and HTS campaigns. Evaluation of the current literature surrounding the 
discovery of small molecule inhibitors of the protein interaction between WDR5 and Myc 
revealed that our primary screening assay was not optimal for the discovery of potent 
inhibitors for this interaction. Opportunities for identifying inhibitors for this interaction 
could have been improved by heavier investment in the biophysical characterization of 
the protein interaction between Myc and WDR5 and leveraging this biophysical insight to 
guide the development of a structure-based screening assay. Such structure-based 
screening assay could have improved the opportunities to finding site-specific binders at 
the onset of our primary screens.  
Future studies for the drug discovery could involve leverage of those recently 
identified compounds to attenuate the deregulated cell growth, metabolism, survival, 
and/or differentiation of cancer cells in Myc-driven cancers. Screens of these compounds 
or derivatives of these compounds could be performed to identify subsets of specific Myc-
driven cancers that could profit from the treatment of these Myc-WDR5 inhibitors. Such 
studies could provide novel chemical tools and small molecule therapeutics for Myc-




A.5. Additional Figure 
 
Figure SA.1. Approach for Rational Design of Myc Probes for Myc-WDR5 Competitive Binding Assay. A) Previously 
solved protein structure of WDR5 (grey) interacting with Myc peptide (magenta). Interactions between the aromatic 
residues of WDR5 (F266, yellow) and aliphatic residues of Myc (V264 and Y226, green and cyan) were targeted. 
Structure of WDR5 and Myc peptide obtained from PDB (4Y7R). B) Aromatic residue substitution at 264 or 265 position 
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